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Abstract  
Introduction: 
The human endometrium undergoes cyclical changes of proliferation, 
differentiation and shedding. This cyclical process has been described as an 
inflammatory process.  Menstrual abnormalities account for the morbidity of a 
large population of females in their reproductive age. Aberration in endometrial 
angiogenesis has been implicated in the mechanism of heavy menstrual bleeding 
(HMB).  Although the precise mechanism for control the endometrial 
neoangionesis is not fully understood, vascular endothelial growth factor and 
other cytokines such as cyclooxygenases, prostaglandins, interleukin -8 and 
leukocytes have been implicated in both endometrial pathologies and 
angiogenesis dysregulation. In addition, heavy menstrual bleeding results from 
upregulation of the expression/synthesis of these local markers. 
 Uterine fibroids are the most common benign tumor affecting the female 
reproductive tract. Heavy menstrual bleeding is the main presenting complaint 
of women with uterine fibroids. However, the mechanism by which uterine 
fibroids cause heavy menstrual bleeding has not been elicited yet. Therefore, 
the mechanism of action of different available treatments for this condition, 
including uterine artery embolisation is unclear. This thesis is based on the 
hypothesis that a) uterine fibroid changes the physiology of endometrium and we 
aimed to find out whether these markers work in a different way in heavy 
menstrual bleeding in those with uterine fibroids and those without., In addition 
I we wished to study whether uterine fibroid upregulate these local markers in 
heavy menstrual bleeding, whereas uterine artery emolisation down-regulates 
them.  
Methods: 
This thesis describes the use of endometrial samples, taken with a Pipelle 
sampler, collected from women with heavy menstrual bleeding both with uterine 
fibroids and also with normal uteri, to estimate the difference in the 
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endometrial expression of the factors likely to be involved in the control of 
menstrual bleeding between the two groups. 
 Results: 
The study found no differences between the expression of both either proteins 
or  mRNA for the cytokines under investigation By using endometrium, 
myometrium and different types of fibroid tissue collected from women who had 
hysterectomies with the complaint of heavy menstrual bleeding, there was 
higher expression of VEGF, COX-2, PGE2 and IL8 proteins in fibroid than 
myometrial tissue. However, the level mRNA of expression for VEGF, COX-1, 
COX-2, IL8 and EP2 showed no differences between myometrial and fibroid 
tissue. 
 In the same group, endometrial expression of these markers for women who had 
no hormonal therapy before operation compared with that for women who 
received gonadotropin releasing hormone agonists (GnRH), higher expression of 
VEGF mRNA in women who had GnRH agonists than those who had no any 
hormones. In fibroid tissue, GnRH downregulated the expression of VEGF protein 
and other cytokines compared with those not on any hormonal therapy. In 
addition, the estimated serum levels of these factors, indicating a higher level of 
IL8 in the GnRH group than in the other group. 
Conclusion: 
It seems that theses markers play a role in HMB mechanism in both uterine 
fibroid and normal uteri group in same manner. In addition, they have a 
fundamental role in the growth of uterine fibroids as well. 
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GRP-α Growth-related protein-alpha 
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HBEGF Heparin binding epidermal growth factor  
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HIF-1 hypoxia inducable factor-1  
HMB Heavy menstrual bleeding  
ICAM-1. Intercellular adhesion molecule 1 
IgG Immunoglobulin-G 
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NSAIDs Non-steroidal anti-inflammatory drugs 
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PGG2 Prostaglandin G2  
PGH2 Prostaglandin H2 
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uNK uterine natural killer 
VEGF Vascular endothelial growth factor 
VEGF-R1/ Vascular endothelial growth factor- receptor 1 
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1.1 The human uterus and endometrium 
The uterus is an essential for reproduction. It is a near pear shaped 
fibromuscular organ composed of a smooth muscle outer layer and uterine cavity 
which is lined by the endometrium. The uterus consists of the body of the uterus 
and uterine cervix. The smooth muscle cells of the uterine wall are steroid 
responsive, undergoing hypertrophic and hyperplastic changes during a woman’s 
reproductive life. Pre-puberty, the body of the uterus is nearly equal to the 
cervix in size. However, it can double its size under the influence of oestrogen 
during puberty. The hyperplastic and hypertrophic capabilities of smooth muscle 
cells of the uterus, which are influenced by placental steroids, allow the size of 
the body of the uterus to increase in line with growth of the developing fetus. 
The endometrium lines the uterine cavity (body of the uterus) and it is a 
dynamic tissue undergoing cyclical changes, involving regeneration and 
remodelling to prepare for possible implantation. These cyclical changes occur 
throughout the menstrual cycle and are under the influence of the ovarian 
steroids hormones. Menstruation, which is the bleeding period, signals the end of 
one cycle and the beginning of the next. Following the menstrual phase 
(menstruation), the estradiol level rise in blood leading to growth and 
proliferation of the endometrium and this time represents the proliferative 
phase of the menstrual cycle. After ovulation, the corpus luteum produces 
progesterone, the dominant hormone during this phase (secretory phase). 
Progesterone in association with estradiol prepares the endometrium for possible 
implantation. In the absence of pregnancy, the corpus luteum regresses leading 
to decline in the sex steroids hormones levels and triggering mechanism of 
menstruation. 
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1.2 Endometrial morphology 
1.1.1 Endometrial structure 
The endometrium consists of a superficial functional layer, which is shed during 
menstruation , and deep basal layer from which endometrial regeneration take 
place.  
1.2.1.1 Proliferative phase 
The proliferative phase is the pre-ovulatory phase of the menstrual cycle. All 
tissue components of endometrium during this stage display signs of proliferation 
which peak on cycle days 8-10 [1]. The hallmarks of proliferation changes are 
increased mitotic activity in epithelial and stromal cells, and nuclear 
Deoxyribonucleic acid (DNA) and cytoplasmic Ribonucleic acid (RNA) synthesis. 
During this phase the surface epithelial regenerates and epithelial glands 
gradually elongate and curve. The stroma is dense, containing spindle shape 
cells and stromal oedema tends to regress through the proliferative phase. 
Before ovulation, during the late proliferative phase, the surface epithelium 
becomes more swollen and glands become more tortuous. The stroma by this 
stage is moderately dense and actively growing. These proliferative alternations 
are more prominent in the functionalis layer than the basalis layer. The biologic 
rationale for the environmental variation in proliferative indices may lie in the 
different physiologic functions of the functionalis versus the basalis layer. Where 
the functionalis is the seat of blastocyst implantation, the basalis layer provides 
the origin for regeneration of the endometrium following the menstrual shedding 
of the functionalis layer. Although estradiol (E2) is the prominent sex hormone in 
the pre-ovulatory period, many authors have demonstrated that intracellular 
oestrogen receptor (E2R) and progesterone receptor (PR) concentrations are 
highest during the pre-ovulatory period of the menstrual cycle[2-7], confirming 
the hypothesis that PR synthesis is mainly induced by E2 in the target cells via 
the E2-receptor complex mechanism. Therefore, the presence of PR in the 
proliferative phase is a good evidence of endometrial E2 sensitivity.  
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1.2.1.2 Secretory phase 
After ovulation, the E2-primed endometrium undergoes secretory differentiation 
which is dominated by the action of progesterone.  The daily changes during the 
secretory phase are specific to post-ovulatory endometrium. These alternations 
are useful for dating the endometrium and to determine whether ovulation has 
taken place. Because of widely physiological changing, secretory phase can be 
divided into three stages; early, mid and late secretory. 
1.2.1.2.1 Early secretory: 
During this stage the epithelial gland cells acquire sub-nuclear intracytoplasmic 
glycogen –rich vacuolation and the nuclei lose their pseudostratification 
configuration. Additionally, there is increase in gland diameter and tortuosity. 
1.2.1.2.2 Mid-secretory stage 
This stage represents the post-ovulatory days 5-9 and the intra-glandular 
secretion reaches the maximum levels during this period and coincides with the 
time of blastocyst implantation. In addition, because of the transudation of 
plasma from circulating blood in endometrial mucosa, this time of the menstrual 
cycle is characterised by marked stromal oedema. This alternation may be 
mediated by prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) and coincide 
also with rising E2 and P levels. Toward the end of this stage the spiral arterioles 
become much more prominent. 
1.2.1.2.3 Late secretory stage 
This is the period from post-ovulary day 10 to menses, where predecidualization 
takes place and consists of cytonuclear enlargement with mitotic activity, and 
formation of pericellularlaminin rich basement membrane particularly of the 
epithelial cells [8]. Furthermore, predecidual cells may be seen around the 
arterioles. Accompanying the predecidual alternation there is stromal regression 
and loss of endometrial height. In the absence of pregnancy, gland secretion 
reduces and involution of the epithelial gland occurs. 
 
1.2.1.3 Menstrual stage 
The menstrual cycle commences from the first day of the menstrual bleeding, 
and the upper two thirds of the endometrium (functionalis layer) are shed. It 
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appears that the menstrual tissue is the result of the enzymatic autodigestion 
and prostaglandin related ischemic necrosis of non-gestational 
oestrogen/progesterone primed endometrium[9]. The remaining endometrium 
(deep functionalis and basalis layer) begin the regeneration from the third day 
and starts in the glandular and stromal elements [10] (Figure 1.1). 
 
 
Figure 1.1:  Depiction of changes at the endometrial level for hormonal fluctuations 
throughout the menstrual cycle. 
 
1.2.2 Endometrial blood vessels 
The endometrium is supplied by the radial branches of the arcuate arteries in 
the myometrium which derive from the uterine arteries. This blood supply is 
critical for menstruation. The blood vessels in the upper two third of the 
functional layer of endometrium are characterised by their spiral shape which is 
unique for menstruating species [11].  Such vasculatures are involved in the 
mechanism of menstruation by being involved in leukocytes influx and 
vasoconstriction. Furthermore, these blood vessels undergo cyclical changes 
such as dramatic growth, disruption, re-modelling and repair [12]. These 
vascular changes are a part of preparing the endometrium for the implantation 
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process, and supporting a healthy pregnancy, but if pregnancy does not occur, 
the vascular changes are associated with per-vaginal bleeding.  
These arterioles have a strong structure due to a tight connection between the 
endothelial cells and basement membrane. They are highly sensitive to ovarian 
hormones and, therefore, thought to be controlled with the steroid hormones 
[13].  The growth and the differentiation of these blood vessels are mediated in 
the presence of oestrogen receptors (ER) and progesterone receptors (PR) within 
the smooth muscle cells. However, other observations have demonstrated that 
endothelial cells in the endometrium do not express ERα and PR but do express 
ERβ [14]. Therefore the effect of steroid hormones on endometrial blood vessels 
may occur in an indirect way mediated by local molecules and certain 
components of the basement membrane such as heparin sulphate. This reduces 
the stabilisation of the blood vessels and it shows decrease during the menstrual 
phase of the cycle [15]. Also, fibronectin[16] and thrombospondin[17] , in 
addition to various matrix metalloproteinases (MMPs),which can breakdown the 
basement membrane are involved.  
There are leukocyte populations present within the endometrial stroma. These 
populations vary in type and number in the endometrium across the menstrual 
cycle and throughout the pregnancy. Endometrial leukocytes include T and B 
cells, mast cells, neutrophils, macrophages, and uterine natural killer cells (uNk). 
Details about each immune cell are presented later in this thesis(chapter 4). 
Regardless of the variation in endometrial leukocyte populations within the 
endometrium throughout the menstrual cycle, interestingly, all of them increase 
significantly in late secretory phase and during the menstruation. These cyclical 
changes in immune cell number implicate direct or indirect regulation by sex 
steroid hormones, whether oestrogen and /or progesterone. However, the 
majority of leukocyte populations do not express the classic ERα or PR. 
Therefore, the control of their appearance by the ovarian sex hormones is most 
likely to be indirect. Nevertheless,  uNK immune cells display ERβ and 
glucocorticoid receptors (GR) [18],which raisesthe possibility concept that 
oestrogen and glucocorticoids act directly on uNK cells to influence gene 
transcription in the endometrium and decidua [18].  
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Monoclonal antibodies used in immunohistochemicalanalysishave a vital role in 
distinguishing endometrial leukocyte from peripheral immune cells. However, it 
is not clear whether the increased immune cell number within the endometrial 
stroma is solely the result of in situ proliferation or whether there is also influx 
of immune cells from the peripheral circulation into the endometrium.  In 
addition, many of the endometrial leukocytes display different phenotypes, and 
subtypes, where some have been described to express MMPs and to release 
cytokines and protease.  
Each Endometrial leukocyte population has different roles in the endometrial 
stroma according to their time of up-regulation across the menstrual cycle, their 
ability to release or activate cytokines and their activation pathway. For 
instance, the largest leukocyte population in the endometrium during the late 
secretory phase and pregnancy comprises uNK cells [18, 19]. These cells are 
located in the endometrium in close contact with endometrial glands and spiral 
blood vessels, which suggest a role in vascular growth and remodelling [20]. In 
addition, the uNK cell is the main type of leukocyte in the endometrial stroma 
during implantation, placentation and decidualization[19, 21, 22]. These 
immune cells may have a strong relationship with the uterine stromal cells, as 
interleukin 15(IL15), prolactin and some soluble factors, which are released by 
the uterine stromal cells, may mediate the effect of oestrogen and progesterone 
on uNk cells [23, 24]. This relationship is supported by the strong association 
between ectopic decidua and presence of uNK cells [19]. 
Neutrophils generally have faint endometrial expression across the menstrual 
cycle, however, neutrophils show abundant expression immediately before 
menstruation[25]. This sudden influx of neutrophils into the endometrium is 
timed with the withdrawal of progesterone, and this raises a thought that 
withdrawal of progesterone triggers the infiltration of neutrophils into the 
endometrial stroma. Neutrophils have the ability to synthesise and release a 
wide range of immunoregulatory cytokines and hence initiate and augment the 
cellular and humoral immune  response [26]. In addition, many studies have 
pointed out the role of neutrophils in mucosal defence as well as in 
menstruation [27, 28].  
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Another type of leukocyte in endometrium is the macrophage which displays a 
cyclical pattern of expression across the menstrual cycle, and corresponds to 
approximately 20% of endometrial leukocytes in the late secretory phase [22, 25]. 
Macrophages also produce a wide range of regulatory molecules which may have 
a role in stimulating  production of pro-inflammatory cytokines from adjacent 
cells[25].  
The Mast cell is another uterine leukocyte, although there is no change in the 
number and the distributions of mast cells across the menstrual cycle. Mast cells 
are activated in late secretory phase before menstruation, giving a suggestion of 
a role of mast cells in upregulation of MMP before the onset of menstruation [29-
31]. Mast cells are characterised by its content of tryptase alone or tryptase and 
chymase[32]. 
1.3 Steroid hormones and their receptors in 
endometrium 
The ovarian sex steroid hormones, oestrogen and progesterone have the main 
role in the cyclical endometrial proliferation and degeneration. These 
endometrial changes are under the control of variation in steroid hormones 
concentration[33].  The response to this fluctuation in steroid hormones is 
mediated by oestrogen and progesterone receptors (ER and PR respectively). The 
classical oestrogen and progesterone receptors are nuclear receptors ,which 
localise between the cytoplasm and the nucleus[34]. 
The endometrium contains stromal, epithelial glandular and endometrial 
vascular cells, in addition to perivascular endometrial cells. The sex steroid 
receptors have been expressed temporally and spatially in the endometrium [14].  
Endometrial proliferation is under the control of oestrogen and endometrial 
repair, therefore, is thought to be an oestrogenic event. Progesterone, on the 
other hand, exerts anti-oestrogenic effects by inhibiting the endometrial 
proliferation and enhancing the glandular differentiation. However, interestingly, 
these progesterone effects are mediated through its receptors, which only exist 
in oestrogen primed endometrium. Thus, the presence of PR indicates a 
functional ER pathway. Both oestrogen and progesterone receptors are up-
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regulated in stromal and epithelial glandular cells during the proliferative phase, 
while ER reaches the peak of its expression in the late proliferative/early 
secretory phase. During the secretory phase, there is reduction in the expression 
of both oestrogen and progesterone receptors particularly in epithelial glands 
due to the action of progesterone at the transcriptional and post-transcriptional 
level.  
Oestrogen and progesterone receptors are expressed in different subtypes. For 
instance, the ER has two subtypes known as ERα and ERβ, each of them resulted 
from distinct genes. Furthermore, their level of expression is variable in 
different cellular compartment in the endometrium. ERβ exist in splice variants 
ERβ1 and ERβCX/ ERβ2 in the endometrial stromal cells and the epithelial glands 
in both functional and basal layers of endometrium. In the smooth muscle of the 
uterine wall, the expression of ERα and ERβ is demonstrated during the 
proliferative phase with higher expression of ERα than the expression of ERβ. On 
the other hand, the ERα mRNA and protein are reduced in its expression within 
the functional layer of the endometrium during the secretory phase, and 
characterised by sharp decline in the stromal cells, although there is a gradual 
decline in epithelial glandular cells[35]. ERβ1 maintains its level across the 
menstrual cycle, and ERβCX/β2 decreases in the glandular epithelial of the 
functional layer in the mid-secretory phase [36, 37]. ERα has been identified in 
perivascular cells but not in the endothelial cells. On the other hand, ERβ is 
largely detected in endothelial cells of blood vessels within the endometrium in 
late secretory phase and in the perivascular cells as well as [14, 38]. In addition, 
ERβ has been found in the uNK cells in endometrium [18].  
The progesterone receptor is also present in two subtypes, known as PRA and 
PRB. In contrast to the ER, PR subtypes are transcribed from two different 
promoters that originated from one single gene. The PRA has a shorter amino 
acids chain than that of PRβ. By there, the PRA is considered to be a shorter 
form of PRB. Each isoform has an individual transactivational function which is 
different for each cell type and ligand. However, PRB is transcriptionally more 
active than PRA [39, 40]. On the other hand, PRA can block PRβ and stop the ER 
activity in several instances. Both isoform are up-regulated during the mid to 
late proliferative phase in both endometrial glandular and stromal cells. In 
addition, both of them are decline in endometrial glandular cells during the 
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secretory phase due to high levels of progesterone. Nevertheless, PRA remains 
prominent in the stromal compartment mainly around the endometrial 
vasculature during the secretory phase, and could be the main isoform mediating 
the progesterone action in endometrium during this phase [41, 42]. Both PR 
subtypes are not present in endometrial endothelial cells or leukocytes, 
indicating an indirect action of progesterone on them.  PR receptors are 
expressed in the basalis layer of endometrium throughout the menstrual cycle, 
demonstrating different regulatory factors of this deeper layer of the 
endometrium than these of the superficial shedding layer [35]. 
Whereas the transcriptional effect of oestrogen and progesterone is mediated by 
classical nuclear receptors, alternative membrane receptors may be involved in 
their non-genomic action [43, 44]. Furthermore, in previous study, fast signal 
beyond the nuclear compartment was noted for both oestrogen and 
progesterone, which may be mediated via non-nuclear transduction pathway 
[45]. 
1.4 Prostaglandins 
Prostaglandins are lipid-derived eicosanoids that modulate many biological 
functions in several body systems including the CNS, cardiovascular, 
gastrointestinal, genitourinary, endocrine, respiratory, reproductive, and 
immune systems[46]. In addition, the prostaglandins have been implicated in a 
wide range of diseases including cancer, inflammation, cardiovascular disease, 
hypertension, and reproductive dysfunctions. Prostaglandins are potent bioactive 
messengers derived from the arachidonic acid (AA), which first extracted from 
the male reproductive tract in 1930s, and noted to decrease the blood pressure 
and cause smooth muscle contraction. The first prostaglandin isomers were 
identified in 1950s and 1960s, and may be divided according to the substituents 
in their cyclopentane ring into the A, B, C, D, E, F or J series. Later arachidonic 
acid (20-carbon tetraenoic fatty acid) was identified as precursorof 
prostaglandins, and the later known as a C20 carboxylic acid related family. The 
activation of phospholipase enzyme results in liberation of the arachidonic acid 
from plasma membrane phospholipids or dietary fat. The cyclooxygenase (COX) 
reaction through which AA is enzymatically cyclised and oxygenated to yield 
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endoperoxide-containing prostaglandin G2 (PGG2) is completed by adding the 
15-hydro-peroxy group, and then followed by a reduction in that group to a 
hydroxyl group via a separate peroxidase active site on the enzyme, as result an 
intermediate form of prostaglandins known as prostaglandin H2 (PGH2) is formed 
[47, 48] (Figure 1.5). Isomerases and oxidoreductases produce various bioactive 
prostaglandin isomers using PGH2 as substrate, and these are named according 
to the synthase enzyme, for instance, prostaglandin E2(PGE2) is synthesised by 
prostaglandin-E-synthase (PGES), prostaglandin F2α (PGF2α) is synthesised by 
prostaglandin-F-synthase (PGFS),prostaglandin D (PGD) is produced by 
prostaglandin-D-synthase (PGDS),prostacyclin (PGI2) by prostaglandin-I-synthase 
(PGIS),and thromboxane A2 (TXA2) by thromboxane synthase (TXS)[46, 49]. 
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Figur1.2: Depiction of Prostaglandins synthesis from arachidonic acid by cyclooxygenase 
pathway (cyclooxygenase1 and 2, Cox1 & COX2 respectively). Prostaglandin G2 as 
precursor to other types of prostaglandins as following: prostaglandinE2 (PGE2) by 
prostaglandin-E-synthase (PGES), prostaglandin F2α (PGF2α) by prostaglandin-F-synthase 
(PGFS), prostaglandin D (PGD) by prostaglandin-D-synthase (PGDS), prostacyclin (PGI2) by 
prostaglandin-I-synthase (PGIS), and thromboxane A2 (TXA2) by thromboxane synthase 
(TXS). 5-hydroperoxyeicosatetraenoic acid (5- HPETE) synthesis by 5-lipoxygenase and 11, 
12&15Hydroxyeicosatetraenoic acid (11, 12&15-HETE) synthesis by11, 12 or 15- 
lipoxygenase. 
 
Induction of prostaglandin by mitogens and proinflammatory agents, as well as 
down-regulation of prostaglandin by glucocorticoids was the most presenting 
data regarding the potential of more than one COX behind this. In addition, 
observational data indicated that prostaglandin synthesis and release is different 
in some situations, such as in activated platelets, where it occurs within a few 
minutes after stimulation. In other cases, such as in mitogen-stimulated 
fibroblasts, prostaglandin synthesis may take longer (hours) to occur. 
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Furthermore, many investigators observed that prostaglandin induction as well 
as increased level of PG can be occurred without or with minimal an increase in 
the seminal vesicle COX enzyme which was found to be present in most cells and 
tissues investigated [50].  Also the action of glucocorticoids on PG synthesis and 
seminal vesicle COX levels is not completely understood, which strongly 
decreased PG synthesis but generally had little to no effect on seminal vesicle 
COX levels. Various hypothesises were suggested a consistencybetween these 
observed phenomena, and the most common of which was that changes in 
substrate delivery were responsible for these fluctuations in PG synthesis. 
Some authors haveconcluded that monocytes may contain two pools of COX under 
lipopolysaccharide stimulation, witheach of them with a different sensitivity to the 
lipopolysaccharide. Another study used giant two-dimensional protein gel 
electrophoresis, proteins immunoreactive with COX-1 antibodies that were induced in v-
src-transformed cells[51, 52]. The evidence in these and other early studies was 
consistent with two different inducible and constitutive COX isozymes encoded by 
separate genes but was also compatible with other explanations. Studies of cell division 
helped to demonstrate the mechanism by which COX enzymes upregulate the PG 
production in inflammation and other physiological condition [53, 54]. Later on, a new 
inducible COX enzyme was reported from studies in chicken and mouse [55, 56], 
contributing to the identification of COX-2. Thus the inducible enzyme cloned in these 
studies referred to as COX-2 and the seminal vesicle form of the enzyme as COX-1.  
Different COX-1 splice variants have been identified in different species, and one of 
these is a brain specific splice variant identified in dog and termed COX3. This consists 
of an intact and unspliced COX-1 transcriptthat retains intron-1.The COX-3 variant 
produces protein thought to havethe ability to reduceprostaglandin synthesis relative to 
COX-1.  Analgesic/antipyretic drugs such as acetaminophen and dipyrone favourably 
inhibit this activity[57]. 
The biological action of prostaglandins is mediated through their receptors, 
which are designated by the letter P and a prefix D, E, F, I and T, and have the 
form DP, EP, FP, IP and TP referring to PGD, PGE, PGF, PGI and TXA2respectively.  
PGE2 exerts its effect through four subtype receptors, EP1, EP2, EP3, EP4.  
These receptors are G-protein coupled receptors using alternate and sometimes 
opposing intracellular pathways.  These receptors are derived from a separate 
gene, with extra splice variant for EP3,FP, and TP which are different in their C-
terminal [58]. FP, TP, and EP1 receptors specially couple in response to an 
increase in cell calcium and induce Ca mobilisation via Gαq, leading to smooth 
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muscle contraction to be contractile receptors. EP2, EP4, DP, and IP receptors 
stimulate cyclic adenosine monophosphate (cAMP) via Gαs and are called 
relaxant receptors as they cause smooth muscle relaxation, whereas the EP3 
receptor preferentially couples to Gi, inhibiting cyclic AMP generation, and is 
thus called an inhibitory receptor which causes smooth muscle contraction. 
However, some of EP3 splice variants in specific cell types can elevate the cAMP 
[58]. 
In addition to the prostanoids that act principally via plasma membrane-derived 
G-protein-coupled receptors, several COX products can activate nuclear 
receptors of specific classes, and stimulate the nuclear receptor pathway [59]. It 
was found that these nuclear-acting prostanoid ligands inhibit the IκB kinase 
activity and thereby block the NFκB transcription factor pathway [60], 
suggesting that nuclear-acting prostanoids may act to down-regulate 
angiogenesis [61],and raise the possibility that the COX pathway may induce 
anti-angiogenic effects by nuclear-acting prostanoids. Therefore,a number of 
COX-2-selective inhibitors have been developed to control the anti-inflammatory 
and anti-neoplastic activities of the COX-2 isoenzyme. Inhibition of the COX 
isoenzyme activity and/or expression may be the basis of future development of 
anti-inflammatory and anti-neoplastic drugs. 
Cross communication between some prostanoid receptors (EP2 and FP) and 
epidermal growth factors receptors has been demonstrated, resulting in 
activation of receptor tyrosine kinases (RTKs). The signal mechanism behind this 
activation is not fully elucidated. However, many intracellular and extracellular 
mechanisms have been suggested involves auto-phosphorylation of RTKs, 
activation of transmembrane matrix metalloproteinase and extracellular release 
of heparin binding epidermal growth factor (HB-EGF),and phosphorylation of the 
mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 
signalling pathway [62, 63].  
 The physiological role of prostanoids is complex.However, recent progress in 
understanding both the disruption of the effects of respective gene and the use 
of receptor selective compounds gives insight into the physiological role for each 
receptor. It has been demonstrated that each prostanoid receptor has multiple 
functions, and that their expression is regulated in a context dependent manner 
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that sometimes results in opposite, excitatory and inhibitory, outcomes. In 
addition, the balance of prostanoid production and receptor expression has been 
demonstrated to be important for homeostasis of the human body[64]. 
1.5 Vascular endothelial growth factor (VEGF) 
This cytokine is produced by endothelial cells is hypoxic conditions and it exerts 
its effect by binding to two types of tyrosinase kinase receptors on the 
endothelial cells. These are VGEF receptor 1, which is responsible of the 
organization of endothelial cells in tubes, and VGEF receptor 2, that induces 
endothelial cell migration and proliferation. Both receptors are upregulated in a 
hypoxic environment (Figure 1.8). VGEF is a glycoprotein and has a role in 
enhancing the mitosis of endothelial cells as well as their permeability. The 
most important form is VEGF 165.  
 
1.6 Cytokines (interleukin 8) 
Interleukin (IL)-8 is a member of the C-X-C family of chemokines that has high 
affinity binding to G- protein coupled receptors, IL8-1 (CXCR1) and IL8-2(CXCR2), 
a G-protein-activated second messenger system. [65, 66]. The IL8-1 is more 
specificIL-8, while the CXCR2 is less specific to IL8 and responds to several 
additional chemokines including growth-related protein-α (GRPα), neutrophil-
activating peptide-2, and epithelial-derived neutrophil attractant-78[65, 67]. 
The common characteristic shared by all chemokines that activate the CXCR2 is 
a specific sequence in the amino terminus, which seems to function as a 
recognition sequence for receptor binding and activation. 
Early studies concentrated on the effect of IL-8 on neutrophils. It has been found 
that neutrophils respond to IL-8 in different mechanisms including, calcium 
mobilisation, actin polymerisation, enzyme release and chemotaxis [68, 69].It is 
thought that CXCR2 may play an active role in the initiation of neutrophil 
migration distant from the site of inflammation, where the concentration of IL-8 
is at the picomolar level. The low affinity CXCR1 may play a more active role in 
mediating IL-8 signal at the site of inflammation, where the concentration of IL-
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8 is high[70],indicating that neutrophil chemotaxis is primarily mediated by the 
CXCR1.  
Apart from neutrophils, many cell types have been shown to express IL-8 
receptors. These cell types include monocytes, macrophages, and endothelial 
cells [71, 72]. Although activation of the CXCR2 can enhance cell proliferation 
oftumour cells[73], the physiological role of IL-8 receptors on non-hematopoietic 
cells is not fully understood, however,  a role in cell movement is expected [74]. 
IL8 like other related chemokines, which have NH2 ELR sequence, may have 
angiogenic properties. It has been suggested that the CXCR2 is the endothelial 
cell receptor that mediates this angiogenic response, because of the 
chemotaxicproperty of IL8; it causes cytoskeletal rearrangement due to 
activation of both the CXCR1 and the CXCR2. However, both temporal and 
qualitative differences exist between the behaviour of the two receptors. 
Consequently, progressive receptor activation through two signalling pathways 
may regulate endothelial cell cytoskeletal responses to IL-8. In addition, in 
fibroblast, through activation the small G protiens (Cdc42, Rac, and Rhc), IL8 
may help in forming a meshwork of actin filament at the leading edge of 
migrating cells [75]. Furthermore, formation of stress fibre can be enhanced by 
the activation of Rho protein, and then inserted into focal adhesion complexes. 
In fibroblasts, the activities of these three proteins thought to be arranged in a 
ranked manner, where activation of one of them turns to activate the other. 
However, depending on cell type and possibly the activation pathway, the 
relationship between the different small G proteins may vary. In the endothelial 
cells, activation of Rac protein by thrombin leads to endothelial cells retraction 
[76]. In addition, it was reported that IL-8 initially activates Rho and actin stress 
fibre formation in endothelial cells due to activation of the CXCR1. Afterward, 
Rac is activated in a CXCR2-dependent manner, leading to cell retraction and 
gap formation between adjacent cells. 
1.7 Angiogenesis in the normal endometrium 
Angiogenesis is the development of new microvessels from existing vessels and it 
involves microvascular endothelial cells. Physiological angiogenesis rarely occurs 
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in adults except during episodes of wound healing, and in the ovary and the 
endometrium during the reproductive life of females. Angiogenesis is vital for 
development and differentiation of human endometrium that are necessary for 
implantation, as well as for maintenance of pregnancy [77].The rapid cyclic 
growth of the endometrium demands a dynamic changing of its vascular supply. 
A complex process of vascular and glandular proliferation, differentiation, 
sloughing and regeneration occurs each month. These periodic alterations are 
applied to most of endometrial compartments and are controlled largely by 
ovarian steroids. Theses massive changing throughout the menstrual cycle 
(discussed above in the proliferative and secretory phases), including increased 
glandular cells, stromal fibroblasts, and vascular endothelial cells, and 
enlargement of endometrial glands during the proliferative phase and 
differentiation to cells of the functional layer of the endometrium, increased the 
ratio of glands to stroma, stromal oedema and stromal cell decidualization take 
place during the secretory phase. This cyclic growth of the endometrium is 
accompanied by extensive vascular modification in the horizontal branches 
supplying the basal layer and vertical branches supplying the functional layer, 
and more obvious in the spiral arteries and end-arterioles, which play a critical 
role in the regulation of uterine bleeding during the menstrual cycle. These end 
arterioles are highly sensitive to ovarian steroids, where it is noticed that the 
endometrial vascular architecture changes throughout the menstrual cycle, 
corresponding to the changes in the uterine epithelium and stroma. Moreover, 
there is a gradual increase in branching and coiling of spiral arterioles, in 
parallel to an increase in the length and coiling of endometrial glands.  
Vasoconstriction of the distal segments of the spiral arteries occurs in response 
to progesterone withdrawal, and 4 days laterdiffuse necrosis, inflammation, and 
vascular thrombosis occurs resulting in menstruation.  
The serial events that lead to angiogenesis begin through stimulation of the 
endothelial cell by hypoxia. As consequence, activation of the endothelial cell 
with production of vascular growing factors takes place.Migration of the 
endothelial cells with disruption of the basement membrane seems to be a first 
event, followed by proliferation and the formation of tubes with periendothelial 
support.  Subsequently a new blood vessel is formed. The promotion of migration 
of endothelial cells is a complex process where proteases like plasmin have a 
critical role in stimulating the migration of endothelial cells across the matrix of 
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the cells. Multiple studies have demonstrated the importance of smooth muscle 
cells together with endothelial cells in the process of developing new blood 
vessels (Figure1.3). It is thought that proliferation of smooth muscle cells is an 
intrinsic element in angiogenesis. Many of these mechanisms are mediated 
through cytokines, which act by binding to tyrosinase kinase membrane 
receptors.  
 
Figure 1.3: Figure showing the migration and proliferation of endothelial cells and smooth 
muscle cells during the formation of new blood vessels from existing blood vessels. 
 
1.7.1 Growth factors and angiogenesis 
Following menstruation, endometrial vessels in the shedding layer need to be 
reconstructed. Therefore, development of endothelial cells and smooth muscle 
cells is promoted to form capillaries and larger vessels [10]. This process of new 
vasculaisation is promoted by several angiogenic factors [78]. The main 
angiogenic factor is vascular endothelial growth factor (VEGF), also termed 
vascular angiogenic factor.  
It is known that ovarian steroid hormones regulate changes in the human 
endometrium during the menstrual cycle, and endometrial cells are very 
sensitive to oestrogen. Growth factors can regulate endometrial proliferation 
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and differentiation and may mediate the effects of oestrogen and progesterone 
on the endometrium in an autocrine and /or paracrine manner. Although the 
effects of growth factors and sex steroids on epithelial and stromal development 
have been investigated in several studies, little is known about factors that 
affect the endometrial vasculature throughout the menstrual cycle. It is thought 
that endothelial cells do not respond directly to oestrogen or progesterone, and 
growth factors may play a role as local mediators of the effects of ovarian 
steroids on endometrial vessels. The angiogenic basic fibroblast growth factor 
(bFGF) has been excluded as mediator of endometrial angiogenesis, as its levels 
do not change in human endometrial biopsies during the menstrual cycle and 
increase after menopause. On the other hand, vascular endothelial growth 
factor (VEGF) peptide and mRNA are present in human endometrial biopsies 
obtained during all phases of the menstrual cycle and VEGF is localised to both 
glandular epithelium and stroma. Consistent with the hypothesis that VEGF may 
be a paracrine regulator of the effects of sex steroids on endometrial 
angiogenesis, VEGF gene expression is increased by the addition of estradiol to 
human endometrial carcinoma cell lines. Estradiol also increases VEGF 
expression by primary human endometrial cells in culture. These observations 
suggest that VEGF may play an important role in the regulation of endometrial 
angiogenesis throughout the human reproductive cycle (Figure 1.4). Therefore, 
VEGF is thought to play a crucial role as endothelial cells growth and survival 
promoter. It appears that VEGF expression in the whole endometrium is low 
during the proliferative phase, increases during the secretory phase and reaches 
the maximum levels during menstruation. This supports a hypothesis which 
suggests induction of hypoxia rising from constriction of spiral arterioles, which 
precedes bleeding, leads to increased production of VEGF by endothelial cells to 
promote angiogenesis. However, there is no clear pattern of VEGF protein 
expression throughout the menstrual cycle, although expression is greater in 
glands than stroma. 
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Figure1.4: Figure showing the VEGF signalling pathway in endothelial cell 
 
 
1.7.2 Cyclooxygenases and angiogenesis 
Cyclooxygenase enzymes (COX) (prostaglandin H2 synthase) are the enzymes 
responsible for the conversion of arachidonic acid from membrane phospholipids 
to prostaglandin H2 (PGH2), the common precursor of various forms of PGs. The 
main two COX isomers, COX-1 and COX-2 consist of 600-602 (depending on the 
species) and 604 amino acids, respectively. Despite a similarity in the primary 
structures, the isoenzymes show differences in the patterns of expression and 
cellular function. COX-1 is found constitutively expressed in most mammalian 
tissues and helps in maintenance of the cellular physiological functions, such as 
platelet aggregation and cell homeostasis. COX-2 is normally expressed at a very 
low level in most tissues and is highly inducible by growth factors, cytokines, and 
tumour promoters. Cyclooxygenase-2 exerts its effects through its reaction 
products. Cyclooxygenase-2 is found to be expressed in newly formed blood 
vessels within tumours grown in animals, which suggested that cyclooxygenase-2 
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modulates angiogenesis by augmenting the release of angiogenic peptides, such 
as VEGF, thymidine phosphorylase, bFGF, and nitric oxide. On the other hand, 
VEGF can induce COX-2 via multiple mechanisms and that COX-2 can increase 
VEGF via hypoxia inducible factor-1 (HIF-1). The role of COX-2 enzyme in 
angiogenesis further exacerbated by decreasing the anti-angiogenic factor 
 
 
1.7.3 Prostaglandins and angiogenesis 
Prostaglandins are part of a family of biologically active lipids derived from 
arachidonic acid by the action of phospholipase. Terminal PGs are subsequently 
produced by specific prostaglandin synthase enzymes from PGH2. In the case of 
PGE2 and PGF2α, it was found that microsomal prostaglandin E synthase-1 and -2, 
cytosolic prostaglandin E synthase, and prostaglandin F synthase are expressed in 
the human endometrium. Prostaglandins have a primary role in pathological 
conditions such as inflammation, hypertension and cancer but are also essential 
for normal physiological function such as in the female reproductive system. 
Prostaglandins are important regulators of endometrial function. Their secretion 
is controlled by both endocrine and paracrine mediators. Potential paracrine 
regulators of endometrial origin include cytokines, growth factors and histamine. 
Therefore, the levels of prostaglandins in the human endometrium throughout 
the normal menstrual cycle are variable. For instance, the levels of 
prostaglandin F2α and prostaglandin E2 are low during the proliferative phase of 
the cycle and both of them have nearly similar level in this phase. However, 
prostaglandin E2 rises significantly during the secretory phase, put remains lower 
than the level of F2α during the secretory phase. The prostaglandin E2 level is 
highest at menstruation. Dysregulation of endometrial prostaglandins production 
can cause menstrual cycle disorders, infertility and uterine malignancies. PGs 
are not stored within cells, but are synthesized as required in response to stimuli. 
The first step in their synthesis is the release of arachidonic acid from the 
cellular phospholipids, by the action of the enzyme phospholipase A2. Following 
biosynthesis, prostaglandins exert their function through G protein coupled 
receptors. If COX-2 activity increases in cells, its metabolite (PGE2), affects 
metabolic pathways via specific receptor subtypes (EP1-EP4 for PGE2), EP2 is 
likely important in the epithelial cell compartment, whereas EP4 is highly 
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expressed in stromal and hematopoietic cells. Both receptors are coupled to the 
heterotrimeric Gs protein and regulate the cAMP/protein kinase-A pathway. It is 
thought that cyclooxygenase 2 (COX-2) COX-2 in the epithelial compartment 
signals via the EP2 receptor in an autocrine manner and via the EP4 receptor in a 
paracrine manner. PGE2 is a potent inducer of angiogensis and induces the 
expression of angiogenic regulatory proteins such as VEGF. On the other hand, it 
sis suggested that VEGF induce COX-2 mRNA expression, hence it increases the 
PGE2 concentration in the surrounding area. Afterward, PGE2 enhance the 
expression of VEGF. So it seems that PGE2 directly stimulates the angiogenesis, 
a part of VEGF signalling, and further induces VEGF expression. In addition, the 
effect of VEGF on angiogensis may be mediated by PGE2 secretion. . It is thought 
that PGE2 may up-regulate HIF-1 mRNA and protein via the EP2 receptor and this 
upregulation is dependent upon epidermal growth factor receptor (EGFR) kinase 
activity. The endometrial HIF-1 activation may occur via a PGE2-regulated 
pathway. 
 
 
1.8 The role endometrial immune cells in angiogenesis 
It is well known that the hormonal and local immune response is involved in the 
recognition and maintenance of pregnancy and it is suggested that alternations 
in the local immune system are controlled by steroid hormones, secreted by the 
ovary and placenta. When no pregnancy happens, the same immune cells are 
involved in changes in the endometrium that result in menstruation. 
The withdrawal of progesterone from the endometrium is associated with 
features similar to an inflammatory event, where this up-regulate some 
inflammatory mediators and induce COX-2. These local events result in an 
elevation of local prostaglandin concentrations (PGE and PGF2α) and there may 
be synergism with the chemokine IL-8. The substantial peri-menstrual influx of 
leucocytes consists of neutrophils, macrophages and other immune cells that 
influx from circulation. These leukocytes themselves are sources of cytokines 
that further augment leukocyte influx. There is infiltration of leukocytes and 
release of prostaglandins as well as development of stromal oedema. Interleukin 
8(IL-8) as a-chemokine, is chemotactic for both neutrophils and natural killer 
cells (NK), having a perivascular setting in the human endometrium. 
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Furthermore, IL-8 mRNA expression is also localised to the perivascular cells of 
late secretory endometrium. IL-8 is produced by monocytes and fibroblasts and 
there is evidence that it has an angiogenic character.  Furthermore, the action 
of IL-8 may directly affect endometrial cell proliferation. The important 
relationship between PGE2 and IL8 may have an important effect on neutrophil 
chemotaxis, which is markedly elevated by low levels of PGE. 
Most studies have not demonstrated the connection between expressions of 
endometrial angiogenic factors and new vessel growth. However, it was found 
recently that a strong relationship exists between vascular endothelial growth 
factor (VEGF) immunolocalised in intravascular neutrophils and endothelial cell 
proliferation in each of the subepithelial capillary plexus, functionalis and 
basalis regions of the human endometrium. There is an indication that the 
neutrophil VEGF has a role in the development of the subepithelial capillary 
plexus and functionalis microvessels during the proliferative phase of the 
menstrual cycle. It has been suggested that neutrophils are an intravascular 
source of VEGF for vessels that undergo angiogenesis by intussusception and 
elongation. 
 
1.9 Menstruation: 
Human endometrium is subjective to cyclical changes throughout a women’s 
reproductive life. These changes represented in injury and repair and are 
regulated by steroid hormones. Oestrogen and progesterone are the two 
principal sex steroids influencing endometrial growth, differentiation and 
function, and they are implicated in endometrium pathology as well. Nowadays, 
there is a great knowledge about the role of steroid hormones in the onset of 
menstruation and in the process of endometrial repair.  Simply, menstruation is 
a shedding of the superficial layer (functional layer) of the endometrium. 
Sequential events occur before, during and after this vital event. Menstruation is 
a complicated process that has been described as inflammatory pathway [79].  
 
1.9.1 The mechanism of normal menstruation 
The menstrual cycle is a physiological process regulated by a complex hormonal 
system with positive and negative feedback mechanisms. This mechanism is 
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associated with changes in sensitivity of peripheral tissues. Regular, pulsatile 
secretion of gonadotrophin releasing hormone (GnRH) from the hypothalamus is 
the primary event to drive the system. In response to this secretion, the 
pituitary gland releases follicle stimulating hormone (FSH) and luteinizing 
hormone (LH). The FSH facilitates the action of LH on the ovary, which in turn 
permits the synthesis of estradiol and progesterone, following by negative 
feedback of estradiol and inhibin on the hypophysis cerebri. Ovulation is caused 
by peak levels of LH, but it is dependent on progesterone levels. Synthesis of 
progesterone by the corpus luteum precedes the negative feedback of 
progesterone at the hypothalamic level. At the endometrial level (the functional 
layer) the number of sex steroid receptors increases during the proliferative 
phase and decreases during the secretory phase. In the absence of pregnancy, 
the corpus luteum is collapsed leading to a rapid decline in the ovarian steroids 
hormones, which triggers a compound of events within the functionalis layer of 
endometrium.  Induction of menstruation was blocked by adding-back 
progesterone up to 36 hours  following the decline in steroid hormones, but no 
suppression of menstruation  occurred after 36 hours  [80]. This observation 
gives a suggestion that menstruation occurs as result of withdrawal of 
progesterone, and the different up-regulation of PR across the menstrual cycle 
may influence this action as an early events through PR- positive cells and later 
it depends on PR –negative cells. 
 
Markee and his colleagues in 1978 transplanted a fragment of human 
endometrium into the anterior chamber (iris) of rhesus monkey’s eyes and his 
direct observations have provided the initial understanding of the mechanism of 
menstruation. The development of the implanted graft involved progressive 
episodes including, increased the coiling of spiral arterioles, vascular stasis, 
alternation of vasoconstriction and vasodilatation episodes, and perivascular 
bleeding. Marked regression of the developed grafts was noted after oestrogen 
and progesterone withdrawal [11]. All these previous events may be caused and 
controlled by wide range of molecular and cellular mechanisms. Some of these 
mechanisms are well understood and others need to be fully elucidated.  
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Proinflmmatory mediators, such as prostaglandins and cytokines, for instance, 
are produced by perivascular cells in response to the concentration of 
progesterone.  In addition, the spiral arterioles themselves may have a role in 
menstruation through a vasoconstriction and enhance leukocytes influx into the 
endometrium. The prostaglandins act as proinflammatory mediators and they 
are locally produced from the arachidonic acid by the action of cyclooxygenase 1 
and 2 .The expression of prostaglandins in many compartments of endometrium 
varies across the menstrual cycle and tends to increase during menstruation. For 
instance, prostaglandin F2 α (PGF2 α) causes vasoconstriction of blood vessels and 
leads to reduction in  the blood flow to the endometrium[33]. PGF2α is 
upregulated during the mid-secretory phase and still has high expression during 
the menstruation. On the other hand, prostaglandin E2 is responsible for 
vasodilatation and it is mainly increased during the menstruation with less 
concentration than that of PGF2α [81]. Upregulation of prostaglandins is 
associated with increase in the expression of locally acting mediators such as 
interleukins, angiogenic factors, and protease enzymes all these mediators 
which thought to have a role in infiltration of leukocytes into the endometrium 
and some leukocytes can release and activate cytokines as well.  
All these events have guided authors who searching the menstrual event to 
describe the mechanism of menstruation process as interaction between ovarian 
hormones and immune system [82] and in other ward it is an inflammatory 
process under the control of the ovarian hormones[79]. 
 
 
1.10 Heavy menstrual bleeding (HMB) 
Menstruation has been described as an inflammatory event with a complex 
interaction of sex steroids, prostanoids and cytokines leading to tissue 
degradation followed by a coordinated process of tissue regeneration and repair. 
The mechanism starts with progesterone withdrawal of which leads to up-
regulation of COX-2 and subsequent generation of the potent vasoactive 
prostaglandins PGE2 (a vasodilator) and PGF2α (a vasoconstrictor). Heavy 
menstrual bleeding, which was formally known as menorrhagia, is defined as 
excessive menstrual blood loss that interferes with women’s physical, emotional, 
social and quality of life[83]. 
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 In 1966 a Swedish study, which was based on measuring the haemoglobin in the 
menstrual blood loss, found that the average of menstrual blood loss was about 
40 ml, and that the incidence of anaemia among women who complained of 
heavy menstrual bleeding increased with menstrual blood loss more than 60ml 
per menstrual cycle and 90% centile of the distribution represented the cut-off 
point in the objective defining of heavy menstrual bleeding (≥80ml/per 
menstrual cycle)[84]. Nevertheless, clinically, approximately 50% of women 
complaining of HMB have objectively measured blood loss of  80ml or less[85]. A 
wide range of population may suffer HMB in their reproductive age (10-30%), 
which may broaden and affect half of them of perimenopausal age [86]. In the 
UK, nearly 800,000 women every year are seeking medical advice because of the 
highly socio-economic impact of this condition[83], and in earlier report about 5% 
of women would ask for medical advice because of the condition and fifth of 
those women are at risk of hysterectomy because of the condition[87]. 
 
 
1.10.1 Heavy menstrual bleeding in normal uteri 
In the absence of microscopic and/or macroscopic appearance of uterine 
pathology, heavy menstrual bleeding known as idiopathic HMB, and clinically 
called dysfunction uterine bleeding [88]. The vast majority of women with HMB 
have normal endometrium. Nevertheless, a small proportion of those women 
may have a defective clotting mechanism, such as Von Willebrand’s disease [89, 
90] and deficiency of PAI [91]. Progesterone may have the ability to stimulate 
the protease inhibitors as plasminogen activator inhibitor -1 (PAI-1)[92]which 
can result in enhancing the thrombus formation. In normal menstruation, 
progesterone withdrawal, which is the key event in menstruation, may stimulate 
the secretion of plasminogen activator and opposite the previous action. 
Therefore, the reduction in the clotting function is a feature of menstruation, 
and clotting deficiencies diseases are most properly co-factors or a combination 
of factors resulting in HMB.  
The incidence of HMB in women with normal uteri could be a result of 
disturbances in the local endometrial environment. This modification could be 
mediated by alternations in the expression, signalling and receptors of local 
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endometrial factors, which have important role in the establishment and 
maintenance of vascular haemostasis.  Genetic factors may have a role in the 
heavy menstrual blood loss as well, where there was a link between the 
menstrual blood loss in monozygotic but not in dizygotic [93]. 
 
1.10.1.1 Cytokine alternations 
It is widely agreed that menstruation is mainly an inflammatory response of 
endometrium to withdrawal of progesterone. Hence, an aberration in this 
mechanism can lead to heavy menstrual blood loss. The pro-inflammatory 
cytokine transforming growth factor-α (TGF-α) was found to be increased in 
menstrual effluent in women with heavy menstrual blood loss compared with 
that of women with normal menstrual blood loss[94].  
Prostaglandins appear also to play important roles in the human endometrium, 
and in women diagnosed with heavy menstrual bleeding. The first demonstration 
of these markers was in menstrual fluid where vasoactive substances were 
demonstrated to posses the ability to induce contraction in strips of ileal muscle. 
Afterwards, these substances were identified and termed PGE2 and PGF2α. These 
are the most abundant prostaglandins in endometrium and menstrual fluid 
[95].Their expressionis increased in the total PGs in endometrium of women with 
HMB [96]. Endometrial PGE2 shows increase in its expression, signalling and the 
synthesis pathway in women with HMB. The endometrial expression of COX-2 
during the secretory phase is also higher in women with HMB than in women with 
normal menstrual blood loss[97]. In addition, the number of PGE receptors 
(EP2and EP4) is greater in endometrium in women with HMB compared with that 
in the normal controls. PGE2 synthesis and signalling have a direct correlation 
with the menstrual blood loss [98, 99]. Other vasodilatory factors such as 
prostacyclin (PGI2) and nitric oxide synthesis are increased in endometrium in 
women with HMB and may up-regulate the PGE2 synthesis pathway via a positive 
feedback mechanism [100]. 
On the other hand, prostaglandins up-regulate the expression of COX-2, 
arachidonic acid metabolism and prostanoids biosynthesis in many functional 
conditions. Because of the increased expression of prostanoids in endometrium 
of women with HMB, COX enzyme inhibitors have been introduced as mode of 
treatment. COX enzyme inhibitors may reduce the menstrual blood loss by 30% 
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[101-103].  Prevention of PG synthesis is the mechanism of action of non-
steroidal anti-inflammatory drugs (NSAID), while the femanate  group such as 
sodium meclofenamate and mefenamic acid works by reducing PG synthesis and 
suppressing PGE2 binding to its receptors[104].  
 
1.10.1.2 Angiogenic alternations 
Local hypoxia,which follows withdrawal of progesterone has a crucial role in 
postmenstrual endometrial repair. The hypoxic inducible factor-1 (HIF-1) seems 
to co-ordinate tissue responses. This factor mediates its action through two 
subunits, HIF-1 α and HIF-1β. Activation of HIF-1 which take place in absence of 
oxygen, enhances transcriptional activity of genes with hypoxic response 
elements, in particular factors which mediate endometrial remodelling and 
angiogenesis. The expression of HIF-1α has been observed in the endometrium 
during the late secretory and menstruation phases.  Transcriptional activity, 
translocation, and protein stabilisation of HIF-1α,is thought to be enhanced by 
some inflammatory mediators such as tumour necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), and PGE2. The cytokine IL-1 has the ability to enhance the 
expression of hydroxyl steriod dehydrogenase-1 (11βHSD-1)[105]. This enzyme 
converts cortisone to cortisol, which is an inflammatory steroid product and 
which has been observed expressed at high level during menstruation, suggesting 
its role in the postmenstruation repair. The action of this enzyme is reversed by 
type 2 enzyme (11ΒHSD-2), leading to decrease in the cortisol. The level of 
11βHDSD-2 is largely elevated in women with HMB [106], and consequently, the 
action of cortisol as an anti-inflammatory and angiostatic factor would decrease, 
which may result in dysfunction of angiogenesis in the endometrium and delayed 
repair. Therefore, menstruation as inflammatory process may have a direct 
impact on post-menstrual tissue repair.  
Increases in vasodilatation and lack of vasoconstriction associated with HMB 
condition, may limit or prevent the perimenstrual hypoxic event in the 
regrowing zone of endometrium. As a result, the endometrial repair process may 
be delayed. Non hypoxic conditions cause inactivation of HIF-1, which may cause 
a decrease in the transcription of angiogenic repair factor, and subsequently 
may prolong the menstrual bleeding. VEGF is one of the genes targeted by HIF-1. 
Some authors found a decrease in the VEGF mRNA levels in the menstrual 
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effluent and in endometrium biopsied in women with HMB [94]. This low level of 
VEGF-A would detrimentally affect migration and differentiation of vascular 
smooth muscles and contributes to defective initiation of coagulation. As a 
result, delay in repair the damaged vessels and an increase in menstrual 
bleeding may result. 
Upregulation of the expression of COX enzymes and prostaglandin receptors 
enhance the production of angiogenic factors and down-regulate the expression 
of anti-angiogenic factors. Many angiogenic factors are upregulated by COX 
enzymes in the endometrial epithelial cells such as bFGF, VEGF, and angiopiotins. 
The anti-angiogenic factors such as thrombospondind, angiostatin, and 
endostatin act as potent vasoconstrictors, and down-regulation of their 
expression would enhance vasodilatation. Hence, the balance between the 
expression of the angiogenic and anti-angiogenic factors is essential for normal 
menstruation, as their balance may determine the degree of permeability and 
leakage at menstruation. Therefore, the overexpression of COX enzymes in the 
endometrium of women with HMB may lead to dysregulation in the expression of 
these factors and imbalance between their function.  
Other angiogenic factor such as endothelin, which has strong vasoconstriction 
property on the smooth muscle cells, is expressed in the endometrial cells 
including the endothelium.  Neutral endopeptidase enzyme has the ability of 
suppress the endothelin action, hence reduce the permeability. This enzyme is 
decreased in premenstruation, leading to increase in the endothelin in this time.  
Increased the enzyme level has been noticed in endometrium in women with 
HMB, resulting in decline in the endothelin and fragile endometrium.     
 
1.10.1.3 Vascular alternations 
Many reports have demonstrated major alternations in the structure of 
endometrial blood vessels of women with heavy menstrual bleeding. It has been 
noticed that there is increased in the endothelial cell proliferation in comparison 
with the endothelial proliferation index observed in normal controls [107]. This 
may cause alternation in the vascular permeability, which as consequence may 
affect the availability and accessibility of many endocrine and paracrine factors 
which have fundamental role in menstruation.  
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HMB has been associated with increase in PGE2 levels in endometrium and this 
increase is greater than that of PGF2α, resulting in decrease in thePGF2α/ PGE2 
ratio[108], resulting in less vasoconstriction of spiral arterioles prior to 
menstruation. Furthermore, the decline in the endothelin-1, which is a potent 
vasoconstrictor factor, may result in further deterioration in the constriction of 
the endometrial blood vessels particularly perimenstruation[109]. It has been 
noticed that the wall circumference of endometrial blood vessels in women with 
HMB is larger than that in women with normal menses [110]. In addition, it was 
noticed that smooth muscle in the endometrial blood vessels walls in women 
with HMB are less in their proliferation during mid-late secretory phase[111] and 
maturation than that of the normal controls[112]. This alternation in spiral 
arterioles maturation may result in further insufficient vasoconstriction and 
reduced the blood flow resistance; as consequence increase in the menstrual 
blood loss. All this may delay the endometrial repair due to limitation in the 
hypoxic insult in the basal layer of the endometrium in women with HMB. 
 
 
1.10.2 Heavy menstrual bleeding in presence of uterine 
fibroids 
Uterine fibroids are the most common pelvic tumours of the female genital tract. 
They are benign smooth muscle tumours that arise from the uterine myometrium 
[113]. Although all women at reproductive age can be affected by fibroids, they 
largely affect women aged from 40 to 50 years old [114] with an approximate 
prevalence of 30% [115],and they increase in prevalence to 77% among women in 
the USA population [116]. Fibroids are particularly common in African women 
compared to Caucasian women [117] as they have some familial tendencies [118]. 
However, Baird, et al., 2003 pointed out that the most Caucasian and African 
women develop fibroids and the difference is that African women develop 
fibroids at earlier age than white women, have more severe symptoms and a 
longer period of sustained growth [119]. There may be one single uterine fibroid 
or multiple fibroids with different size and locations (classification of uterine 
fibroids is addressed in section 8.1.1). The pathophysiology of these tumours 
remains unknown, although, there is a hypothesis that each fibroid is derived 
from a mutation in a single smooth muscle cell [120].  
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Most fibroids are asymptomatic and are accidently discovered during a clinical or 
ultrasound examination. However, uterine fibroids can cause severe symptoms in 
15-30% of women [115, 121]. Patients with symptomatic fibroids may present 
with menorrhagia, impairment of fertility, pressure symptoms such as urinary 
incontinence, constipation and abdominal pain. Despite the benign nature of 
fibroids, they have a significant level of morbidity depending on the size, 
anatomic location of the tumour and reproductive status of the women. One of 
the main symptoms of fibroids is heavy menstrual bleeding (HMB), which takes 
one of two patterns, increase in the amount of blood loss per cycle or prolonged 
vaginal bleeding [122]. This symptom can lead to medical issue (iron deficiency 
anaemia) and social problems present in social embarrassment and improper 
work life because of the need to change sanitary towels frequently. 
 In the United States, the uterine fibroids are the first reason for hysterectomies, 
where 200,000 hysterectomies, 30,000 myomectomies, and thousands of uterine 
artery embolisation and high intensity focused ultrasound procedures are 
annually performed to remove or destroy uterine fibroids. In addition, the 
annual cost of managing uterine fibroids is estimated to be between $5.9-34.4 
billion [123]. 
Although increasing attention to research on this tumour, the pathogenesis of 
this disorder is not well defined. Many authors have been focused on the 
initiation of uterine fibroids and how does transformation of normal smooth 
muscle cell to abnormal smooth muscle cell occur. Furthermore, they have been 
working to understand the growth of the clinically apparent tumour. Many have 
studies pointed out that genetic, cellular predisposition, sex steroid hormones 
and growth factors play an important role in the development and the growth of 
uterine fibroids. 
The cellular origin of uterine fibroids are still not fully understood, but many 
observations suggested that each fibroid is originated from transformation of a 
single somatic stem cell of the myometrium under the influence of steroid 
hormones [124], and earlier studies suggested that uterine fibroids are a 
monoclonal tumour [113].The histologic composition of uterine fibroids includes 
disordered smooth- muscle cells submerged in abundant extracellular matrix. 
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The leiomyoma cells have moderate rate of proliferation and formation of 
extracellular matrix account an important part of the fibroid expansion.  
During the reproductive age of woman, myometrium undergoes multiple cycles 
of growth changes because of the effect of ovarian hormones or pregnancy 
hormones. Theses phases of alternation make stem cells more vulnerable to the 
development of mutations. A single gene mutation such as affecting the gene 
encoding mediator complex subunit 12 (MED 12), or a chromosomal 
rearrangement increasing the expression of HMGA2, or other some somatic gene 
defect, may transform a normal myometrial stem cell to fibroid stem cell, which 
may have the ability to divide in an uncontrolled manner and develop into 
mature fibroids tissue [125]. Because of these sequential changing, the mature 
fibroid cell may acquire epigenetic changes such as DNA methylation and histone 
modification [126]. In the addition, some cell regulatory markers which play a 
vital role in fibroid growth such as β-cathenin and TGF-β, where changing in 
their signal pathways  can happen by the original single hit, leading to 
alternation in cell proliferation , survival [127, 128] and formation of 
extracellular matrix, all this may result in the clonal expansion pattern of stem 
cells within normal myometrium. Although the majority of cells within this clone 
differentiate and develop a phenotype similar to that of normal myometrial 
smooth cells, they still have the characteristic of original mutation or 
chromosomal rearrangement for supporting further growth [124].  
The ability of myometrial tissue to respond to the ovarian hormones for the 
physiological expansion during the secretory phase of the menstrual cycle or 
pregnancy may be applied to the fibroid tissue. It has been noticed that most 
uterine fibroids shrink after menopause, and changing levels of oestrogen and 
progesterone that associated with the early pregnancy and postpartum period 
has a great effect on fibroid growth [129, 130]. In addition, GnRH agonists, 
which decrease the level of circulating ovarian hormones, are able to suppress 
the growth and reduce the size of uterine fibroids [131, 132]. Theoretically, 
these observations support the idea of the dependency of uterine fibroids on the 
ovarian hormones. Researchers who are interested in uterine fibroids noticed a 
high concentration of oestrogen receptor α and progesterone receptors in fibroid 
tissue and thought that signal pathway of theses hormones pass through a 
paracrine mechanism to the stem cells as the later have remarkable low level of 
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ER and PR with comparison to fibroids and normal myometrial cells. Thus, some 
authors would consider a class of antiprogestin as the most specific medical 
approach, which targeting the growth mechanism of fibroids [133-135]. 
Growth factors can be produced from many cell types but they are mainly 
secreted from the smooth muscle cells and fibroblast cells. Growth factors have 
a wide range of biologic effects, and largely act over short distances by either an 
autocrine or paracrine mechanism. Growth factors are considered crucial factors 
in controlling cell proliferation and over expression of either the growth factor 
or its receptor may contribute to tumorigenesis. Growth factors activity is 
affected mainly by specific binding sites on the surface of the target cells, with 
subsequent message transmission via signal pathways in the cell.  
Several growth factors and their receptors have been recognized in both 
myometrium and uterine fibroids. TGF- β consists of three isoforms and it has 
two types of receptors in myometrial cells TGF- β І and ΙΙΙ. TGF- β functions as a 
promoter of mitogenesis and up-regulator to the synthesis of several components 
of extracellular matrix.  
It has been found that TGF- β3 value is significantly higher in the fibroid cells 
than the myometrium and TGF- β3 expression increased in fibroids with no 
difference in the TGF- β1 expression. The effect of TGF- β as stimulator and as 
inhibitor depends on several factors including, the target cells, the amount of 
TGF- β, and presence of other growth regulators. It is though that TGF- β may 
act as stimulator for smooth muscle cell proliferation and production of extra-
cellular matrix particularly when present in low level (TGF- β3- TGF- β1). This 
finding has been supported by a study that examined cultured smooth cells from 
the aorta treated by TGF- β and found stimulation of autocrine secretion of 
PDGF, revealing the indirect effect of TGF- β on the proliferation of smooth cells. 
On the other hand, down regulation of PDGF- R has been found in the presence 
of a high value of TGF- β. The regulatory effect of progesterone on TGF- β 
emerged when a study observed that unusual increases in TGF- β3 mRNA levels 
in the secretory phase relative to the proliferative phase in fibroids. However, 
there is no difference in the TGF- β levels in myometrium cells throughout the 
menstrual cycle. In addition, one study pointed out no significant effect of TGF- 
β on the cell proliferation. Important point with regard TGF- β is that the gene 
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coding for TGF- β is located near 14q23-24 the most common chromosomal 
rearrangement in fibroids. 
 
The majority of the symptomatic patients with fibroids experience heavy 
menstrual bleeding. There is a strong association between uterine fibroids that 
destroy the uterine cavity (submucosal fibroids) and heavy menstrual blood loss 
in comparison with other types of uterine fibroids. However, to our knowledge, 
there is no estimation of the proportion of women with uterine fibroids who had 
HMB.Women with HMB are more likely to have fibroids and women with fibroids 
can be asymptomatic. Furthermore, postmenopausal women with submucosal 
uterine fibroids and using hormonal therapy were found to have two fold higher 
risk of abnormal uterine bleeding than women without submucosal fibroids.  
Therefore, other pathological reasons for abnormal uterine bleeding such as 
coagulopathies e.g. Von Willebrand’s disease as discussed above, should be 
excluded before attributing HMB to fibroids. On the other hand, others have 
concluded that only 25% of patients with submucosal fibroids may have heavy 
menstrual bleeding, revealing uterine fibroids regardless their size or site may 
have paracrine molecular effects on the adjacent endometrium that are 
extensive enough to cause HMB [136].  
The mechanism by which fibroids cause HMB is unknown. Whereas in the past it 
was thought that abnormal bleeding associated with fibroids was due to 
disturbance in the ovarian hormones [137], today it is believed that abnormal 
vaginal bleeding is because of uterine factors, especially if it is confirmed that 
no steroid hormones differences have been found between women with fibroids 
and women without fibroids [138].  
Several theories tried to explain the pathophysiology of HMB associated with 
fibroids. Increase the endometrial surface area because of fibroids is one of 
aetiological factors that has been considered in the literature. However, no 
effect of this factor was found on idiopathic HMB, which makes this suggestion 
controversial [139]. High vascularity of the uterus associated with fibroids is 
another possibility for the mechanism of HMB. Additionally, recent reports have 
emerged describing the relation between development of fibroids and 
dysregulation of several growth factors, or their receptors, leading to vascular 
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dysfunction and angiogenesis, which contributes to dysregulation of vascular 
structure in the uterus, subsequent to HMB [122].  
Another explanation has taken the interference of fibroids with the normal 
uterine contractility into account, but the less effect of fibroids on the 
contractility of blood vessels rejects this suggestion and considers it only as a 
major reason for dysmenorrhoea associated with fibroids. Compression of 
fibroids on the venous plexus of the adjacent tissues causes congestion to the 
myometrium and endometrium lead to abnormal uterine bleeding [140]. Because 
of the role of prostaglandin PG and endothelin in the rise of HMB make some 
authors to think about them as factors in the mechanism of HMB with fibroids, 
particularly when one of these studies used PG synthetase inhibitor as a 
treatment for HMB and found decrease in the blood loss, but the result was not 
statistically significant. Endometrium ulceration and endometriosis that 
associated with fibroids especially the submucosal ones is an additional reason 
for HMB [141]. However, fibroid women with HMB should be investigated with 
the aim of excluding any other pathology particularly when HMB is not a feature 
of fibroids.  
The early studies suggest that increases in the endometrial surface could be a 
reason for heavy menstrual bleeding (HMB) in fibroid uterus; in addition, there is 
a basic modification in the vascular structures of the fibroid uterus. Alternation 
in vascular structure is demonstrated by change in venous structures in the 
endometrium and myometrium resulting in a fragile and engorged plexus (venule 
ectasia). This venous ectasia may be because the local action of growth factors 
as consequence of altered synthesis and expression in fibroids. With ectatic 
venules, the haemostatic actions of the platelet and fibrin block may be plagued 
by the bigger diameter of the vessels, which causes the ‘flooding’ seen in 
women with HMB.  
 
A recent explanation of mechanisms of angiogenesis in the fibroid uterus 
demonstrates local dysregulation of vasoactive growth factors or growth factor 
receptors in fibroids or fibroids myometrium. Furthermore, abnormalities in 
arterial structures in fibroid uterus, where fibroids have an increased arterial 
supply has been proved by some traditional studies. The myometrium is a 
massive reservoir for paracrine or endocrine factors that regulate endometrial 
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function and the directional blood flow from the myometrium to the 
endometrium facilitates this interaction. The research for the association 
between uterine fibroids and heavy menstrual bleeding has demonstrated a 
biochemical differences between the fibroid tissue and normal myometrium, 
including increases in some matrix metalloproteinase [142, 143]and antigenic 
and growth factors, basic fibroblast growth factor, transforming growth factor-β, 
vascular endothelial growth factor as well as plasminogen activators and 
inhibitors [144].  
TGF-β may have a direct impact on the endometrial haemostasis and the 
increased levels of TGF-β in the adjacent fibroids to the endometrium can reach 
the endometrial stromal cells and lead to reduction in the production of 
plasminogen activator inhibitor (PAI), anti-thrombin III and thrombomodulin, 
which play a vital role in the local endometrial haemostasis [136]. Furthermore, 
TGF-β plays a role as stimulator of angiogenesis [136] andproduction and  
differentiation of extracellular matrix[145].  
Endometrial haemostasis is a sensitive balanced process between platelet 
aggregation and fibrin formation from one side and platelet inhibition and 
fibrinolysis on the other [146]. The plasminogen activator is increased across the 
proliferative phase and reaches the peak of its level at the mid-cycle, and it 
declines in the secretory phase and then increases again premenstrually. On the 
other hand, the plasminogen activator inhibitor is increased by the end of the 
proliferative phase and through the secretory phase and maximised the level 
during the menstruation [147, 148].This haemostatic mechanism regulates the 
blood flow in normal menstrual cycle. The increased levels of plasminogen 
activator inhibitor expression in fibroid tissue suggest that uterine fibroids may 
be unable to initiate the fibrinolytic process, leading to prevention of the 
thrombolysis process in fibroids-associated vessels. In addition, there is a four-
fold increase in the expression of PAI-1 as well as a reduction in antithrombin III 
and thrombomedulin  in the endometrium of women with uterine fibroids that is 
associated with heavy menstrual bleeding [136],thereby; elevation of PAI may 
contribute to the impaired hemostatic process in women with uterine fibroids, 
resulting in heavy menstrual bleeding. 
The aberrant angiogenesis is associated with the secretion of growth factors such 
as VEGF, TGF-β, fibroblast growth factor (FGF)[149]. Dysregulation of angiogenic 
and regulatory growth factors may further contribute to heavy menstrual 
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bleeding in women with uterine fibroids and the over-expression of growth 
factors or their receptors in fibroids uterus particularly heparin binding group of 
growth factors such as basic fibroblast (bFGF),VEGF, heparin-binding  growth 
factor (HBEGF), platelet-derived growth factor (PDGF) compared to the adjacent 
normal endometrium could cause abnormal uterine bleeding [144]. However, 
under-expression of angiogenic inhibitory factors or vasoconstricting factors or 
their receptors in fibroids may also result in abnormal bleeding. Nevertheless, 
the exact role of these growth factors in heavy menstrual bleeding associated 
with uterine fibroids need to be determined.  
The expression of both growth factors and their receptors may be regulated by 
ovarian steroid hormones, as their expression appears to undergo menstrual 
cycle phase specific up regulation in fibroids tissue compared with normal 
myometrium. Hence, both receptors of oestrogen and progesterone are over-
expressed in fibroids compared with myometrium. There are certain proteins in 
fibroids which appear to undergo menstrual cycle phase-specific up-regulation in 
fibroids compared with normal myometrium such as mRNA for collagen types I 
and epidermal growth factor (EGF) mRNA which the relative overexpression. 
Growth factors or their receptors that are regulated in different way in fibroids 
or the endometrium of fibroids uterus potentially mediate fibroid related HMB 
by acting on vascular tissue and increase proliferation or change vessel calibre. 
Fibroids with their large extracellular matrix content may be a reservoir for 
these factors. Both bFGF and VEGF mainly regulate endothelial cell function and 
hence may promote the endothelial cell migration essential to angiogenesis 
[149]. Heparin binding growth factors such as heparin-binding EGF-like growth 
factor (HBEGF) and platelet-derived growth factor (PDGF) largely regulate 
fibroblast and smooth-muscle cell function and therefore may influence vascular 
smooth-muscle, fibroid or myometrium, or the endometrial stromal cells.  
There appears to be menstrual cycle-specific expression of VEGF in the uterus. 
During the proliferative phase, VEGF mRNA was detected in different cells in the 
stroma with weak expression in the glands and was also detected in the 
myometrium, at the endometrial–myometrial border. In contrast, during the 
secretory phase there was increasing expression in the glands, with peak 
expression in the menstrual phase and with the disappearance of stromal 
expression. In the past, VEGF concentrations were found to be similar in both 
myometrium and fibroids and to have no significant menstrual cycle variability. 
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1.11 Treatment of heavy menstrual bleeding 
1.11.1 Medical treatment of fibroids 
1.11.1.1 Gonadotropin-releasing hormone (GnRH), 
Gonadotropin-releasing hormone (GnRH), also known as luteinising-hormone 
releasing hormone (LHRH), is produced in neurons in the hypothalamus. It is 
transported via axons to small blood vessels (portal vessels) in the median 
eminence, where it is released into the blood. The blood vessels are draining the 
anterior pituitary, allowing GnRH to reach the anterior pituitary in high 
concentrations. In the pituitary, GnRH acts through the GnRH receptors on the 
gonadotropic cells to stimulate the release of follicle-stimulating hormone (FSH) 
and luteinising hormone (LH) to the circulation. The pulsatile secretion pattern 
of GnRH reflects on the cyclic release of LH and to a lesser extent of FSH. 
 
GnRH agonists are known to be used for short-term (≤ 6 months) or for long-term 
(>6months), and in order to avoid the side effects of GnRH on bone density, the 
short-term administration is the most used protocol in the practical field or it is 
combined with hormonal addback. GnRH agonists have been shown to decrease 
the size of uterus as well as the size of fibroids [131, 132], and reduce the 
menstrual blood loss. One possible explanation of the effect of GnRH agonists on 
both the size of uterus and fibroids appears to be the result of decreased levels 
of oestrogen and progesterone (P) that are induced by GnRH agonists, however, 
other mechanisms, including a decrease in the size or number of leiomyoma 
cells, which may cause induction of fibroid degeneration and hyaline necrosis, a 
reduction in extracellular matrix, and/or a decrease in blood flow to the uterus, 
may be important. However, this effect is present only during the therapy 
duration and stop shortly after stopping it, where uterine fibroids return to the 
original size within couple of months[150].  
It has been noticed that the preoperative use of GnRH agonists may improve 
preoperative haemoglobin, and reduce operating times and hospital stays, and 
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allow some cases to have a less invasive operation [151]. There is some evidence 
that reduction in the size of uterine fibroid makes a higher proportion of fibroids 
protrude into the uterine cavity, thus it facilitates the resection and short the 
operating time[152, 153]. Reduction in the operating time is one of the main 
reasons to adopting preoperative use of GnRH agonists for women having 
hysteroscopic resection of submucosal fibroids, especially enlarged fibroids, 
which reduce the risk of excessive fluid absorption and overload. However, there 
is limited evidence supporting preoperative use of this therapy due to lack of 
randomised control trials in this concept. Nevertheless, one of the randomised 
trials does not recommend the routine use of preoperative GnRH therapy for 
hysteroscopic resection of fibroids as no significant benefit was observed 
between cases and controls [154]. 
1.11.1.2 Evonorgestrel intrauterine system (Mirena IUS) 
Evonorgestrel is a progestin, named levonorgestrel because it is the levorotatory 
form of norgestrel. The levonorgestrel-releasing intrauterine system has been 
available since the mid-1970s. It is marketed under the name Mirena.  Mirena IUS 
is a safe and accepTable form of contraception, providing highly effective 
contraception for up to five years. It also has a range of noncontraceptive usage 
including treatment for heavy menstrual bleeding, endometriosis, and 
endometrial hyperplasia. The Mirena IUS has also been used in combination with 
estrogen for hormone replacement therapy and as an alternative to 
hysterectomy. Mirena IUS is planned to provide an initial release rate of 20 
micrograme (μg) per day of levonorgestrel. This decreases to 11 μg per day by 
the end of five years, with an average release rate of 14 μg per day during the 
life of the Mirena IUS. Levonorgestrel-releasing intrauterine system consists of a 
T-shaped polyethylene frame with a steroid reservoir around the vertical stem. 
The reservoir consists of a white or nearly white cylinder, made of a 
levonorgestrel, containing a total of 52 mg levonorgestrel and covered by a 
semi-opaque silicone (polydimethylsiloxane) membrane. The T-body is 32 mm in 
both the horizontal and vertical directions. The polyethylene of the T-body is 
compounded with barium sulfate, which makes it radiopaque. A monofilament 
brown polyethylene removal thread is attached to a loop at the end of the 
vertical stem of the T-body.  
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Levonorgestrel works by thickening the cervical mucosa and suppressing the 
endometrium proliferation. Additionally it produces thin endometrium with 
fragile blood vessels which imperfect for implantation. On the other hand, the 
absorbed level of progestin is below the required level to inhibit the ovulation; 
therefore, most women on this treatment still have regular ovulation.  Mirena 
IUS is indicated for the treatment of heavy menstrual bleeding in women who 
choose to use intrauterine contraception as their method of contraception. In 
women with idiopathic heavy menstrual bleeding, the levonorgestrel-releasing 
intrauterine system reduces menstrual blood loss more effectively than cyclical 
norethisterone (for 21 days) as a treatment for heavy menstrual bleeding. In 
comparison of levonorgestrel-releasing intrauterine system efficacy with 
established medical and surgical treatments, as a part of comparative and non-
comparative studies, it was found that this therapy reduce blood loss by 79-97%. 
However, many gynaecologists advise this therapy for heavy menstrual bleeding 
in women with fibroids, where there is no a clear evidence about the 
effectiveness in case of uterine fibroids. There are a variety of medical 
treatments available for heavy menstrual bleeding, including prostaglandin 
synthetase inhibitors (non-steroidal anti-inflammatory drugs, NIASDs), 
antifibrinolytic agents (tranexamic acid) and oral contraceptive pills. 
Progestogens is used in different forms including, oral, implant, and coil (the 
Mirena coil), but they appear to be less effective where fibroids are the cause of 
symptoms. 
Therefore, the effect of these medications needs to be examined in case of 
heavy menstrual bleeding because of fibroids. The following survey assessed the 
gynaecologists’ beliefs regarding the treatment of fibroids particularly when 
women present with heavy menstrual bleeding in the UK and Libya. 
 
1.11.1.3 Selective progesterone receptor modulators (SPRMs) 
 Introduction of progesterone to the clinical field has provided a great help in 
controlling various reproductive function. Many progesterone receptors 
antagonists have been widely used in fertility control and hormonal therapy. 
Selective progesterone receptor modulators have been developed sine late 1970s 
when mifepristone was first prescribed. Selective progesterone receptor 
modulators are one of the progesterone receptors ligands that synthesised in 
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three different types including selective progesterone agonist, antagonists, and 
mixed (agonist/antagonist ),which effect on many progesterone target tissue 
[155].Mifepristone has unique major antagonist properties allowing its use for 
pregnancy termination. Ulipristal acetate has been used for emergency 
contraception and has been recently authorised for preoperative uterine fibroid 
treatment [156]. Further perspectives for SPRMs use include long term estrogen 
free contraception. However, long term applications will be possible only after 
confirmation of endometrial safety[157]. 
Using SPRMs have shown benefit in inducing amenorrhoea, endometriosis 
associated pain, and reduce the size of uterine fibroids. a number of double-
blind, randomized, placebo-controlled trials have demonstrated the efficacy of 
asoprisnil, mifepristone, telapristone acetate, and ulipristal acetate in reducing 
uterine fibroids and uterine volume, and suppressing bleeding in women with 
uterine fibroids[158]. Asoprinil is a SPRM with high binding affinity to 
progesterone receptor (PR), and no binding affinity to oestrogen receptor, and 
thought to induce amenorrhoea through anti-proliferative effect on the 
endometrial tissue throughout the menstrual cycle [159]. However, the 
mechanism by which SPRMs induce amenorrhoea is still not fully understood. 
Although observation that agonist activity of SPRM prevents endometrial 
proliferation may suggest future use of these agents in prevention of 
endometrial hyperplasia. In addition, other  future applications may include 
endometriosis, endometrial cancer, Cushing's disease, Alzheimer disease or long-
term contraception, are currently in development[158, 160]. 
1.11.2 Surgical intervention 
1.11.2.1 Laparotomies  
Removal of uterine fibroids through abdominal incision only with conserving the 
uterus called open myomectomy, and although myomectomy was performed a 
long time ago (1845), hysterectomy has been the main treatment for women 
who present with symptomatic uterine fibroids for many years because of 
bleeding associated with myomectomy. However, women who undergo 
hysterectomy for very large uterine fibroids have been shown to have an 
increased risk of blood loss with increasing uterine size. Later on, and because 
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of haemostatic and surgical technique development, abdominal myomectomy 
has been used as a conservative treatment for uterine fibroids, and there may 
be less risk of intraoperative injury with myomectomy when compared with 
hysterectomy. In addition, myomectomy may be considered for women with 
large uterine fibroids or difficult fibroids associated symptoms who desire to 
retain their uterus and desire future fertility. Currently, however, there is no 
significant evidence regarding the benefit of myomectomy on reproductive 
outcome as treatment for all types of uterine fibroids, for instance, [161]. 
Myomectomy has been found to relieve symptoms in 80% of women; however, 
unrelieved symptoms and /or the need for repeating the procedure over time 
are frequently reported with this procedure. Therefore, hysterectomy is only the 
definitive treatment of uterine fibroid. 
1.11.2.2 Laparoscopy 
Since 1990 laparoscopic myomectomy has provided an alternative to laparotomy 
when subserosal (since1970s) then intramural fibroid is to be managed 
surgically. However, pros and cons of this procedure as treatment of uterine 
fibroids particularly for women with subfertility is still the subject of debate. 
Laparoscopic myomectomy offers the possibility of a minimally invasive 
approach to treat subserosal and intramural fibroids by surgery when there are 
only a small number of them. When this procedure is conducted by experienced 
surgeons, the risk of peri-operative complications is reduced in particular, the 
bleeding risk associated with myomectomy. In addition, the procedure may have 
less post-operative risk of adhesions as compared with laparotomy, and 
spontaneous uterine rupture seems to be rare after laparoscopic myomectomy, 
but further studies are needed to obtain clear evidence about the strength of 
the hysterotomy scars after this technique in comparison with that obtained 
after laparotomy[162, 163]. Nevertheless, the risk of recurrence seems to be 
higher after laparoscopic than after open myomectomy. Many studies were 
launched to compare between the effect of laparoscopic myomectomy and the 
effect of open myomectomy on the reproductive outcome, and up to date, there 
is not a certain conclusion regarding the benefit of either of these methods. This 
uncertainty in the conclusion is most properly because of a lack in the 
randomised control trials with this at the end point [161]. On the other hand, 
two randomised control trial compared laparoscopic to open myomectomy, and 
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demonstrated no significant evidence of the superiority of laparoscopic 
myomectomy regarding the live birth rate, clinical pregnancy rate, caesarean 
sections rate, miscarriage rate[164, 165]. However, analyses and interpretation 
of this data should take into account that these studies are small number 
studies. 
1.11.2.3 Hysteroscopy 
Hysteroscopic myomectomy was introduced to the gynaecology clinical practice 
as result of development of the urological resectoscope, with instrumental 
modification since 1980s. Nowadays, hysteroscopic myomectomy is the 
treatment of choice for submucosal fibroids associated with heavy bleeding, and 
reproductive issue. Hysteroscopic myomectomy has been shown to be safe and 
effective in the control of menstrual disorders, and in improving the fertility 
rate [166]. However, no evidence on beneficial effect of the procedure on 
fertility rates for submucosal G1 and intramural fibroids. The selection of 
hysteroscopic technique is mainly dependent on the intramural extension of the 
fibroid- on one hand, and on personal experience and available equipment on 
the other [167]. Hysteroscopic resection by slicing technique still represents the 
main procedure for treating submucosal fibroids and about 40% of hysteroscopy 
procedure are performed under anaesthesia [168], even though, out-patient two 
step hysteroscopy has been proposed.  
The pre-operative use of GnRH has shown to improve hysteroscopy visibility and 
reduce blood loss during operation [169]. Most techniques aim at the 
transformation of an intramural fibroid into a totally intra-cavity lesion, thus 
avoiding a deep cut into the myometrium. The hysteroscopic resection of 
submucosal fibroids is a safe and highly effective long-term therapy for carefully 
selected women presenting with abnormal uterine bleeding and fertility 
problems, where it increases the odds ratio of pregnancy rate in women with 
unexplained infertility, however, the evidence is still inconclusive[170]. In one 
randomised study, the odds ratio for pregnancy was 1.88, 2.04, and 3.24 after 
hysteroscpic myomectomy for submucosal, intramural, and combined 
submucosal and intramural respectively, and the odds ratio of miscarriage in the 
same study was 0.63 after myomectomy for submucosal fibroids and 0.89 after 
intramural and 0.50 after combined submucosal and intramural [171]. 
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1.11.2.4 Vaginal myomectomy 
Although vaginal myomectomy was identified for the first time in the middle of 
the 20th century, this procedure has not been widely adopted. Vaginal 
myomectomy, in well-selected cases, is feasible, well tolerated technique, and 
associated with short operating and recovery time [172]. This procedure 
isthought to be useful even in cases of large, numerous, and intramural fibroids 
and allows optimal uterine wall reconstruction with minimal tissue trauma. 
When uterine fibroids are large, numerous and intramural, laparoscopic 
myomectomy would not be easy unless it is performed by a skilled surgeon.  
Vaginal myomectomy is more effective to avoid the abdominal trauma and have 
better operative field than laparoscopic and hysteroscopic procedure, in 
particularly for large intramural fibroids. In addition, it is not constrained by 
limitations such as location, size and number of fibroids. Furthermore, vaginal 
myomectomy has a shorter operating time than laparoscopic myomectomy, 
whilstothers find vaginal myomectomy equal in operation time to laparoscopic 
myomectomy. Additionally, another author pointed out that vaginal 
myomectomy had significantly longer hospitalisation and gas and bowel recovery 
time and more transient high fevers, but the difference in blood loss was not 
significant in some findings and significantly shorter in others[173]. Lack of high 
quality studies and absence of systemic review is the main reason that the 
controversies are still existed in the evaluation of vaginal myomectomy and 
laparoscopic myomectomy. 
1.11.2.5 Endometrial ablation 
Endometrial ablation (EA) is a destruction technique that targets the endothelial 
surface of the uterine cavity in order to destroy and remove endometrial 
tissue.This procedure was introduced to the clinical field in Germany in the 
1930s, and it became more popular in the latter part of the 20th century. In 
1995 endometrial ablation started to be performed under the hysteroscopy 
vision in the UK, and helped to decrease the number of hysterectomies for HMB 
by 64% between 1995-2002 [174]. The initial performance of this destructiove 
method was by using electrocautery through loop and rollerball (80%), laser 
(18%), and radiofrequency (2%)[175]. The most recent data from the UK (2004-
2006) shows that 60% of surgical methods were used for women with HMB in the 
Chapter 1 S.Abukhnjr 2014 69 
 
premenapousal age [176]. However, the first generation method had minimal 
impact on hysterectomies in the UK [177]. Currently, EA can be performed under 
endoscopic direction with the neodymium:yttrium alumnum garnet laser(rarely 
used), with  radiofrequency resectoscope, or with an expanding array of 
nonresectoscopic EA systems. Obviously, most but not all of the complications 
associated with resectoscopic endometrial ablation are eliminated with 
nonresectoscopic endometrial ablation. Many studies and trials in the literature 
assessed the sufficiency of endometrial ablation for heavy menstrual bleeding, 
and evaluated the long term outcome for this method. In addition, large number 
of studies compared between the first and second generation of endometrial 
ablation regarding the technique itself and the long outcome. There was no 
conclusive results up to date, however, no evidence of significant difference 
about the long term outcome of both generation of EA, and less perioperative 
complications and shorter time operation were associated with the second 
generation. On the other hand, more technical failure was noticed with the 
second generation [178]  The procedure was originally designed as a less invasive 
alternative to hysterectomy for the symptom of heavy menstrual bleeding 
unrelated to structural pathology of the uterus, which was not responsive to 
medical therapy.  
More recently it has become apparent that the procedure can be performed in 
the presence of submucosal fibroids, with limitation in number of size and 
location criteria or combined with hysteroscopic resection. However, serious 
morbidity has been reported with all of the newer systems to date.  Long term 
satisfaction among the majority of well-selected patients treated in clinical 
trials, but repeat surgery, usually hysterectomy, is performed in 25% to 40% by 5 
years after surgery. Some authors thought that moving the procedure to out-
patient sittings may enhance its efficiencies.  
1.11.3 Less invasive intervention 
1.11.3.1 Uterine Artery Embolisation 
Uterine artery embolisation (UAE) is a relatively new procedure by which 
transcatheter bilateral injection of small particles is performed through the 
femoral arteries to block the uterine arteries. Since 1995, this procedure has 
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been offered as alternative therapy to surgical interventions for women with 
symptomatic uterine fibroid particularly associated with HMB [179]. Although 
there is a concern  regarding the post- procedure pain, post embolisation 
syndrome, reduced ovarian reserve and early menopause, UAE seems to have 
less complications in comparison with other surgical technique, and appeals to 
women who desire to avoid major surgery and keep the uterus. Nevertheless, 
there is uncertainty about the effect of UAE on fertility and on pregnancy 
outcome [180], although live births were recorded [181, 182]. Hence, women 
with fibroids who desire future fertility need carful counselling. Notably, there is 
a good rate of patient satisfaction after long term follow up in women with HMB, 
with no significant difference compared with other surgical methods. In 
addition, there was no difference between the UAE and myomectomy regarding 
major complication. However, the later procedure reported better fertility rate 
than UAE, but the evidence was not appreciated because of low cohort study 
[183]. Also a higher rate of new fibroids formation was identified in women 
underwent myomectomies compared to UAE after 5 years evaluation [184]. On 
the other hand, reintervention rate was higher among women who had UAE 
compared no reintervention after myomectomies.  
 
1.11.3.2 Magnetic-resonance guided focused ultrasound surgery 
Magnetic-resonance-guided focused ultrasound surgery (MRgFUS) is a non-
invasive thermo-ablative technique that uses focused high-energy ultrasound to 
remove fibroid tissue. As in the usual diagnostic ultrasound, the ultrasound 
waves pass through the anterior abdominal wall. Significant heating only occurs 
where the waves converge at the focus. Magnetic resonance guidance provides 
continuous imaging of the fibroid and other vital structures such as bowel, 
bladder and sacral nerves.  
MRI scans identify the tissue in the body to be treated and are used to plan each 
patient's procedure. MRI provides a three-dimensional view of the targeted 
tissue, allowing for precise focusing and delivery of the ultrasound energy. MRI 
also enables the radiologist to monitor tissue temperature in real-time to ensure 
adequate but safe heating of the target. Immediate imaging of the treated area 
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following MRGFU helps the radiologist determine if the treatment was 
successful. MRgFUS was approved by the US Food and Drug Administration in 
2004, while NICE recommended that the procedure should be used in an audit 
and research setting. Significant improvement in quality-of-life parameters has 
been reported in women undergoing MRgFUS. MRgFUS is safe and effective 
treatment for uterine fibroids [185]. There are no urgent surgical procedures or 
bowel injuries, which are reported in many early studies of new investigational 
devices for uterine fibroids. Furthermore, women who have treatment with 
MRgFUS do not appear to have post-embolisation syndrome symptoms that 
associated with UAE. Patient undergoing MRgFUS usually has short recovery time 
and return to work after approximately 1 day, compared with 10-13 days after 
UAE and approximately 6 weeks after open myomectomy or 8weeks after 
hysterectomy. However, a proportion of further treatment was reported [185]. 
 MRgFUS can be considered as minimal invasive procedure alternative to other 
surgical and radiological procedure for treating uterine fibroids that improve 
quality of life and fertility. However, other report pointed out better score of 
quality of life and low reintervention rate recorded with UAE than MRgFUS [186]. 
Pregnancies have been reported and their outcome seems to be similar to that 
of age matched women who have fibroids but no treatment (). In addition, 
greater experience, device improvement, and availability to larger number of 
patients  is required to increase the outcome of the procedure [187]. Where 
there are limited centres in the US (20 centres) and only 2 units in the 
Uk.Furthermore, the position of MRgFUS as treatment of fibroid need to be 
established in comparison with the other available treatment modalities by 
means of randomized controlled clinical trials. 
1.11.3.3 Myolysis 
Laparoscopic myolysis was introduced as a minimally invasive technique for the 
treatment of fibroids in the late 1980s. The procedure action aims to destroy the 
fibroids tissue using a number of focused energy delivery systems such as 
supercooled cryoprobes, radiofrequency electricity devices and focused 
ultrasound monitored by real time magnetic resonance imaging. These different 
energy sources are delivered by a laparoscope and in some instances by a 
hysteroscopy technique for both thermomyolysis and cryomyolysis. In the 
Chapter 1 S.Abukhnjr 2014 72 
 
cryomyolysis technique, a cryoprobe is inserted into the centre of the fibroid, 
and tissue ablation is achieved by creating an iceball within the fibroids, 
repeated freeze/ thaw cycles are needed to achieve the desired effect. A 
reduction in the fibroids size after cryomyolysis is poorly achieved comparing to 
other myolysis techniques. In addition, it might lead to serious renal failure as a 
result of the release of myoglobin. The thermomyolysis therapy is designed to 
transmit heat into the target tissue causing coagulative necrosis, which may be 
suitable for large size fibroids,while maintaining three dimensional control of 
energy delivery to thermally destroy the target volume. Laparoscopic myolysis 
may be effective in aggravating fibroids shrinkage, with a decrease in size of 
fibroids and some decline in the uterine size as well [188], and this technique 
can be applied as an alternative to laparoscopic  myomectomy in selected 
patients for instance women with large and multiple intramural fibroids, 
patients who approaching the menopause aged , patient over 40 years old age or 
those who completed their family [189-191]. However, the technique should be 
assessed in a prospective randomized controlled trial versus other minimally 
invasive techniques as evidence regarding the procedure based on case series 
[188]. 
1.12 Hypothesis and aim 
Normal menstruation is a result of interaction between inflammatory markers, 
antigenic factors and the endocrine system. The causes of menstrual 
abnormalities include heavy menstrual bleeding (HMB) and are not fully 
understood. However, it is recognised that local cellular and molecular signalling 
events are implicated in changes in the endometrium physiology and lead to 
HMB.  
Uterine fibroid is fibromuscular benign tumour in the female reproductive tract 
during child bearing age. It affects a wide range of women throughout the world. 
The most presenting symptom of fibroids is menstrual abnormalities, including 
heavy menstrual bleeding. However, the mechanism by which fibroids lead to 
HMB is not known and there is no group studied it yet.  
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This thesis is based on the hypothesis that uterine fibroid is contributed to HMB 
in different ways that may happen in absence of any uterine pathology. 
The aims of the project were to: 
 Estimate the role of endometrial physiology in the aetiology of heavy 
menstrual bleeding in women with uterine fibroids  
 To evaluate the role of COX, PG, VEGF and inflammatory factors (IL8) in 
this process 
 To determine whether these factors act differently in women with uterine 
fibroids compared with those showing no uterine pathology.
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2. Materials and methods 
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2.1 Subjects 
The subjects in this study were women of reproductive age who had regular 
menstrual cycles lasting between 21 and 35 days. Biopsy specimens were 
collected from 79 women presented with the complaint of heavy menstrual 
bleeding (HMB). Some of these women had uterine fibroids and they were 
recruited from the hysteroscopy clinic (Stobhill hospital, Glasgow) and  
intervention radiology clinic (Gartnavel hospital) (group 1, G1, n=22). Others 
underwent hysterectomy as treatment for their uterine fibroids (group 2, G2, 
n=16).  Uterine fibroids in all participants were diagnosed by ultrasonography or 
magnetic resonance imaging (MRI). In group two (G2),there were 41 women who 
had no evidence of uterine abnormality but who had presented to the 
hysteroscopy clinic with HMB (comparative group) (Table 2.1&Figure 2.1). The 
study protocol was approved by the ethics committee West of Scotland REC 5, 
REC reference number (10/S1001/1).  
Participants filled in a questionnaire obtaining their demographic and clinical 
data (see Appendix 1), including, menstrual history, gynaecological and obstetric 
history as well as drug history. Subjects completed the Pictorial  Blood 
Assessment Chart (PBAC) at least during one period[192]. All women had to sign 
a consent form. The subject’s details will be addressed in the results section of 
each chapter. 
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Figure 2.1: summary of the recruited subjects in the study, including drop out subjects and 
final analysed number of subjects samples in each group. 
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Table 2.1: Summary of demographic details of participants 
The character  Fibroid 
group(G1) 
N=45 
Normal uteri 
group(G2) 
N=30 
P 
value 
Age  45.72±0.93 44.83±0.79 0.47 
BMI 27.98±0.87  29.50±1.2 0.33 
Length of period 
<3 days 
3-5 
5-7 
7-10 
>10 
 
N=0 
N=10 
N=15 
N=12 
N=8 
 
N=3 
N=3 
N=15 
N=7 
N=2 
 
Hormonal assays (mean±SE): 
LH (mIU/mL) 
FST(mIU/mL 
E2 (pmol/L 
Progesterone (nmol/L) 
 
3.95±0.72 
9.5±2.5 
333±66 
9.6±2.8 
 
 
6.2±(2.2) 
9.2±2.8 
435±139 
9.8±3.3 
 
0.33 
0.95 
0.51 
0.97 
Types of uterine fibroids: 
Submucosal 
Intramural 
Subserosal 
multiple types of fibroids 
 
(n= 12) 
(n= 17) 
(n=7) 
(n=9) 
  
Excluded biopsies: 
No PBAC was provided 
Not adequate for endometrial 
staging 
Inactive endometrium  
 
(n=3) 
(n=3) 
 
(n=4) 
 
(n=10) 
(n=1) 
 
(n=5) 
 
Endometrial staging: 
Proliferative 
Early secretory 
Mid-secretory 
Late secretory 
 
(n=10) 
(n=8) 
(n=4) 
(n=2) 
 
(n=8) 
(n=4) 
(n=5) 
(n=1) 
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2.2 Histological Studies 
2.2.1 Biopsy specimen- Collection 
2.2.1.1 Biopsy specimen- Collection- Uterine biopsies  
2.2.1.1.1 Group one 
 
Endometrium was collected by means of a Pipelle sampler from women who 
attended the hysteroscopy clinic in Stobhill hospital to investigate their heavy 
menstrual bleeding and from women who underwent uterine artery 
embolisation. In addition, uterine biopsies including,endometrium , myometrium 
and fibroidstissue, were collected from fresh hysterectomisedfibroid uteri 
specimen by a pathologists in the pathology laparatory, Glasgow Royal Infirmary 
hospital (GRI). The endometrial biopsieswere collected at the time of 
hysteroscopy during the first attendance and at the time of Uterine Artery 
Embolisation (UAE) which performed in the radiology department, Glasgow 
Gartnavel hospital. All hysterectomy operations were performed in the 
gynaecology department, GRI. 
 
2.2.1.1.2 Group two 
 
In G2, Endometrium was collected by means of a Pipelle sampler from women 
who attended the hysteroscopy clinic in Stobhill hospital to investigate their 
heavy menstrual bleeding with no evidence of uterine pathology.  
 
 
2.2.1.2 Biopsy specimen -Collection- Blood samples 
 
A five millilitre blood sample was obtained in a lithium heparin bottle at the 
time of having the uterine biopsies (endometrial, myometrium and fibroid 
tissue) from all participants for hormonal assessment including estradiol, 
progesterone, Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). 
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In addition, serum was collected for the measurement of cytokines: tumour 
necrotising factor-α (TNF-α), transforming growth factor-β(TGF-β), interleukin 
1,6 and 8(IL1, 6, and 8) and c reactive protein CRP), Proangiogenic (VEFG A) and 
intercellular adhesion molecule -1(ICAM-1). 
 
 
2.2.2 Biopsy specimen -Handling and storage 
2.2.2.1 Biopsy specimen -Handling and storage-uterine biopsies  
In both G1 and G3 ,every Pipelle endometrial biopsy was divided immediately 
into two parts, where one part was put in formalin and sent to the pathology 
department in the Glasgow Royal Infirmary hospital (GRI) for paraffin embedded 
block process. The second part was put directly in RNA later solution, Ambion R 
0901 RNA Later® (0.5-1 cm of tissue sample in 5-10 ml of the solution 
respectively) and stored in -20Cº freezer (Reproductive and Maternal Medicine 
laboratory. McGregor building, 2nd floor, Glasgow Western Infirmary). After two 
weeks, biopsies were transferred to a cry-pot by using liquid nitrogen and stored 
in -80 Cº till used. Note, when there was not enough pipelle sample obtained the 
whole tissue was sent for histopathology assessment and paraffin block process.  
RNA was then extracted from the blocks (see below). 
 
In G2, the pathologist was informed in advance about the arrival of the specimen 
and during the hysterectomy the excised fibroid uterus was taken immediately 
(within 5 minutes) to the pathology department GRI where biopsies from 
endometrium, myometrium and from each type of fibroid( submucous, 
intramural and subserosal) were taken by the pathologist. The biopsies were put 
in RNA later within a maximum of 10 minutes from removal of the uterus and 
they were stored in same manner as above.  
 
2.2.2.2 Biopsy specimen -Handling and storage- blood samples 
Blood samples were centrifuged at 13000 rpm for 15minutes in temperature 4°C. 
The serum was put in 6 tubes (0.5ml in each tube) then 3 tubes were stored in 
each of two different -80C° freezers. 1 ml serum from each sample was sent to 
the biochemistry department-GRI where estradiol, progeterone, Luteinizing 
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Hormone (LH) and Follicular stimulating hormone (FSH) assays were assessed 
using ARCHITECT reagent for each assay through the ARCHITECT ί System.  
 
2.3 Blood loss assessment 
The Pictorial Blood Loss Assessment Chart (PBAC) was used to estimate how 
much blood women lose during their periods. This is an internationally validated 
chart[192]. Participants had the chart with them at home when they attended 
the hysteroscopy clinic to fill in when they had their period. For participants 
who were on the list for hysterectomy or uterine artery embolisation,the 
pictorial chart was sent to them in advance to complete during their periods. 
Women indicated the degree to which the sanitary wear was soiled by indicating 
the number of slightly, moderately and heavily soiled pads and tampons that 
they used.  Assessment of blood loss using this chart and the results from this 
study are detailed in Chapter 3. 
 
2.4 Histological dating 
Histological dating was carried out by Professor Williams, University of Edinburgh 
according to Noyes et. al.[193],to confirm the stage of the menstrual cycle. All 
histological stages were consistent with patient’s last menstrual period (LMP) 
and circulating estradiol and progesterone concentrations in venous blood 
obtained was collected at the time of tissue collection. Consistency between 
these three parameters has been approved to be robust method for 
characterising endometrial samples [194]. Endometrial samples where there was 
not enough for dating the endometrium were excluded from our analysis. 
 
 
2.5 Real Time quantitative Reverse Transcription 
Polymerase Chain Reaction (RT-PCR) 
The standard PCR a laboratory method that allows exponential amplification of a 
targeted DNA molecule, then the amplified DNA is detected at the end of the 
reaction which can be time consuming. The real time quantitative PCR follows 
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the general principle of the PCR technique, however, reverse transcriptase 
enzyme is used to generate complementary DNA from mRNA. In addition, the 
amplified DNA is detected as the reaction progresses in real time. Because of the 
simultaneous amplification and detection, quantification is performed once per 
cycle (Figure 2.1). This quantity can be either an absolute number of copies or a 
relative amount when normalised to DNA input or additional normalising genes. 
 
 
 
Figure 2.2: Shows summary of processes involved in real time PCR 
 
2.5.1 RNA extraction 
RNA isolation was performed in a biosafety cold hood after all work surfaceshad 
been cleaned up using either 75% Ethanol or Zap RNase and  all other equipment 
such as pipettes, forceps and the homogenizer were also carefully cleaned to 
prevent contamination. 
 
2.5.1.1 Isolationof RNA from frozen samples 
Tissue samples were kept frozen on dry ice while weight measurement was 
taken. The balance was zeroed with cold cryo-pot on it and quickly the tissue 
sample was added to the pot and weighed. The weight of samples taken was 
between 50 and 100mg, large pieces of sample were ground into smaller pieces 
using a cold mortar, spatula and scrape and adding liquid nitrogen some ties to 
keep them cold. Every sample was transferred to a glass tube containing Trizol 
solution (1ml of Trizol was added to 50-100mg of tissue sample), then were 
homogenized using a hand held homogenizer and separated into 1ml aliquots in 
autoclaved 1.5 eppendorf tubes. The tubes were incubated at room temperature 
(RT) for 5 minutes to permit complete dissociation of nucleoprotein complexes. 
0.2ml of chloroform were added to each 1ml Trizol and shaken vigorously in 
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order not to reduce the RNA yields. Tubes were incubated for 3 minutes at room 
temperature before they were centrifuged at 13,000 rpm for 15 minutes at 
4°C.The  upper aqueous phase was transferred to fresh autoclaved tubes and 
0.5ml of Isopropyl alcohol was added to each 1ml Trizol used in the initial 
homogenization to precipitate RNA from the aqueous phase. A second 
centrifugation was performed at 13,000 rpm for 10 minutes at 4°C after tubes 
were incubated for 10 minutes at room temperature. The isopropyl alcohol was 
decanted and a small white pellet was left at the bottom of the tube. 1ml of 75% 
of ethanol was added to each tube then vortexed. At this stage some sample was 
stored in - 80C°and the rest of the protocolcontinued later on. The third 
centrifugation was done at 10,000 for 5 minutes at 4°C. Ethanol was poured off 
and the tubes tapped carefully in order not to dislodge the pellet and left to dry 
for 10 minutes at room temperature. Appropriate amounts of 
Diethylpyrocarbonate (DEPC) treated water were added to each tube according 
to the pellet size (range between 40µl for a large pellet and 15 µl for the 
smallest one). Tubes were then vortexed, centrifuged quickly and incubated 
twice for 5 minutes at 65°C in heating block. Tubes kept on ice all the time 
during Nanodrop measurement and then stored at -80C°. 
 
2.5.1.2 Isolation of RNA from formalin –fixed paraffin- embedded samples  
Extraction of RNA from formalin-fixed paraffin- embedded tissue (FFPE) was 
required for some samples where there was no fresh stored tissue. Many 
protocols have been described to extract RNA from FFPE samples. Most of these 
protocols follow similar basic principles and the RNA is extracted by spin column 
purification according to: deparaffinization, followed by  cell disruption with 
heated proteinase K, then  RNA isolation by alcohol precipitation [195]. 
I used Ambien kit 1975 (Recover All total nucleic acid isolation kit-Life 
technologies, Paisley, UK) and followed the protocol as directed. I practiced the 
method at the Molecular Pathology, Pathology Department-GRI supervised by Dr 
David Millen.  
A histological section of 10-μm thickness was cut from each block using a 
conventional microtome. A separate blade was used for each block to prevent 
contamination. The section was collected by cleaned forceps in an Eppendorf 
tube (I worked on 2-3 tubes at a time). The section was deparaffinazed by 1 ml 
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of xylene added to the tube, mixed then centrifuged at 10,000rpm for 5 minutes 
at 4°C, followed by repeated addition of 1 ml absolute alcohol to the pellet. It 
was vortexed then centrifuged at full speed for 5 minutes. Alcohol was aspirated 
and discarded without disturbing the pellet. The pellet was allowed to air dry at 
room temperature for 10minutes before the addition of lysis buffer. 400µl of 
digestion buffer and 4µl of protease were added to the samples (from the kit).  
The tubes were mixed gently, then placed into the rotatory oven at 50°C and 
incubated with rotation for 3 hours. Proteinase K incubation at high temperature 
allows efficient degradation of proteins that have cross linked with each other 
and RNA.  . In the most recent protocol proteinase K incubation for 15 minutes 
only is effective, but I preferred to use the longer incubation as it was assessed 
and recommended by people working in the Molecular Pathology, Glasgow Royal 
Infirmary GRI.After proteinase K incubation, RNA was isolated by quantification 
and qualification of RNA by adding 480µl additive solution from the Ambion kit. 
The solution should be white and cloudy after mixing, and then it turned clear 
by addingabsolute alcohol to each tube. At this stage, a filter cartridge was 
placed into one of the collection tubes supplied in the kit.  
The mixed solution was pipetted into the filter cartridge and centrifuged at 
10,000 rpm for 60 seconds to pass the mixture through the filter then the flow 
through solution was discarded. The filter cartridge was washed by 700µl and 
500µl of wash 1 and wash 2/3 solution respectively. DNase mix was added to the 
centre of the filter, where the mix including DNase buffer 6µl, DNase 4µl and 
nuclease free water 50µl. A master mix was made when more than one sample 
was processed.  
The washing process was repeated after 30 minutes incubation at RT once with 
500µl of wash 1 and washed twice with 500µl wash 2/3.  The filter cartridge was 
transferred to a fresh collection tube and 15µl of nuclease free water, heated to 
95°C, added to the centre of the filter. The tube was incubated for 60 seconds 
at room temperature then centrifuged for 1 minute at 13,000 rpm to pass the 
mixture through. The collected sample volume was checked by the Nanodrop 
and stored at -80°C. 
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2.5.2 RNA quantification and qualification 
The quantity of total RNA extracted above was examined by using an automated 
spectrophotometer (RNA 6000 Nonodrop). The concentration of total RNA in an 
aliquot of 1μl of sample was determined (ug/ul) and the ratio of optical density 
at a wavelength of 260nm to a wavelength of 280nm (260:280) was additionally 
calculated. The sample was considered not to have sufficient purity for use in 
further work when it had 260:280 ratios less than 1.6. Quality and integrity of 
the extracted RNA was examined by Agilent 2100 Bioanalyser system. This was as 
a paid service from the Biochemistry Department, University of Glasgow 
(Glasgow Biomedical Research Building). Only RNA that displayed intact 18Sand 
28S peaks was reverse transcribed (RT) to cDNA for real-time PCR analysis. RNA 
integrity number (RIN) for the tested samples with clear 18S, 28S peaks was 
between 3 to9.  
After about half of our samples had been analysed by Agilent bioanalysis, I 
noticed that Nanodrop measurement results in addition to Ct values of 
endogenous control only appeared to be a good indicator for the purity of RNA 
samples that were used for the Taquman technique.In contrast to the microarray 
method, which needs high RNA Integrity Number (RIN) (≥ 7); there is no a clear 
cut-off point ofRINis required for Taquman process. Therefore, usable RNA 
samples may be discarded as poor quality because of low RIN.  However, using 
the endogenous control values to evaluate the quality of extracted RNA is a 
detection sensitivity way as it requires significant hands-on time to complete 
loading and preparation of TaqMan plate.  
 
2.5.3 Quality of RNA yield from paraffin versus RNA yield from 
frozen samples 
Four samples were used to compare RNA extraction from frozen paraffin 
embedded tissue. The quantity of RNA recovered from the FFPE samples was 
lower than that recovered from frozen samples at approximately 60 ng/µl from 
FFPE compared to approximately 1200 ng/µl from frozen samples. This 
translated to lower absolute quantities of the mRNAs of interest as indicated by 
higher CT values compared to those from the frozen samples. The mean B-actin 
CT from FFPE samples was 36, versus 26 from frozen samples. This potentially 
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indicates more RNA degradation from the FFPE samples compared to that from 
the frozen samples.Delta CT values, which reflect on the relative mRNA 
expression, do not appear to have been affected by the lower RNA yield, as 
there is no significant difference between delta CT in the frozen compared to 
the FFPE samples (p= 0.67) (Figure2.2). 
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Figure 2.3: Delta CT values for a vascular marker obtained from frozen and paraffin 
embedded samples. 
 
 
2.5.4 Generation of complementary DNA (cDNA) 
Quantification of gene expression was achieved using the sample of mRNA 
extracted above. Batches of 30 µl of cDNA was synthesised from approximately 
5µg of total RNA from each sample using the High Capacity cDNA Reverse 
Transcription kit( Life technologies, Paisley, UK) according to manufacturer’s 
protocol. 
Each time a patch of cDNA was made, a simultaneous control experiment was 
performed on a sample of ‘spare’ total RNA. The master mix for the control 
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sample excluded the multiscribe reverse transcriptase (MRT), and therefore it 
acted as negative control run for each 96 well TaqMan plate (Table 2.2). 
 
 
 
Table 2.2: Content of TaquMan master mix and No RT. 
Preparations Sample volume of 
mastermix 
No RT mastermix 
10xRT Buffer 1ul 1ul 
25xdNTPs 0.4ul 0.4ul 
10xrandom primers 1ul 1ul 
Multiscribe reverse 
transcriptase 
0.5ul 0 
Superasin (1U/ul) 0.5ul 0.5ul 
Nuclease free water 1.6ul 2.1ul 
Total per reaction 5.0ul 5.0ul 
Total volume 30 ul(15.0ul of 
mastermix+15.0ul of RNA 
sample) 
10ul(5.0ul+5.0ul of 
RNA sample) 
 
 
All primer probes used for gene expression quantification such as human ACTB (B 
actin), cyclooxygenase 1 (COX-1), cyclooxygenase 2(COX-2), interleukin8 (IL8), 
vascular endothelial growth factor-A (VGEF-A), vascular endothelial growth 
factor receptor 1(VEGFR1) and vascular endothelia growth factor receptor 
2(VEGFR2) were purchased as predesigned, inventoried ‘Spans exons’ TaqMan 
Gene Expression Assays from Life Technologies. The details of the probes used 
are shown in Table 2.3.  
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Table 2.3: Target assays mixes and endogenous control probes used in QPCR. All probes 
(except EP2) were inventoried and obtained from Applied Biosystems, Cheshire, UK. 
Gene 
symbol 
Gene name Assay ID Supplier 
B actin Human ACTB(B-Actin) 
endogenous control 
4310881E Life 
technologies 
PTGS1 
(COX-1) 
prostaglandin-endoperoxide 
synthase 1 
Hs00377721_m1 Life 
technologies 
PTGS2 
(COX-2) 
prostaglandin-endoperoxide 
synthase 2 
Hs00153133_m1 Life 
technologies 
IL8 Interleukin 8 Hs00174103_m1 Life 
technologies 
VEGF-A Vascular endothelial growth 
factor A 
Hs00900055_m1 Life 
technologies 
FLT1 
(VGEF-R1) 
fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor receptor1) 
Hs01052961_m1 Life 
technologies 
VEGF-
R2(KDR) 
kinase insert domain receptor 
(vascular endothelial growth 
factor receptor2) 
Hs00911700_m1 Life 
technologies 
 
Prostaglandin E receptor 2 (EP2) primers and probe for quantitative PCR were 
designed using the PRIMER express programme (Table 2.4).  PE2 primers and 
probe 1 in 50 dilutions were used for PCR reaction mixture (Table2.5). 
For normalisation of quantitative results, B-actin was used as reference gene.   
1 µl of undiluted cDNA samples required for each probe with a 1 µl of a1 in 10 
dilution of cDNA sample required for B-actin. 
Quantification was implemented on an Applied Biosystems 7900 using 96 well 
plate with a different probe and sample combination in each well.  
The thermal cycler conditions were 50°C for 2 minutes, 95°C for 10 minutes 
followed by 40 cycles of 95°C for 15 second and 60°C for 1 minute. For each 
probe, samples were run in duplicate and control samples were run for every 
second plate using DDW and NRT. 
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Table 2.4: EP receptor2 primers and probe for quantitative PCR from Applied Biosystem 
Primers/probe 
symbol 
Primers/probe sequence Primer/probe Life 
Technologies Ref. No. 
EP2F  5   -GAC CGC TTA CCT GCA GCT GTA C-3 
(forward) 
186475051-60-11 
EP2R 5-TGA AGT TGC AGG CGA GCA-3  
(reverse) 
186475051-70-2.1 
EP2PROBE 5  -CCA CCC TGC TGC TGC TTC TCA TTG 
TCT-3 
 
(6-carboxyfluoroscein labeled) 
186475051-80-1.1 
 
Table 2.5:PCR reaction mixture 
Reagents EP2 primers/probe added volume (ul) added volume  for the 
other assays (ul) 
2xTaquMan mastermix 12.5 12.5  
20xtarget assay mix / 
probe for EP2 
1.25 1.25 
DDW 3.75 10.25 
EP2F 3.75 - 
EPS 3.75 - 
 
 
 
 
Chapter 2 S.Abukhnjr 2014 89 
 
2.5.5 Selection of endogenous control gene 
Expression levels of target genes should be normalised to expression levels of 
internal control genes as normalisation is a common feature of most transcript 
quantification techniques. The endogenous control gene (housekeeping gene) 
should show a constant expression level in the tissues of interest. However, it 
has been demonstrated by a number of studies that frequently used control 
genes such as β-actin and GAPDH display significantly variable transcript levels 
not only  in cells of different histological origin but also under various 
physiological or experimental conditions[196]. This study examined the stability 
of expression levels of three endogenous control genes β-actin, glyceraldehhde-
3-phosphate dehydrogenase (GAPDH) and 18S in six tissue samples of 
endometrium, and five myometrium and uterine fibroids tissue samples in order 
to identify the best one to use as endogenous control gene for normalisation, the 
expression profile for each gene was determined for these samples. Each taqMan 
Assay was run in duplicate for each sample. The Ct values were then used to 
determine the average Ct and Standard Deviation (SD) for each gene across the 
different samples. The SD was used to identify the gene with the lowest SD 
(Table2.6). The result shows that B-actin was the control gene with narrowest SD 
variation among the samples (SD of B-actin was 1.85; SD of GABDH was 2.06 and 
3.78 SD of 18S). Although S18 was abundant in all uterine tissue, it was the least 
stably expressed gene with highest variability amongst the genes (Figure 2. 3) as 
well as the widest SD variation. Therefore, 18s was excluded as endogenous 
control gene. To confirm the result β- actin and GABDH were examined for a 
further 11 endometrial samples and β-actin had the narrowest SD .Thus I chose 
β-actin as the best endogenous control gene in this study. 
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Table 2.6:Differences in RNA transcription level between β--actin, GAPDH and 18S in uterine 
tissue. 
 Endometrial samples Myometrium  samples Fibroids samples 
mean Ct value/SD  
B- actin 24.47/1.85 
 
27.68/3.60 23.96/1.74 
GAPDH 26.20/2.06 
 
30.29/4.66 27.48/3.68 
18S 17.66/3.78 
 
25.37/6.80 16.46/2.61 
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Figure 2.4: Variation of RNA transcription level of β-actin, GAPDH and 18S in endometrial 
samples in women with HMB. 
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2.5.6 Analysis and detection of the target gene expression 
relative to β-actin 
PCR data were captured and analysed using the automated photometric detector 
and detection software (ABI Prism 7900, Sequence Detection System 2.3).The 
threshold value for each probe was determined and used throughout for all PCR 
cycles using that probe (Table2.7). The threshold value indicates the background 
level of fluorescence for that probe.  
The cycle threshold (Ct) value indicates the cycle number at which the 
fluorescence passes the set threshold value (background value); therefore it is a 
way to determine the concentration of the gene of interest. Ct values were then 
determined for each well and since samples were run in duplicate, the mean Ct 
value was used and where the difference between Ct values was more than 1.5 
Ct values, they were excluded and samples repeated. The expression was then 
determined relative to the β-actin value for the sample which provides the   
Delta Ct (ΔCt) value.  ΔCt value is calculating by subtract the Ct value of 
endogenous control from the Ct value of target gene. The lower the Ct value, 
the greater the amount of gene present in the sample.  
 
Table 2.7: Threshold values for relevant genes 
Gene symbol Threshold value 
β-actin 0.360 
COX-1 0.200 
COX-2 0.194 
IL8 0.247 
VEGF-A 0.230 
VEGF-R1 0.264 
VEGF-R2 0.200 
EP2 0.200 
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2.6 Immunohistochemistry (IHC) 
Standard IHC techniques were performed to localise a number of cellular 
proteins within the human endometrium, myometrium and fibroid tissue. All 
protocols were optimised to determine the best condition for maximal 
immunostaining with minimal background staining. 
 
2.6.1 Antibodies 
Antibodies are host proteins found in plasma and extra cellular fluids that serve 
as the first response and comprise one of the principal effectors of the adaptive 
immune system. They are produced in response to molecules and organisms, 
which they ultimately neutralize and/or eliminate. The ability of antibodies to 
bind an antigen with a high degree of affinity and specificity has led to their 
abundant use in a variety of scientific and medical disciplines. As a reagent, 
there is no other material that has contributed directly or indirectly to such a 
vast range of scientific detections. Their use in diagnostic analyses and as 
therapeutics has had a profound impact on the improvement of health and 
welfare in both humans and animals. 
Antibodies are glycoproteins secreted by specialized B lymphocytes known as 
plasma cells. Also referred to as immunoglobulin (Ig), because they contain a 
common structural domain found in many proteins, antibodies are composed of 
four polypeptides. Two identical copies of both a heavy and light chain are held 
together by disulphide and non-covalent bonds, and the resulting molecule is 
often represented by a schematic Y-shaped molecule (Figure 2.4). 
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Figure 2.5: Pictorial representation of a typical antibody structure, showing individual 
chains and regions of variability and constancy. 
 
Depending on the Ig class, up to five structural molecules may be combined to 
form any one antibody. In mammals, there are five classes of Ig (IgG, IgM, IgA, 
IgD, and IgE).In select mammals, IgG and IgA are further subdivided into 
subclasses, referred to as isotypes, due to polymorphisms in the conserved 
regions of the heavy chain. Ig class determines both the type and the temporal 
nature of the immune response. All primary antibodies used in this research 
were the IgG class. Some were polyclonal in nature such as COX-2, IL8, PGE2, 
VEGF, and others monoclonal in nature such as CD56, CD68, and NE. The 
variable domain is specific to the target protein and is responsible for antigen 
binding. Polyclonal antibodies are produced by a variety of cells within an 
animal species. In that, they are immunochemically dissimilar and may react 
against various epitopes on the antigens against which they have been raised 
(Figure 2.6). 
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Figure 2.6: polyclonal antibodies rose against an antigen (Ag). 
 
2.6.2 Formalin-fixed paraffin embedded sample block process 
Tissue processing took place in the pathology laboratory in Glasgow Royal 
Infirmary and the Southern General Hospital. The usual fixative for paraffin 
embedded tissues is neutral buffered formalin (NBF). 10% NBF contains 4% 
formaldehyde by weight and is therefore equivalent to 4% paraformaldehyde. 
Optimal formalin fixation requires adequate time to form cross links, generally ≥ 
24 hours, at room temperature. After this, paraffin processing was performed by 
taking the cassettes through a series of graded ethanol alcohol (EtOH) baths to 
dehydrate the tissues and then into xylene.  Hot paraffin can then permeate the 
tissues. Finally, embedded tissue in paraffin block process took place by adding 
the tissue cassette into melted paraffin according to the process instructions. 
2.6.3 Sections preparation 
Paraffin embedded sample blocks of the study samples were collected from the 
pathology department archive, Glasgow Royal Infirmary (GRI) and the new 
pathology department archive in the Southern General Hospital (2012 onwards) 
after obtaining the histopathology laboratory number. Sections were cut using a 
microtome (Leica RM 2135) 5µ thick. Because of the difficulty in cutting fibroid 
sections, these were cut to a thickness of 3 µ and mounted on superfrost glass 
slides (BDH, Merck House, and Poole) then the Slides heated overnight in oven at 
45°C.  
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2.6.4 ABC IHC method 
2.6.4.1 Deparaffinising and Rehydration 
Xylene was used to remove all paraffin from the tissue sample to give the 
antibodies complete access to the tissue. Before clearing, the samples were 
heated to 55°C for 35 minutes to melt the paraffin and then washed multiple 
times with xylene to remove the paraffin. Next, the xylene was removed by 
graded washes with xylene and ethanol, and then the sample was rehydrated 
through graded washes of ethanol in water, ending in a final rinse in 0.01M 
phosphate buffered saline (PBS). From this point until final mounting, the slides 
should remain wet to avoid nonspecific antibody binding and high background 
staining. 
 
2.6.4.2 Antigen Retrieval  
Formaldehyde forms methylene bridges between proteins, which can obstruct 
the epitope (a short amino acid sequence that the antibody is able to recognize 
as a part of the antigen) recognition by the primary antibodies. Either of two 
methods was used to remove these bridges which were heat-induced epitope 
retrieval (HIER) and proteolytic-induced epitope retrieval (PIER). Temperature, 
pH and time of incubation are critical factors that must be optimised for proper 
antigen unmasking without causing morphological damage. Sodium citrate (pH 6) 
and Tris/EDTA (pH 8) buffers were used as appropriate for microwaving sections 
in pressure cooker. 
 
2.6.4.3 Staining methods 
All immunohistochemistry (IHC) performed by using an indirect staining method, 
where an enzyme labelled secondary antibody directed against the primary 
antibody (Figure4). This allows for amplification of the primary antibody-antigen 
complex thereby enhancing the target signal. Furthermore, the use of a 
biotinylated secondary antibody allows for subsequent incubation with pre-
formed avidin-biotin complex thereby the use of the high affinity that avidin has 
for biotin can lead to further amplification of signal. Because of the high affinity 
of avidin for biotin the binding can be strongly irreversible. If these complexes 
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attached to an enzyme-substance system, the amplified antibody-antigen 
complex can be visualised. This tertiary signal amplification increases the 
sensitivity of staining techniques, which helps to reduce unwanted background 
staining. 
 
2.6.4.4 Controls  
Validation of all IHC protocol was carried out by the inclusion of control tissue 
slides. To assure the primary antibodies worked specifically to their target, the 
inclusion of positive and negative controls were required. For negative controls, 
the primary antibodies were omitted. For the positive controls, tissue samples, 
which are known to express the protein of interest, were used in the experiment 
(Table 2.8). This inclusion is required to ensure that the immunostaining 
achieved is within the expected cellular compartments. 
 
 
Table 2.8: The used positive control tissues for different antigens in this study 
Antigen Positive control tissue 
VEGF Kidney 
PGE2 ovary 
IL8 Tonsil 
COX-2 Colon  
CD56 Colon 
CD68 Tonsil 
NE Tonsil 
 
 
 
2.6.4.5 Background immunostaining 
Before using antibodies to detect proteins by immunohistochemistry (IHC), all 
epitopes on the tissue sample were blocked to prevent the nonspecific binding 
of the antibodies. Otherwise, the antibodies or other detection reagents may 
bind to any epitopes on the sample. Therefore, the blocking step for IHC was 
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performed just prior to incubating the sample with the primary antibody. The 
general protocol was to incubate the fixed, embedded, mounted, cleared and 
unmasked IHC sample with the appropriate blocking buffer for 30 minutes at 
room temperature based on the optimised protocol specific to each antibody and 
target antigen. Normal serum was the common blocking reagent, because the 
serum carries antibodies that bind to reactive sites and thus prevents the 
nonspecific binding of the secondary antibodies used in the assay. A critical 
factor, though, is to use serum from the species that the secondary antibody was 
generated in, as opposed to the species of the primary antibody. Serum from the 
primary antibody species would bind to reactive sites, but the secondary 
antibody would recognize those non-specifically-bound antibodies along with the 
antibodies bound to the target antigen. Prevention of peroxidase activity and 
reduction of background staining can be obtained by submerging the section in 
hydrogen peroxide (H2O2). In addition, incubation of sections in avidin/biotin 
solution to block avidin /biotin activity can result in very low background 
staining. Standard IHC techniques were performed to localise a number of 
cellular proteins within the human tissue. All protocols were optimised to 
determine the best conditions for maximal immunstaining with minimal 
background staining.  
 
2.6.5 General immunohistochemistry protocol 
Tissue sections of 3µ thickness were heated before use in oven at 55°C for 35 
minutes. Slides were then dewaxed by placement in xylene for two ten-minute 
episodes. Afterward, sections were rehydrated through graded alcohols,100% 
ethanol (2× 5min), 95% ethanol (2× 5min), 90% ethanol (2× 5min)and 70% ethanol 
(5min)before receiving five-minutes wash in 0.01 M phosphate buffered saline 
(PBS,PH 7.6). Endogenous peroxidase activity was blocked by exposing slides to 
0.5% H2O2 in Methanol (300 ml Methanol + 5 ml H2O2) for 30 minute after two 
washes in PBS (2×10min). Antigen retrieval was then carried out by putting 
buffer solutions in pressure cooker (Lakeland Plastics Ltd, Cumbria, UK) for 15 
min at full power to come to the boil, then slides added to the buffer solutions 
and slides, microwaved for 8min on full power (after 3 min the cooker should be 
at pressure and slides microwaved under pressure for 5min), followed by a 20 
minute cooling period in the same buffer solutions. 
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 Sections were then washed in distilled water for 5 minutes then in PBS for 
another 5 minutes. After drawing a wax ring around each tissue section, sections 
were incubated in the appropriate blocking, non-immune serum for 30 minutes 
in an humidified chamber at room temperature (the blocking serum was for the 
same species that secondary antibodies were made in) before incubating them 
overnight at 4°C within the primary antibody solution. 
 Immunohistochemical staining techniques were optimised for each individual 
protein of interest. The protocols used for individual primary antibodies are 
summarized in Tables 8&9. Positive controls were used in every protocol to 
determine the best condition for maximal immunostaining with minimal 
background staining. Sections were washed in PBS (2×5min) then incubated for 
30 minute in a biotinylated secondary antibody (an antibody with biotin 
covalently linked to its structure raised against the specific species of the 
primary antibody) 1 in 200 dilutions. 
 During this incubation time, a solution of preformed avidin/biotin-peroxidase 
enzyme complex (ABC Elite, VICTASTAIN, PK6100, and Vector Laboratories kit) 
was prepared 30 minute before use. Avidin /biotin solution was prepared by 
adding two drops of A buffer to 5ml PBS and mixed well then adding two drops 
of B buffer, which are included in Vector Laboratories kit , and mixed well, then 
incubated for 30 minute in room temperature.  The avidin- biotinylated 
peroxidase complexes are small and highly active, allowing greater tissue 
diffusion and binding to the biotinylated secondary antibody. The peroxidase-
based sensitive detection system is more sensitive than regular ABC methods, 
allowing better detection of biotinylated targets and hence less detection of 
non-specific background antigens. Sections were washed in PBS (2×5min) in 
between steps before applying the next incubation. Peroxidase substrate, 
diaminobenzidine tetra hydrochloride (DAB, DAKO Corp, Ca, USA) was then 
employed as the chromagen. The peroxidase enzyme leads to oxidation of the 
DAB substrate, resulting in a sTable enzyme –substrate complex (reaction time 
was for 10 min) and a brown precipitation, allowing visualization of the sites of 
positive immunoreactivity. 
 Sections were washed for 5 minute in distilled water before counter staining 
with Harris’ Haematoxylin (for 10-15 sec.).Subsequently, sections were washed 
with tap water for seconds then dehydrated in ascending grades of ethanol and 
then final incubation in xylene (2× 10 min) was performed prior to mounting in 
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DPX. The used IHC protocol for each marker was summarised in Table 2.9 &Table 
2.10.  
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Table 2.9: Summary of IHC protocols 
N
e
g
a
ti
v
e
 
c
o
n
tr
o
l 
 O
m
it
 P
A
 
O
m
it
 P
A
 
O
m
it
 P
A
 
O
m
it
 P
A
 
T
e
rt
ia
ry
 
a
m
p
li
fi
c
a
ti
o
n
o
n
 
 A
B
C
 E
li
te
 
V
e
c
ta
st
a
in
 
A
B
C
 E
li
te
 
V
e
c
ta
st
a
in
 
A
B
C
 E
li
te
 
V
e
c
ta
st
a
in
 
A
B
C
 E
li
te
 
V
e
c
ta
st
a
in
 
A
n
ti
g
e
n
 
re
tr
ie
v
a
l 
 0
.0
1
 M
 -
 
N
a
  
c
it
ra
te
 
0
.0
1
 M
- 
 
N
a
  
c
it
ra
te
 
0
.0
1
 M
- 
N
a
  
c
it
ra
te
 
0
.0
1
 M
- 
 N
a
  
c
it
ra
te
 
S
e
c
o
n
d
a
ry
 a
n
ti
b
o
d
y
 
In
c
u
b
a
ti
o
n
 
3
0
 m
in
s.
 
  
 R
T
 
3
0
 m
in
s.
 
  
 R
T
 
3
0
 m
in
s.
 
  
R
T
 
3
0
 m
in
s.
 
  
R
T
 
C
o
n
c
. 
1
:2
0
0
 
1
:2
0
0
 
1
:2
0
0
 
1
:2
0
0
 
S
p
e
c
ie
s 
H
o
rs
e
 –
 
b
io
ti
n
y
la
te
d
 
G
o
a
t-
 
b
io
ti
n
y
la
te
d
 
R
a
b
b
it
- 
b
io
ti
n
y
la
te
d
 
R
a
b
b
it
- 
b
io
ti
n
y
la
te
d
 
P
ri
m
a
ry
 a
n
ti
b
o
d
y
 
in
c
u
b
a
ti
o
n
 
4
°
C
 
O
v
e
r 
n
ig
h
t 
4
°
C
 
O
v
e
r 
n
ig
h
t 
4
°
C
 
O
v
e
r 
n
ig
h
t 
4
°
C
 
O
v
e
r 
n
ig
h
t 
C
o
n
c
. 
1
:2
0
0
 
1
:2
0
0
 
1
:5
0
 
1
:5
0
0
 
S
p
e
c
ie
s 
G
o
a
t 
R
a
b
b
it
 
G
o
a
t 
G
o
a
t 
A
n
ti
g
e
n
 
 V
E
G
F
- 
A
 
P
G
 E
2
 
  IL
 8
 
C
O
X
-2
 
 
Chapter 2 S.Abukhnjr 2014 101 
 
Table 2.10: Summary of IHC protocols for leukocytes 
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2.6.6 Scoring and analysis of immune-reactivity 
The immunostaining of intensity of epitopes in all antibodies stained sections 
was assessed in the semi-quantitative manner on the 4- point scale: 0= no 
immunostaining, 1= mild immunostaining, 2= moderate immunostaining, 3= 
intense immunostaining. In endometrial sections, glandular and stromal tissue 
scored separately. The 90% of tissue sections weremeasured with a computerised 
image analysis system (Version 4.0, Digital Image Hub, Leica biosystems) and 10% 
were scored by the research fellow. For COX-2, PGE2, and IL8, double scoring 
with the same research fellowwas performed. The correlation 
coefficientbetween manual scoring, automated scoring and between double 
scoring methods wasaccepted at ≥ 0.7. Detail of scoring method for the used 
antibodies was provided in each relevant chapter. 
 
 
 
2.7 Statistics 
Descriptivestatistics were used when it was appropriate. TaqMan data were 
collected on Microsoft excel sheet. Mann-Whitney test was used to compare 
between groups for non-parametric data and results expressed in median values 
(95%Cl). ANOVA and Kruskall-Wallis test used as appropriate. Spearman 
correlation coefficient used for association between variables. Fisher test was 
used to compare between categorical data Results were statistically significant 
with p value ≤ 0.05. Details of when each test used was addressed in each 
relevant chapter. Minitab 16 Statistical Software was used for data analysis and 
GraphPad Prism 6 was used for creating the graphs. 
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3. Assessment of menstrual blood loss 
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3.1 Introduction 
Heavy menstrual bleeding (traditionally known as menorrhagia) is a common 
complaint in gynaecology. It not only affects women’s quality of life but leads to 
iron deficiency anaemia [197-200]. Heavy menstrual bleeding is subjectively 
defined as excessive menstrual blood loss, which interferes with a woman’s 
physical, social, emotional, and/or material quality of life[83]. It can occur 
alone or in combination with other symptoms. Objective assessment of blood 
loss defines an upper limit of 80ml during the whole period[201].In fact ,there is 
a wide variation in the quantity of blood lost by women at menstruation[202, 
203]. Clinicians usually enquire about the number of sanitary towels and 
tampons used, number of days of bleeding ,the presence of clots and flooding 
episodes, the duration of bleeding and measure the haemoglobin in order to 
estimate the severity of the complaint and determine treatment. However, 
there is  no correlation between menstrual blood loss and these 
parameters[204].  Approximately 50% of women presenting with the complaint of 
heavy menstrual bleeding have an average blood loss<80 ml during the 
completely period [192, 204]. Therefore, history alone is not reliable indicator 
of menstrual blood loss [205, 206].  
 
3.1.1 Alkaline Haematin Method 
Objective assessment of menstrual blood loss using dedicated and time-
consuming methods is not available for routine clinical use. This includes the 
alkaline-haematin-method which is the current gold standard method for 
quantification of menstrual blood loss[207]. However, this method is expensive 
and inconvenient for patients. Nevertheless, it is a very valuable method in 
scientific research. In this method, as Hallberg and Nilsson descried[207], 
measurement of menstrual blood loss involves extraction of haem from used 
sanitary towels using 5% sodium hydroxide, (about 100ml/ sanitary product), 
then incubation of the sanitary items in the 5% sodium hydroxide solution for 48 
hours to allow conversion of haemoglobin to haem. During the same time period 
a stored sample of the patient’s venous blood should be used to create a 1:200 
dilution of blood with 5% sodium hydroxide, an aliquot should be stored 
alongside the menstrual blood collection.  
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After 48 hours, an aliquot from the mixture of sanitary products and 5% sodium 
hydroxide is obtained and filtered and diluted by measured addition of further 
sodium hydroxide, to create a close colour match with the control venous blood 
solution. From the theoretical total volume of sodium added, is therefore 
possible to calculate by multiplying the added volume by dilution factor. The 
optical density (OD) of menstrual blood loss solution and venous blood sample 
are then measured using spectrophotometry. The menstrual blood loss is then 
calculated as a quantity of the patient’s own venous blood using the following 
equation[208].  
 
MBL=                                                           
                         ) 
 
 
 
3.1.2 Pictorial Blood Loss Assessment Chart (PBAC) 
Pictorial Blood Loss Assessment Chart (PBAC) is a Semi-quantitative assessment 
of blood loss that compares the sanitary item’s stain with given diagrams[192]. 
This method has been developed as a simple and cheap technique of menstrual 
blood loss assessment which is more accurate than recording the number of 
towels and tampons used since ittakes into account the degree to which 
individual items are soiled with blood. This is an important factor as women use 
a varying quantity of towels and tampons to collect similar amounts of menstrual 
blood[203]. Using an appropriate cut-off point would have high positive 
predictive and negative predictive values regarding heavy menstrual blood 
loss[203, 209]. Other studies reported that the chart was useful with 88% 
sensitivity, 52% specificity and a false positive rate of 59% [210]. Nevertheless, 
reproducibility of results of PBAC was challenged in this study and other studies 
[203, 209, 211]. In addition, a recent study found that PBAC is a simple and 
accurate tool for semi-objective measurement of menstrual blood loss that can 
be used easily in the clinical field [212]. The correlation between pictorial 
assessment results and values measured by the alkaline-haematin-method was 
comparatively good, however the amount of blood not captured by sanitary 
substances is significant[213]. 
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3.1.3 Other methods of blood loss assessment 
Other bleeding characteristics such as the number of sanitary materials used is 
highly dependent on the socio-economic status and the individual hygienic needs 
[203]. Although simple non-laboratory methods  such as, counting and weighing 
sanitary towels and tampons, and sanitary items or bleeding diaries are widely 
used, they only provide qualitative information on menstrual blood loss which 
makes them of less values [213]. 
 
 
3.2 The aim of this chapter 
 Menstrual blood loss was estimated in the study in order to confirm that 
participants had heavy menses. Additionally, we attempted to find out a 
correlation between the heaviness of blood loss and the expression of the 
relevant vascular markers (VEGFA, PGE2, IL8, COX-2, and COX-1) in the 
endometrium.  
 
3.3 Material and method 
3.3.1 Subjects 
All target subjects in this study were women who were experiencing regular 
heavy menstrual bleeding with cyclic interval between 21 and 35 days. Pictorial 
Blood Loss Assessment Chart (PBACs) was provided to 79 women who had their 
uterine biopsies taken with their consent to participate in the study. 
3.3.1.1 Group 1  
 54 women were studied in the first group (women were underwent hysteroscopy 
as part of their investigations for heavy menstrual bleeding). 
3.3.1.2 Group 2 
16 women were in the second group (women had hysterectomy as treatment for 
their uterine fibroids). 
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3.3.1.3 Group 3  
Nine subjects in were women had uterine artery embolisation as treatment for 
their uterine fibroids. 
 
3.3.2 Pictorial Blood Loss Assessment Chart (PBAC) 
PBAC was validated by Higham in 1990. The chart consisted of a series of 
diagrams representing slightly, moderately, and heavily soiled tampons or 
towels, a mark or number was made in the appropriate box at the time that 
each towel or tampon was discarded. Women with a pictorial chart score of 100 
or more (cut-off point) during one menstrual period, which corresponds to a 
blood loss of more than 80 ml considered the upper limit of normal for menstrual 
blood loss and thus being heavy menstrual bleeding. 
 
3.3.2.1 Distribution of PBAC 
The women included in this study had an explanation of how PBAC should be 
used and a simple instruction about how to fill in the chart when they attended 
the hysteroscopy or the radiology outpatient’s clinic (the first and the third 
subject group respectively) and all subjects were asked for completion with 
their next menses. Women who had a hysterectomy for their fibroids were 
provided with PBAC at the pre-assessmentclinic or by post to their address a few 
weeks before their surgery according to the waiting list. In an attempt to avoid 
the effect of prescribed drugs for the HMB, participants who attended the 
hysteroscopy clinic were asked to complete the PBAC when they had the next 
period, and they were provided with a stamped envelope to return it back to the 
research office address (3rd floor McGregor building, Glasgow Western 
Infirmary). Subjects in the second and the third group were asked to bring the 
PBAC when they come to have either their hysterectomy or uterine artery 
embolisation performed. A copy of a PBAC chart, completed by a subject in the 
study, is provided in appendix 2. 
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3.3.2.2 Calculation of PBAC 
A slightly soiled towel was scored 1 point, a moderately soiled towel was scored 
5 points, and a towel that is saturated with blood was scored 20 points. 
A slightly stained tampon was scored 1 point, a moderately stained tampon was 
scores 5 points and a tampon that is fully saturated was score 10 points. Blood 
loss in clots and flooding were also indicated and calculated as follows. A clot 
size of 1p scored 1 point; a 50p-sized clot scored 5 points, and flooding also 
scored 5 points. The total score was calculated by multiplying the number of 
used towels by the relevant score point. A score of 100 or greater was the cut-
off point indicates heavy menstrual bleeding. 
 
3.4 Statistics 
PBAC score was not normally distributed so correlations were tested with the 
Spearman rank test for correlation between observations.  Differences between 
groups were evaluated by Mann-Whitney test and Kruskall-Wallis tests, as 
appropriate. 
 
3.5 Results 
In the hysteroscopy clinic, about 25% of subjects (13 participants) did not return 
their Pictorial Blood Loss Assessment Chart (PBAC), three of these women were 
women with uterine fibroids and10 of them had no uterine pathologies. 
Therefore, they were excluded from our analysis. In the second subject group, 
all PBACs were completed and returned to us. The PBAC score of 66 women who 
complained of heavy menstrual bleeding ranged from 8 to 1860 (median 343.5). 
Nearly 11% of women who had no hormonal therapy (8 subjects) had PBAC score 
less than 100 (range between 8 and 99, median 54.5). Three women out of seven 
who were on a continuous progestogen had PBAC score less than 100 (two of 
them in the first group and had score of 11 &12 and the third subject in the 
second group had score of 36).  
 
 
Chapter3 S.Abukhnjr 2014 109 
 
 The relationship between the pictorial chart score and the length of bleeding 
time is shown in Figure3.2. This plot shows that women had an average of 7 days 
of bleeding time every month, and there was positive correlation between the 
PBAC score and the longer duration of the bleeding time (r=0.397,P= 0.001, 
Spearman correlation).  
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Figure 3.1: Scatterplot illustrating PBAC score against days of menstrual bleeding (length of 
period). 
 
 
 
The median of the pictorial chart score for women with uterine fibroids and 
women with no uterine pathologies, whether they had pictorial chart score more 
or less than 100 is recorded in Table3.1. 
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Table 3.1: Summary of the median of PBAC score for participants in the study 
PBAC 
score 
Total 
subjects 
number 
Median 
of PBAC 
score 
No 
pathology 
Fibroid  Mann-Whitney 
No./score 
median 
No./score 
median 
95%Cl P 
value 
≥ 100 57 515.5 18/674 38/464 -1999.9,382.8 0.735 
< 100 7 54.5 1/11 6/61 5.9,91.0 o.066 
 
 
 Mann-Whitney test was used to find out differences in heaviness of menstrual 
bleeding between women with uterine fibroids and women with no uterine 
pathology. There was no difference between the medians of PBAC score for 
women with no uterine pathology and women with uterine fibroids (median= 
515.5, 95%Cl (-199.9, 382.8) & P=0.7). When women with HMB and a score less 
than 100 were compared, the difference between medians of PBAC score for 
women with normal uteri and women with uterine fibroids was large (50.5), 
although it was not statistically significant (95%Cl (5.99-91.00) & p=0.066).  
 
The number of towels and tampons used is plotted against the pictorial chart 
score for each patient (Figure3.2) to point out the relation between them. 
Higham in 1990 found a positive correlation between the total number of 
sanitary items used and the menstrual blood loss in ml (r=0.74). 
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Figure 3.2:  Scatter plot illustrating the number of sanitary towels and tampons used against 
PBAC score. Statistical analysis was performed using a Spearman correlation test. 
 
 The finding in this study estimated the correlation between number of towels 
and tampons used and the pictorial scores, and a positive correlation was found 
(r= 0.76, P<0.0001, n=65). 
The genes of interest in this study have been recognised as those involved in the 
control of menstrual bleeding and pictorial chart has been approved as a 
consistent blood loss assessment technique, thus there may be a relation 
between the level of each gene expression and PBAC score. However, our data 
could not find a relationship between these variables and the PBAC score. 
Furthermore, there was no difference between the endometrium expression of 
cyclooxygenase1, cyclooxygenase2, interleukin 8 and prostaglandin E2receptor2 
(EP2) genes in patients with PBAC score less than 100 and patients with PBAC 
score ≥ 100 (Figure 3.3-3.5). However, VEGFA showed higher expression in 
endometrium of women with low PBAC score than the expression in 
endometrium of women with high PBAC score (95% Cl (68.1, 638.8) & P= 0.01). 
All these women had no hormonal therapy. 
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Figure 3.3: The box plot in this Figure illustrates the difference in the relative expression of 
COX-2 and COX-1 mRNA in endometrium between women with low PBAC score and others 
with high PBAC score. (Log scale is depicted). 
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Figure 3.4: The box plot in this Figure illustrates the difference in the relative expression of 
IL8 and EP2 mRNA in endometrium between women with low PBAC score and others with 
high PBAC score.(Log scale is depicted). 
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Figure 3.5:The box plot in this Figure illustrates the difference in the relative expression of 
VEGF-A mRNA in endometrium between women with low PBAC score and others with high 
PBAC score.(Log scale is depicted). 
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3.1 Discussion 
The pictorial blood loss assessment chart has been approved as a reliable 
subjective tool for estimating menstrual blood loss that is validated to the 
objective estimation method of blood loss (alkaline haematin method). In this 
study, instructions on how to fill in the pictorial blood loss assessment chart 
were not communicated appropriately to the participants since details of 
interpretationof the scoring were also included in error. In addition, the  
description of how to complete the chart which is provided  at the bottom of the 
chart may not have been sufficient for the majority of them to understand 
exactly how to complete it and it would have been better to show them how to 
fill in the chart in person. In addition, as already mentioned, the instructions for 
analysis were accidentally included on the PBAC chart as shown in appendix 
2.Women, who were sent the chart by post, had an opportunity to clarify how to 
complete the PBAC chart during a phone call. Two patients, one in the first 
group and other in the third group, put only a mark in the appropriate box but 
they did not indicate the towel number that they had used. One of them (a 
woman in the third group) had time to provide another completed chart before 
the performance of her procedure and the other was not included in the result.  
Although some authors pointed out that about 50% of women who complain 
heavy menstrual bleeding actually have a normal menstrual blood loss, in this 
study (excluding women who were on hormonal therapy) only seven women who 
had complained of heavy menstrual bleeding  (10% of participants) had low 
pictorial chart score (below 100 the usual cut of point). Two of them had 
pictorial chart score of 97 and 99.  It is not clear whether these two scores were 
due to the patient having normal menstrual bleeding (an average amount of 
menstrual blood loss <80ml) or due to the monthly menstrual bleeding variation. 
One of the women with low pictorial chart score, who had a hysterectomy as 
treatment for her uterine fibroids, had a history of gonadotrphin releasing 
hormone agonist administration and the patient had the last injection three 
months before her biopsy was taken. Therefore, the patient was fitted our 
inclusion criteria. Another woman in the same group admitted that 
dysmenorrhoea was bothering her rather than the heavy bleeding.  One of the 
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two women in the third group with low pictorial chart score underwent 
hysteroscopy investigation (under general anaesthesia) a few months before the 
uterine artery embolisation and the patient thought that the hystroscopic 
procedure reduced her menstrual bleeding.The remainder of the women with 
low pictorial chart score had been referred for the first time by their general 
practitioner to the gynaecologist (hysteroscopy clinic) to investigate their 
complaint of heavy menstrual bleeding without any previous history of any 
treatment.  
There is aconcern about the accuracy of the way in which some women 
completed the pictorial chart, particularly since the instructions given contained 
the methods of analysis which might have influenced the way the charts were 
completed as described above. The patients were attending the hospital for 
clinical reasons, and the pictorial blood assessment chart may be considered as 
an interesting tool but it is not normally part of their clinical evaluation. Hence, 
some of them may not complete the chart in an appropriate way. Higham and 
her colleagues in 1990 admitted that they increased the accuracy of the pictorial 
chart assessment in their study by asking the women to use the uniform types of 
towels and tampons that were supplied by the trial, while in this study where 
participants used their own towels and tampons.  
The median for pictorial chart scores of 343.5 was high, where it was three fold 
of the median score for Hingham’s population in 1990. Some of observations of 
pictorial scores in this study were ≥ 1000, which corresponds to approximately a 
blood loss of ≥750ml[192] (cited in [214]). This very large amount of blood loss 
would lead to severe anaemia, which was not the case with those patients. 
These women may use small size and /or low absorbency sanitary materials. 
Patient’s hygiene and perception of the degree of soiling tampons and towels 
could also be an explanation for these high pictorial score.  
The pictorial  scores analysis  found there was not any difference in  the scores 
between women  who complained of heavy menses with uterine fibroids and 
women with normal uteri, and there was no correlation between pictorial scores 
and  expressions of the genes known to be associated with the control of 
menstrual bleeding with the exception of VGEFA where expression in the 
endometrium for women with pictorial scores <100 was higher than VGEFA 
expression in the endometrium for women with pictorial score ≥ 100. Women 
who complained of heavy menses and some of whom underwent medical and 
Chapter3 S.Abukhnjr 2014 117 
 
surgical intervention for this reason,  may have menstrual blood loss within the 
normal range as pictorial score less than 100 which corresponds to <80ml blood 
volume, and with higher numbers indicating heavier bleeding. The results of 
pictorial blood loss assessment  in the study are supported by the significant 
differences in VGEFA mRNA levels between women with heavy menstrual 
bleeding (≥ 100) and women with normal menstrual bleeding (<100) where this 
conclusion about the VEGFA levels in normally and heavily menstruated women 
was previously demonstrated [94].  In this study the levels of mRNA encoding 
VEGF-A in the menstruated endometrium from women with heavy menstrual 
bleeding was significantly reduced, the median ∆Ct being –7.87 in women with 
normal menstrual bleeding (range –13.17 to –6.70) and –7.31 in the HMB group 
with a P < 0.016. Nevertheless, other investigations have found an increase in 
the VEGF- A and it’s two receptors in endometrial blood vessels  collected from 
women with heavy menstrual bleeding[215]. This study documents a reduction in 
the expression of VEGF in endometrium in association with a reduction in 
menstrual blood loss in women who had heavy menstrual bleeding with uterine 
fibroids but who were using progestin in the form of a levonorgestrel-releasing 
intrauterine device[216], meaning that the data are not comparable. 
 
3.6 Conclusion 
Pictorial blood loss assessment chart (PBAC) is a semi-objective means of blood 
loss estimation in the research field with good acceptance by patients.Evaluating 
the effectiveness of available treatments of heavy menstrual bleeding, such as 
medical and the less invasive interventional methods, for example, uterine 
artery embolisation, can be one of the uses of the pictorial blood assessment 
chart. Unfortunately, for the reasons described above, this part of the research 
project was unsuccessful and results difficult to interpret. Any conclusions from 
these data must be interpreted with caution. However, it appears likely that the 
VEGF-A was less in women with significant HMB as this is in agreement with 
other studies. 
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4. The immune response of human endometrium in 
presence of uterine fibroids .Is HMB one of 
consequences? 
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4.1 Introduction 
The human endometrium is an important site of innate immune defence, giving 
protection against uterine infection. Such protection is vital to successful 
implantation and pregnancy. Therefore, the human endometrium works as  other 
mucosal surfaces and it produces a wide range of natural antimicrobial peptides, 
these peptides are expressed by both epithelial cells and endometrial leukocytes 
and they appear to be governed by the stage of the menstrual cycle[217], and 
provide protection throughout the menstrual cycle and in pregnancy. There is a 
strong suggestion that interaction between steroid hormones, leukocytes and 
locally produced cytokines and growth factors is involved in this protection 
mechanism [82, 218]. The cellular composition of endometrium is always 
changing in parallel with the daily cyclic hormonal alternation. After the 
menstruation and shedding of epithelial tissue, re-epithelialisation is initiated 
from the stem cells in the glands present in the basalis layers and from the 
residual raft of luminal epithelium. The full thickness of endometrium is 
restored by the end of the proliferative phase of the cycle where throughout 
that phase both stromal fibroblast and cells in association with the blood vessels 
(endothelial and vascular smooth muscle cells) undergo mitosis. Differentiation 
of many of these cells including decidualisation of some stromal cells takes place 
during the secretory phase.   
 
 
4.1.1 Leukocytes expression in human endometrium 
The population of lymphomyloid cells is governed with the different phases of 
the cycle, thus their total and relative number vary throughout the menstrual 
cycle and reach the greatest abundance during the premenstrual phase[219]. 
They include eosinophils, macrophages, neutrophils, endometrial granular 
lymphocytes (natural killer (NK) cells), T cells, B cells and mast cells. All these 
cells can synthesise and release an abundance of cytokines and proteases, 
including the matrix metalloproteinases (MMPs). Subpopulations of these cell 
types with different phenotypes are present in the endometrium and others with 
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apparently similar phenotype to those in the endometrium can be functionally 
different from those in the blood of the same individual. Thus at least some of 
the cells which traffic into the endometrium must change in phenotype in 
response to the new environment. In addition, it is not clear whether the 
increase in the number of leukocyte subpopulations in the late secretory phase is 
related to in situ proliferation or to migration from the peripheral circulation or 
both of these processes. Whether these processes are driven directly by ovarian 
hormones or are mediated by other factors such as chemokines or adhesion 
molecules is obscure. Leucocytes account for 10% of endometrial stromal cells in 
normal proliferative and early secretory phase endometrium and numbers 
increase to over 20% of stromal cells in the mid and late secretory phase[220]. 
Leukocytes can be found in endometrium within the stratum basalis, where they 
often form lymphoid aggregates. In the stratum functionalis, they may be 
scattered singly, form small aggregates around glands and blood vessels or are 
found in an intraepithelial position as well as within glandular lumina [221]. 
They are believed to have a role in implantation, decidualization and 
placentation [222]. The presence of these cells in endometrium is dependent on 
progesterone although this may be an indirect action[223]. 
 
4.1.1.1 Macrophages 
Macrophage cells in tissue arise by differentiation of monocytes that migrate 
from blood. Macrophages display heterogeneity in their phenotype, and subtypes 
have been described according to expression of MMP-9[30], activin β [224],and 
MT1-MMP [225].Infiltration of macrophages increases from the proliferative 
phase throughout the menstrual cycle to reach highest expression in the late 
secretory phase[220, 226, 227],around the time of implantation and throughout 
pregnancy[228] and form 20% of the leukocyte population at this time. An 
increase in the macrophage infiltration in progestin exposed endometrium and 
abnormal uterine bleeding has been documented[229]. The concentration of 
macrophages  in endometrium is mainly  increased around the endometrial 
glands[230] and at the implantation site in early pregnancy[231].  Macrophages 
have a role in debris removal at the materno–fetal interface and may help 
prevent the initiation of an immune response to the trophoblast [232].In 
addition, the act of phagocytosis of apoptotic cells suppresses the release of 
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proinflammatory mediators from macrophage cells [233]. In this way, they might 
act to optimise the inflammatory environment at implantation. Furthermore, 
macrophages have the ability to actively initiate apoptosis of unwanted cells 
during tissue remodelling [234] and may play a role in blastocyst invasion. The 
endometrial macrophage has also been shown to express oestrogen receptor-β 
and oestrogen-related receptor-β [235]. However, the endometrial macrophages 
do not express the progesterone receptor and oestrogen receptor α [236, 237], 
but are recruited by a host of macrophage attracting chemokines. Macrophage 
activation is reflected in a continuous spectrum of phenotypic changes, that 
rapidly leads to alternation in macrophage function in response to local 
environmental signals such as surface receptors and secreted molecules[238, 
239].These can produce molecules that stimulate and regulate MMP9 such as 
cytokines[240],tumour necrotising factor α (TNFα) and interleukin-1β (  IL-
1β)[241].  
 
4.1.1.2 Neutrophils 
Neutrophils are polymorphonuclear cells and they are the most abundant 
leukocytes in the human immune system. They contain specific secretory 
granules which contain a varied range of regulatory molecules. However, these 
molecules differ according to the neutrophil maturation stage. They initially 
interact with the wall of the blood vessel during transmigration and 
subsequently with the endometrial decidua and extracellular matrix (ECM) 
during passage through the tissue[242]. It is thought that neutrophilsare 
dominant in the initial leukocyte influx into  the tissue[26], and are associated 
with tissue damage in inflammatory disorders. Neutrophils are identified in 
endometrium by their morphology and by immunolocalisation of the neutrophil- 
specific protease-elastase. In normal endometrium the neutrophils are hardly 
detected, however, there is an abrupt increase in their infiltration  in the 
premenstrual phase[25] and high expression in areas of endometrial breakdown 
in patients treated with high doses of progestin[230, 243]. Neutrophils as 
macrophages, have varied phenotypes but only some of them are positive to 
MMP9[243] or activin β,which play a role in cells differentiation and 
apoptosis,[224]. Moreover, some neutrophils have a membrane type MT-
MMP,which has a role in activation of latent MMP-2 [29]. Neutrophil 
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granuleenzymes can activate latent forms of proinflammatory molecules such as 
interferon gamma (INF-γ) and interleukin-1 β (IL1β)[27, 244]. In addition, 
intraepithelial neutrophils contain INF-γ which has a role in macrophage 
activation and  this  may  demonstrate a potential interaction between 
leukocytes at menstruation[245]. It was pointed out that neutrophils enter the 
endometrium from the spiral arterioles, since decidualization and the 
accompanying chemokine secretion occurs initially close to these vessels. The 
vessels themselves express chemokines at this time [27]. 
 
4.1.1.3 Mast cells 
The mast cells secrete many vasoactive and pro-inflammatory molecules and 
share in the inflammatory process by vasodilatation and enhancing the 
infiltration of leukocytes and thus causing direct tissue damage by releasing 
their proteases. There are subtypes of mast cells in the endometrium depending 
on the expression of cell –specific serine proteinases or tryptase, which are 
present mainly in endometrial functionalis layer. The functionalis is only positive 
for mast cells with this specific proteinase, chymase is present only in the 
endometrial basalis layer[32]. Mast cells precursors in peripheral blood reach the 
uterus and differentiate to the mature form in situe [246]in response to 
chemokines [247], under the control of steroid hormones [248]. Mast cells 
activation occurs in response to tissue oedema prior to menstruation[32]. The 
action of mast cell on extracellular degradation is mainly through activation of 
MMP production[31],including MMP2 [249]and MMP9[250]as well as 
collagenase[251]. Some authors point out that mast cells not only activate MMPs 
but also can produce MMPs themselves, and are stimulated by tumour 
necrotising factor-α(TNFα ) and transforming growth factor-β (TGFβ)[31, 252]. 
The endometrial stimuli for activation of mast cells with its associated release of 
mediators are not known. However, endothelins, which are abundant in 
menstrual endometrium, can activate mast cells via their receptors, providing 
one potential mechanism. Endothelins themselves are inactivated by mast cell 
carboxy-peptidase A3 and clearly a balance must be achieved [253]. 
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4.1.1.4 Uterine natural killer cells (uNK) 
These cells known as endometrial granular lymphocytes[254, 255], express the 
natural killer cell antigen CD56[256]. The uNK cells are localised by staining with 
Phloxina-Tartrazine and by immunolocalisation. They infiltrate into both 
endometrial stroma and intraepitheial cells but it is not known if there is a 
difference in function between the cells in the two different sites [257]. Their 
expression is mainly close to the glands and spiral arteries[258], which suggests 
a role in vascular remodelling[259].The uNK cells found throughout the 
menstrual cycle , count for about 15% of the total number of stromal 
endometrial cells [25], and increases to 25% during the perimenstrual time[254]. 
This high expression at the late secretory phase may be due toproliferation in 
situe. The uNK cells are the most prevalent leukocytes at the time of 
implantation and comprise 70-80% of endometrial leukocytes [22, 260, 261], this 
increase  being enhanced by  human chorionic gonadotrphin hormone 
(HCG)[262]. Furthermore, high uNK infiltration during the secretory phase and in 
early pregnancy suggests a potential regulation by progesterone, although there 
was no evidence of nuclear progesterone receptors [263, 264]. In comparison to 
NK cells in peripheral blood , the uNK cells have cytotoxic activity [265]and have 
bright CD56 expression [260]. The cytotoxic activity increases from the end of 
proliferative phase toward the perimenstraul time indicating a general mucosal 
defence and anti-infection protection mechanism. These cells may be involved 
in immunomodulation at the time of implantation due to the expression of 
proteins with immunomodulation function [266]. Although, uNK cells undergo 
morphological nuclear changes in the premenstrual phase, their high expression 
at this time indicates their terminal differentiation and imminent non-apoptosis 
[267, 268]. A range of cytokines are secreted by uNK cells, which have both an 
immunosuppressive and  growth promoting role, and  this role may be of greater 
importance at the end of the cycle in preparation for pregnancy rather than a 
role in the process of menstruation itself. this concept has been supported by 
Critchely el at.1999[269].  
 
Chapter4 S.Abukhnjr 2014 124 
 
4.1.2 Leukocytes and menstruation 
The inflammatory mechanism of menstruation includes complex sequences of 
events, which depend on interaction between sex steroids hormones and the 
immune system[82].The fall in progesterone and oestrogen levels in the late 
secretory phase initiate this mechanism. Progesterone withdrawal is thought to 
cause inflammatory gene induction, thus leading to an influx of leukocytes. 
Interactions between these cells and decidualised stromal cells facilitate release 
of many pro-inflammatory mediators including chemokines, cytokines and 
prostaglandins.  These pro-inflammatory factors activate the leukocyte and 
boost them to produce and activate a cascade of degradative enzymes, 
particularly matrix metalloproteinases. Thus, a rapid breakdown of the 
extracellular matrix, which is supporting the tissue, takes place. Other opinion 
suggests that sex steroid hormones might simulate the leukocytes directly as 
many of the CD68 positive cells in peripheral blood express progesterone 
receptors[270] and also T helper cells in the endometrial basalis express 
oestrogen receptors[271]. Other studies concluded that large numbers of 
progesterone receptors are not found in endometrial leukocytes, and steroid 
hormones  most probably  influence endometrial leucocyte populations indirectly 
via products of endometrial stromal or epithelial cells that express steroid 
hormone receptors[82, 265]. Because of the leukocyte invasion into the 
endometrium and subsequent production of inflammatory mediators, 
menstruation has been described as an inflammatory event [272, 273]. Although 
many of the molecular and cellular changes at menstruation are well known 
[274, 275], the precise timing of these changes and the interactions that lead to 
the tissue breakdown and repair are still not fully understood because of a tissue 
sample taken from a woman during menstruation is likely to contain a 
combination of pre-menstrual tissue that has not yet started to degrade, tissue 
that is actively degrading and areas that are actively repairing. These are clearly 
obvious in histological samples. 
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4.1.3 Leukocytes and heavy menstrual bleeding 
Menstruation is characterised by an influx of leukocytes, extracellular matrix 
modification and increased vascular permeability. Regulation of the initiation, 
intensity and resolution of the inflammatory response is important for effective 
implantation and efficient repair after menstruation. As discussed above, 
inflammation is a key event during menstruation, thus it is reasonable that 
abnormalities in this process may contribute to menstrual disorders. The cyclical 
endometrial breakdown and repair are highly regulated by synchronisation 
between sex hormone production from the ovary, production and activation of 
pro-inflammatory mediators, and leukocyte influx.  Deviation from this co-
ordination sequence can lead to menstrual disorders, such as heavy menstrual 
bleeding (HMB).  Increased levels of  total prostaglandins in women with heavy 
menstrual bleeding[108] and the pro-inflammatory cytokine TNFα in the 
menstrual effluent in these group of women, [94] is  a further indication of an 
exaggerated inflammatory reaction in menstrual disorders.  
 
4.1.4 Leukocytes and uterine fibroids 
The presence of uterine fibroids, especially submucosalal and intramural fibroids 
may cause deterioration in the inflammatory process in the endometrium by 
increasing the pro-inflammatory mediators such as chemokines, cytokines, 
prostaglandins and matrix metalloproteinases (MMP). The cytokine, transforming 
growth factor-beta (TGF-β) plays an important role in enhancing the trophoblast 
cells attachment to the endometrium. This factor plays a role in the 
proliferation, differentiation and extracellular matrix production, and it is found 
that it has high expression level in fibroid tissue as well[145]. Thus, it may have 
a role in uterine fibroid formation as a consequence of abnormal tissue repair 
and an altered extracellular matrix. The use of gonadotrophin – releasing 
hormone agonists can suppress the level of TGF-β and its receptor[276],as well 
as reducing the size of uterine fibroids. Chemokines, which is correspondence to 
macrophage, may lead to amplification of the inflammatory process in the 
endometrium overlying   the uterine fibroids. These pro-inflammatory mediators 
increase the leukocyte infiltration into the endometrium mainly by 
macrophages. Leukocyte mobilisation, with changes in their phenotypes and 
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activation, provide further degradative enzymes and MMP activators. As a result, 
further tissue breakdown, and longer bleeding time may occur and affectthe 
menstrual blood loss. An increased accumulation of macrophages in the 
endometrium was noted in women with submucosal and intramural uterine 
fibroid. It is thought that this accumulation corresponds to the high production 
of monocyte chemoattractant protein-1(MCP-1), the chemokine CCL2, and levels 
of PGF2α which are also significantly increased in those women[277]. As a result 
of all this, amplification of the inflammatory reaction in endometrium takes 
place and a subsequent detrimental effect on the menstrual cycle may result. 
This chapter aimed to estimate the infiltration of neutrophils, macrophages and 
uterine natural killer cells in the endometrium for women with heavy menstrual 
bleeding and uterine fibroids and compare it to that for women with heavy 
menstrual bleeding and no uterine pathology. 
4.2 Patients and methods 
Discussed in materials and methods chapters 
 
4.3 Results 
4.3.1 Expression of Neutrophil elastase protein (Neutophils) 
The endometrial stromal neutrophil elastase was low in the proliferative, early 
secretory and mid-secretory phases in each group and markedly increased in 
late-secretory and menstrual phase. It was significantly different among the 
phases (P<0.0001, ANOVA test) (Figure 4.1). There was no expression of 
neutrophil elastase in surface and glandular epithelial cells (Figure 4.2). In 
contrast, there was no significant difference among the women with uterine 
fibroids and women with normal uteri across the menstrual cycle. 
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Figure 4.1: The immunostaining score of neutrophils elastase antibody in endometrial 
stromal cells in women with heavy menstrual bleeding across the menstrual cycle, P 
(proliferative), ES (early secretory), MS (midsecretory), LS (late secretory), and Mn 
(menstrual) phases. (Note that y is the loge scale of scoring, t test was used). (Log scale is 
depicted). 
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Figure 4.2: Immunolocalization of neutrophils elastase (a specific marker for neutrophils) in 
endometrial biopsies obtained from women with heavy menstrual bleeding. Immuno-
positive stromal cells in brown colour (cells in blue colour are negative for neutrophils 
elastase) were few during proliferative, early secretory and mid-secretory phases. The 
immunostaining of neutrophil elastase is upregulated in late-secretory and menstrual 
phases. 
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4.3.2 CD56 +cells (uterine natural killer) 
Immunohistochemistry immunostaing identified CD56 expression across the 
menstrual cycle in endometrium for both women with idiopathic heavy 
menstrual bleeding and with uterine fibroids. The expression of stromal CD56 
was upregulated across the menstrual cycle in both groups, with low expression 
in proliferative and early secretory phases and markedly increased during mid-
late secretory and menstrual phase. The expression of CD56+ cells was 
significantly different between mid-secretory and proliferative phase (P<0.01) 
and mid-secretory and early secretory phase (p<0.05). On the other hand, there 
was no difference between other phases (mid-late secretory and menstrual) 
(Figure 4.3). The infiltration of CD56 was in endometrial stroma mainly around 
the glands and blood vessels and occurred singly or in aggregates, however, 
some infiltration of CD56+ cells was noticed in-between epithelial cells (Figure 
4.4). 
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Figure 4.3: Immunostaining score of CD56 in endometrial stromal cells across the menstrual 
cycle, P (proliferative), ES (early secretory), MS (midsecretory), LS (late secretory), and Mn 
(menstrual) phases. (Log scale is depicted). . 
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Figure 4.4: Immunolocalization of CD56 (uterine natural killer) cells in endometrium of 
women with heavy menstrual bleeding. The expression of CD56+ cells is in stromal cells 
across the menstrual cycle; proliferative (A), secretory (B) and menstrual (C). The infiltration 
of CD56+ cells (cells in brown colour) in stromal cells, are singular or in aggregation (E), 
and sometimes immune-positive CD56 cells (brown colour) were found interepithelial cells 
(D). Immune-negative CD56 cells in stromal and glandular epithelial endometrium tissue 
presented in blue colour. 
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4.3.3 CD68 +cells (macrophages) 
The infiltration of CD68+ cells was increased across the menstrual cycle, and it 
was higher in secretory phase than the proliferative phase. However, there was 
no difference between mid-secretory, late-secretory and menstrual phases 
(Figure 4.5). It was noticed that stromal infiltration of CD68 was concentrated 
mainly in area around the endometrial glands (Figure 4.6).  
Our immunostaining data found no difference in the endometrial expression of 
CD68 between women with uterine fibroids and women with normal uteri. 
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Figure 4.5: Immunostaining score of CD56 in endometrial tissue across the menstrual 
cycle,P (proliferative), ES (early secretory), MS (midsecretory), LS (late secretory), and Mn 
(menstrual) phases. (Log scale is depicted). 
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Figure 4.6: Immunolocalisation of CD68 ( a specific marker for macrophages) in endometrial 
biopsies obtained from women with heavy menstrual bleeding. immnuopositive stromal 
cells presented in brown colour and they infiltrated in the endometrium across the 
menstrual cycle; proliferative (B), early secretory (C) and mid-secretory phases (D),late 
secretory (E) and menstrual (F). (A) represents a negative control staining( only blue 
colour). 
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4.4 Discussion 
Menstruation is one of the endometrial functions which are under the control of 
a complex interaction between the endocrine and immune systems. Ovarian 
hormones influence a variety of immune factors within the endometrium to 
prepare it for implantation or menstruation. Endometrial leukocytes play a 
crucial role with cytokines and growth factors in tissue breakdown and repair. In 
other words, the leukocyte may not only influx into endometrium with assistance 
of many cytokines; they may also have the ability to release many cytokines 
themselves. In addition the coordinated sequence of inflammation and 
resolution is important in the regulation of menstruation. Therefore, abnormal 
inflammatory pathways may impact on the amount of menstrual bleeding. This 
abnormal inflammatory pathway is also present in endometrium of women with 
normal uteri and in endometrium of women with uterine fibroids as well as. 
4.4.1 Neutrophils 
Our finding indicated that neutrophil elastase, a key marker for neutrophils, is 
localised in the stromal tissue. In addition, although it was expressed to an 
extent throughout the menstrual cycle, it markedly increased during the late 
secretory and menstrual phase. This result concurred with previous reports[25, 
278]. In addition, it may indicate that neutrophil immigration into the 
endometrium is mainly in response to progesterone withdrawal in the late 
secretory phase. Decidualization is accompanied by an increased number of  
leukocytes[279]. If no pregnancy occurs, the ovarian corpus luteum regresses 
and secretion of both steroids declines at the late secretory phase, triggering 
extensive infiltration by neutrophils, proteolytic breakdown and shedding of the 
endometrium with associated bleeding at menstruation[33, 280, 281].Thus  the 
increase in neutrophils within the endometrium coincides with the upregulation 
of IL8 also in the late secretory phase, where the latter is  associated with 
neutrophils chemotactic function[68]. Stretching of the myometrium in presence 
of uterine fibroids is a mechanical factor that may stimulate neutrophil 
activation and adhesion. In addition, it may promote transendometrial migration 
of neutrophils; this mechanical mechanism can stimulate cytokines production as 
IL8.  
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4.4.2 Uterine killer cells 
The relative number of CD56+ cells (uNK) was increased across the menstrual 
cycle with higher infiltration during the mid and late secretory phase. This is in 
agreement with Bulmer et al [254, 279]and Kitaya et al [282]. This post-
ovulatory increase in the relative number of endometrial uNK cells suggests that 
these cells play a role in uterine events such as pregnancy and menstruation. In 
addition, it may indicate involvement of steroids hormones, particularly 
progesterone in the post-ovulatory rise of uNK cells. However, uNK cells do not 
express progesterone receptors but do express the prolactin receptor, 
oesterogen receptor β and glucocorticoid receptor [18, 24]. In a previous report, 
where  an increase in the uNK cells was noted in endometrium of 
postmenopausal women having hormonal replacement therapy[283], which 
supports  this concept. Nevertheless, aberrant numbers of uNK cells in the mid-
secretory phase was associated with implantation failure and recurrent 
miscarriages [284, 285]. In parallel with other organs, the increase of uNK cells 
in the postovulatory period seems to result from the expansion of two NK cell 
populations with  different origins; one is in situ proliferation of the resident 
uNK population, and the other is the selective influx of a population from the 
endometrial microcirculation[286].  The uNK cells may be able to promote 
angiogenesis as they express some growth factors that are essential for 
angiogenesis such as vascular endothelial growth factor[287], placental growth 
factor, angiopoeitin 2, and NKT5[288]. A large number of uNK cells has been 
found in decidua in early pregnancy, and it has been proposed that uNk cells 
have a role in regulating extravillous trophoblast invasion and spiral artery 
remodelling[289]. In non-conceptual menstrual cycle the number of uNK has 
been reported as either- small or absent in the proliferative and early secretory 
phase[290] and high in mid-late secretory phase. Therefore, as discussed above, 
increases in the number of uNK in mid-late secretory phase endometrium can 
cause dysregulation of angiogenesis which may attribute and associated with 
heavy menstrual blood loss.  In this study it was noticed that the relative number 
of uNK cells was higher during mid-late secretory phases than the menstrual 
phase, however, the difference was not significant. This may suggest a decrease 
in the apoptosis rate of the uNK cells which habitually show a high rate of 
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apoptosis two to three days before menstruation [291, 292]. If pregnancy occurs, 
uNK cells are upregulated and have the highest infiltration into the decidua of 
early pregnancy. Our results suggest upregulation of uNk in heavy menstrual 
bleeding endometrial stroma during secretory and menstrual phases, potentially 
indicating a role of uNK in this condition. 
 
4.4.3 Macrophages 
The immunohistochemistry data showed a high number of CD68 +cells (key 
marker of macrophages) in proliferative phase and reach the peak in mid-late 
secretory and menstrual cycle phases. This is the same pattern of infiltration of 
CD68 +cells in nomal endometrium during the menstrual cycle [220, 226, 227]. 
However, the increase in the relative number of macrophages in endometrial 
stroma has been found to be associated with menstrual abnormality [229]. The 
relative number of macrophages in endometrium is well regulated, temporally 
and spatially during the menstrual cycle. Increased macrophage number across 
the menstrual cycle in women with heavy menstrual bleeding is considered to 
occur by recruiting monocytes from the peripheral circulation and/ or in situ 
proliferation within endometrium [20, 293]. Presence of macrophages in the 
proliferative phase suggests a potential role in regeneration and proliferation of 
endometrium. This cell function may undergo oestrogen-dependent regulation. 
On the other hand, the high number of macrophages during the mid-late 
secretory phase of the menstrual cycle is assumed to suggest specific roles in 
regulation of fertility. Macrophages have been identified as important course for 
pro-inflammatory and anti-inflammatory chemokines. Therefore, upregulation of 
macrophages in endometrium across the menstrual cycle may enhance the 
proinflammatory environment in endometrium and as a consequence , 
dysregulation of  local endometrial  hemostatic mechanisms takes place [294]. 
Unscheduled bleeding is thought to be the most common reason for 
discontinuation of contraceptives [295, 296]. A previous report showed an 
increase in macrophages and their cytokines in the endometrium of women using 
a LNG contraceptive who complained of unscheduled bleeding[229]. Further 
studies using progestin-only contraceptives have also shown an increase in 
endometrial MMPs [297, 298]. These observations highlight the importance of 
dysregulation of macrophage numbers in the context of endometrial bleeding 
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patterns. However, as a role for macrophages in regulation of menstrual function 
is yet to be defined, the actual impact of dysregulation of macrophage function 
and number on endometrial bleeding remains to be determined.  
 
4.4.4 Leukocytes in women with uterine fibroids 
In the present study, there was no difference in the infiltration of the leukocytes 
studied into endometrial stromal tissue in the presence of uterine fibroids. This 
may be because most of the endometrial biopsies were from women with 
intramural uterine fibroids where the uterine cavity was not distorted. In 
addition, there is a concept that variation in the endometrial size due to the use 
of clinical biopsies in the research may obscure the differences between the two 
groups, since the total number of stromal cells was very low in some samples. It 
is important to determine the minimum cell count required to be examined to 
produce a precise result, which is broadly equivalent to counting stromal cells in 
ten microscopic non overlapping fields at a magnification of 400×. However, to 
our knowledge, in the studies carried out to date, leukocytes in tissue section 
were identified by immunohistochemistry and the number of cells expressed as a 
relative number of the total stromal cells. On the other hand, some of these 
findings are conflicting. For instance, in one report the reference range of uNk 
cells in normal endometrial varied from 0.2 to 9.5% of stromal cells [299]and 
from 2.2 to 13.9 in another study[300]. 
4.5 Conclusion 
It seems that the pattern of leukocyte infiltration in endometrium of women 
with regular heavy menstrual bleeding parallels with that in endometrium of 
normal subjects. However, there is upregulation and increase in the number of 
leukocytes across the menstrual cycle which may contribute to heavy blood loss 
at menstruation. In presence of uterine fibroids, the recruitment of leukocytes is 
not different especially when there is uterine cavity distortion. 
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5. Theexpression of VEGF-A in uterine tissue in 
women with HMB in presence of uterine fibroids 
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5.1 Introduction 
The human endometrium undergoes remarkable cyclic growth and regeneration 
in response to various environmental changes, such as hypoxia or complex 
interactions of the female sex steroids during the menstrual cycle. A new 
vascular system develops via angiogenesis and vascular remodelling in the 
endometrium during each menstrual cycle to support cellular growth and 
differentiation[33, 301]. Angiogenesis and vascular remodelling are believed to 
be orchestrated by coordinated interactions of several angiogenic factors in the 
human endometrium [302].Vascular endothelial growth factor (VEGF), stimulates 
endothelial cell proliferation, permeability, migration, and assembly into 
capillary tubes [303, 304]. Most work regarding the regulation of endometrial 
angiogenesis has focused on VEGF [305, 306]. Recent studies have reported that 
VEGF is essential for the rapid burst of angiogenesis that occurs during 
postmenstrual repair and early proliferative phases in the primate endometrium 
and furthermore plays a role in re-epithelialisation of the endometrium[303]. 
 
5.1.1 Vascular endothelial growth factor isoforms and receptors 
Vascular endothelial growth factor is a mitogenic signal protein which works 
mainly on the endothelial cells [307, 308]. Through alternative mRNA splicing, a 
single gene gives rise to several distinct isoforms of VEGF, these different 
isoforms of VEGF have been identified according to their amino acid residue 
length (VEGF121-VEGF165,VEGF189,and VEGF206) [309-311]. These isoforms 
differ in their expression patterns as well as their biochemical and biological 
properties [307]. VEGF165 is the predominant isoform[304], and it is produced 
by normal and transformed cells. Less frequent splice variants have been also 
reported, such as VEGF145 and VEGF183[312]. In the past the term VEGF was 
used to indicate to VEGF-A which is one of the vascular endothelial family. In 
present this family includes VEGFA, B,C,D,E and placenta growth factor 
(PIGF)[313]. Two VEGF receptor tyrosine kinases (VEGFRs) have been identified, 
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 seems to mediate almost all 
observed endothelial cell responses to VEGF, whereas roles for VEGFR-1 are 
more elusive. VEGFR-1 might act predominantly as a ligand-binding molecule, 
sequestering VEGF from VEGFR-2 signalling. In addition, there is a vascular 
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endothelial growth factor receptor-3 (VEGFR-3, Flt-4), a receptor for vascular 
endothelial growth factors (VEGFs) C and D, is specifically expressed on 
lymphatic endothelium and suggested to play a role in the maintenance of 
lymphatic endothelium and/or in lymphangiogenesis [314] (Figure 5.1). 
 
Figure 5.1: Vascular endothelial growth factor isoforms and receptors are depicted above, 
with different colours referencing different ligands of VEGF have different mediate function. 
Both VEGFR1 and VEGFR2 bind to VEGF-A.  
 
 
5.1.2 Expression of vascular endothelial growth factor in human 
endometrium 
 The expression of VEGF-A was determined in all cell types in the human 
endometrium and in all phases of the menstrual cycle [315, 316]. There is a 
strong belief that VEGF production is induced mainly by hypoxia and as a 
consequence, the expression of VEGF is elevated during menstruation [315,317, 
318]. VEGF-A is also increased in the mid-secretary phase [306, 317], which is 
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most likely because of concerted actions of estradiol (E2) and progesterone [319-
324]. These studies clearly indicate that VEGF-A production in human 
endometrium is stimulated by oestrogen. On the other hand, some other studies 
found elevated expression of VEGF-A in the proliferative phase [94,325,326]. It 
has also been suggested that VEGF-A production by cultured endometrial tissue 
is high in peri and post menstrual human endometrium [313, 327], indicating to 
high level of VEGF-A during menstruation and the early proliferative phase.  
 
5.1.3 Vascular endothelial growth factor role in angiogenesis 
Angiogensis is an essential mechanism to support endometrial growth after 
menstruation and to provide a vascularised, receptive endometrium for 
implantation and placenta formation.The vascular growth mechanism in the 
human endometrium and the time frame of various processes included in this 
mechanism are still unclear[328]. Nevertheless, it thought that this mechanism 
is regulated by a combination of systemic and local factors, where their actions 
are coordinated by 17B-estradiol and progesterone and most likely mediated by 
locally acting factors[10]. The vascular endothelia growth factor family is a 
major mediator of angiogenesis [326] and VEGF-A plays the main role in 
angiogenesis induction and vascular remodelling  [10, 329-331]. In addition, it 
plays a crucial role in endothelial cells survival by providing defence action 
againstapoptosis induced by various pro-apoptotic agents [332, 333]. It  was 
found that VEGF-A can stimulate the migration and the proliferation of 
endothelial cells of blood vessel origin  and promotes blood vessel angiogenesis 
and increases vascular permeability in vitro [303, 304, 334, 335]. However, 
VEGF-A may induce proliferation and increase the survival of epithelial cells in 
an autocrine manner [336], and there are also indications that VEGF-A is 
involved in epithelial cell function[313].  
 
5.1.4 Vascular endothelial growth factor and menstrual cycle 
The endometrium undergoes regular cycles of growth and breakdown and is one 
of the few adult tissues in which significant angiogenesis occurs on an ongoing, 
physiological basis progressing from vessel stumps in the basal layer of 
endometrium that remain after menstruation[78]. After menstruation , hypoxia 
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enhances angiogenesis by inducing human endometrial stromal cells to express 
VEGF [337], thus, VEGF regulates epithelial and stromal development in 
endometrium under the influence of oestrogen and progesterone, thereby it 
regulates the growth and differentiation of endometrium during the menstrual 
cycle[303]. Abnormal angiogenic process may lead to menstrual abnormality as 
well. This abnormal angiogenesis reflects the progestational inhibition of 
endometrial blood flow promoting local hypoxia and the generation of reactive 
oxygen species that increase the production of angiogenic factors such as 
vascular endothelial growth factor in human endothelial stromal cells[338].This 
was supported by some data that showed that expression of vascular endothelial 
growth factor (VEGF)-A and its two main receptors, VEGFR-1 and -2, is increased 
in idiopathic heavy menstrual bleeding. Nevertheless, another study found that 
VEGF-A level was higher in women with normal menstrual cycles than that for 
women with heavy menstrual bleeding [94]. 
 
5.1.5 Vascular endothelial growth factor in myometrium and 
uterine fibroids 
The myometrium is the muscular wall of the uterus that undergoes important 
changes in size and cellular properties in many physiological and pathological 
conditions.  The myometrium undergoes some changes during each reproductive 
cycle [339] and remarkable modifications throughout pregnancy [340] as well as 
menopause [341]. The uterine growth during pregnancy represents one of the 
most remarkable events in reproduction, with a massive increase in both size 
and number of myometrial smooth muscle cells, to allow the growing fetus to 
have the necessary support. Myometrial mass and cellular morphology are also 
modified in tumour conditions such as leiomyosarcoma and uterine fibroids [342, 
343].Uterine fibroids are the most common gynaecologic tumours that occur in 
women of reproductive age, but their molecular pathogenesis is still unknown. 
Since the growth of uterine fibroids involves several vascular factors, an 
association between uterine fibroids and growth factors is suspected [344, 345]. 
A number of growth factors, including transforming growth factor-β (TGF-β), 
epidermal growth factor (EGF), insulin-like growth factors 1 (IGF-1)and 2 (IGF-2), 
basic fibroblast growth factor(bFGF), platelet-derived growth factor(PDGF), have 
been detected in myometrium and uterine fibroids[346, 347]. These growth 
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factors have a main role in the process of growth and differentiation of uterine 
fibroids [348]. It has been found by several studies that IGF-1 is the most 
infiltrated growth factor in uterine fibroids [349-351].  
The role of vascular endothelial growth factor (VEGF) in human endometrium has 
been studied by many authors. It is known, as described above, that VEGF 
regulates a number of endometrial functions. However, the role of VEGF in 
myometrium is not adequately identified. The angiogenic role of VEGF in 
malignant tumour growth stimulation was well documented in several studies 
[352-354]. This stimulating action includes enhancing both new angiogenesis and 
branching of already existing arterial and capillary vessels[331], and promoting 
the proliferation of tumour cells and facilitate the metastasis process [354, 355].  
Many authors reported the expression of VEGF in uterine fibroids [354, 356]. 
However, the function of VEGF in uterine fibroids is not clear since it is rare for 
uterine fibroids to transfer to malignancy, and since oestrogens stimulate VEGF 
production in endometrium [324]. Thus, these hormones may promote fibroid 
growth by the stimulation of angiogenesis. 
Because of the growth of uterine fibroids is regulated by ovarian steroids, 
therefore, low estrogenic state, similar to menopause, is associated with the 
decrease of uterine fibroid volume. The same effect is obtained with the 
administration of GnRH-agonist (GnRH-a). where it reversibly suppresses the 
ovarian function, lowering estradiol levels to menopausal values and causing a 
decrease in uterine volume and fibroids[357]. GnRH-a also help to control 
uterine bleeding that are the most common symptoms associated with uterine 
fibroids. After the cessation of GnRH-aadministration, uterine fibroids regain 
their original size, so that in premenopausal women therapy is considered as a 
preoperative treatment. 
 
5.1.6 Aims 
Many studies have focused on the patterns of VEGF-A gene expression in human 
endometrium in normal and heavy menstrual bleeding. This study focuses on the 
transcriptional expression patterns of VEGF-A and its main receptors in 
endometrium from women with heavy menstrual bleeding and uterine fibroids 
and with normal uteri. It aims to determine if there are any differences in VEGF-
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A expression between the two groups. In addition, the study focuses on the 
expression of the same markers in myometrium and uterine fibroids. 
 
5.2 Methods 
5.2.1 Subjects 
The studied subjects were women aged from 39-51 years (premenopausal age) 
with regular menstrual cycles (from 21 to 35 days) who presented to the 
outpatients clinic complaining of heavy menstrual bleeding (HMB) in presence of 
uterine fibroids or no uterine pathology.  Subjects had not received hormonal 
preparation in the 3 months preceding biopsy collection (group 1&2).Women 
receiving hormonal therapy comprise a separate group (group 3). In this chapter 
three subject groups were studied. Ethical approval was obtained from West of 
Scotland REC 5 research ethics committee and written informed patient consent 
obtained before tissue collection. Menstrual blood loss was assessed using the 
Pictorial Blood Loss Assessment Chart (PBAC) as in chapter 3. 
 
5.2.1.1 Group 1 
This group comprised women who attended a hysteroscopy clinic at Stobhill 
Hospital, Glasgow and had hysteroscopy as a part of their heavy menstrual 
bleeding investigation. Some had no uterine pathology and others had uterine 
fibroids. Uterine fibroids were diagnosed by either transvaginal ultrasound or 
hysteroscopy. 
 
5.2.1.2 Group 2 
Women had hysterectomy at the gynaecology department, Glasgow Royal 
Infirmary (GRI) as treatment for their uterine fibroids. Uterine fibroids were 
diagnosed by either transvaginal ultrasound or magnetic resonance image (IMR). 
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5.2.1.3 Group 3 
Women had gonadotrophin releasing hormone injection within 2 to 3 months 
before hysterectomy for uterine fibroids (n=3). 
5.2.2 Tissue collection 
Endometrial samples were obtained from group 1 by means of Pipelle sampler, 
while in group 2 &3, endometrial, myometrial and fibroid tissues were collected 
by pathologists. See section 2.2.2 for biopsies handling and storage). 
Endometrial biopsies were dated according to Noyes criteria (Noyes et al., 1975) 
by a pathologist (Prof. Alistair Williams, University of Edinburgh) and the 
reported last menstrual periods (LMP) (Table 5.1). Circulating estradiol and 
progesterone concentrations were measured at the time of endometrial and 
uterine biopsies and were consistent with the histological assessment (Table 
5.2).  
 
 
 
Table 5.1: Summary of endometrial biopsies collected from women with uterine fibroids and 
women with no uterine pathology that had provided the Pictorial Blood Loss Assessment 
chart back. 
 
Pathology  P ES MS  LS Mn Inactive /excluded Inadequate for 
staging 
Uterine 
fibroids  
10 8 4 1 5 4 3 
normal uteri  8 4 5 2 6 5 1 
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Table 5.2: Serum estradiol (E2) and progesterone (prog.) at the time of endometrial biopsy 
 Uterine fibroid cases Normal uteri case 
Mean E2 
(range) 
(pmol/l) 
Mean prog.( 
range)  
(nmol/l) 
Mean E2 ±SE 
(pmol/l) 
Mean prog.± 
SE (nmol/l) 
Menstrual  49.40(37-72)  4.84(0.4-21) 106.7(65-191) 1.22(0.6-1.8) 
proliferative 329(73-908) 1.54(0.3-3.9) 575(105-3180) 0.55(0.3-1.0) 
Early secretory 399.4(211-830) 18.81(0.3-36) 702(192-1343) 15.58(0.4-
32.6) 
Mid secretory 279(166-389) 9.78(0.3-26) 394.8(141-575) 28.40(9.0-52) 
With GnRH 
agonists 
38.3(37-176) 0.43(0.3-0.5)   
 
5.2.3 Immunohistochemistry 
To investigate the expression of the VEGFA in human endometrium and uterine 
tissue, 3 μm paraffin-embedded sections were de-waxed and rehydrated through 
graded alcohols before endogenous peroxidase activity was blocked by 30 minute 
incubation in 0.5%solution of hydrogen peroxide and methanol.  The  sections 
were incubated for 30 minutes with normal blocking  serum (20% horse serum 
and 20% human serum) before being incubated over night at 4 C˚ with the 
primary antibody polyclonal goat anti- human VEGF-A (Santa Cruz Biotechnology, 
SC-152-G) at 1:200 dilution.  Sections were then incubated with the secondary 
antibody (biotinylated anti-goat IgG (H+ L) AB- 9500 made in horse) after 
washing in phosphate buffer solution (2x 5minutes), and a corresponding post-
primary protocol (section 2.6.5). Sections were counterstained in haematoxylin 
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and mounted in pertex. Human kidney tissue was used as positive control for 
optimising immunohistochemistry protocol (Figure 5.2).Sections were scanned by 
Claire Orange using slide path technique for scoring method.  
 
 
Figure 5.2: Human kidney tissue used as a positive control for VEGF-A 
immunohistochemistry, the brown stained tissue. 
 
 
5.2.4 Quantitative RT-PCR 
RNA was extracted with TRI-reagent (Ambion, life technologies, Paisley, Uk) 
following manufacturers guidelines using phase lock tubes (Microcentrifuge, 
greiner bio-one GmbH, Stone House- England, UK). RNA samples were reverse 
transcribed using MultiScribe (Invetrogen, Life technologies, Paisley, UK) primed 
with random hexamers according to the manufacturer's instructions (see section 
2.5.4). where there was no enough fresh endometrial samples , RNA was 
extracted from formalin –fixed paraffin- embedded samples using Ambien kit 
1975 (Recover All total nucleic acid isolation kit-Life technology, Paisley, Uk) 
according to the manufacturer's instructions (see section 2.5.1.2). Quality of RNA 
 
NC PC 
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was assessed using an automated spectrophotometer RNA 6000 Nanodrop (Lab 
tech.com, Ringmer, East Sussex,UK), only half of the RNA samples were assisted 
by the Agilent 2100 Bioanalyser system in combination with RNA 6000nano chips 
(see details in section2.5.2).Once the RNA was extracted and quantified, the 
PCR reactions were carried out using an ABI Prism 7900 (Applied Biosystems) as 
previously described in section 2.5.6 using duplicate samples. A no template 
control (containing water) was included. Primer and FAM (6-carboxyfluorescein)-
labelled probe are shown in Table 2 (section 2.5.4). Multiple transcript variants 
have been reported for human VEGF and alternative mRNA splicing. a single 
gene gives rise to several distinct isoforms of VEGF, which differ in their 
expression patterns as well as their biochemical and biological properties[307]. 
Three VEGF receptor tyrosine kinases (VEGFRs) have been identified, VEGFR-1 
(Flt-1), VEGFR-2 (KDR/Flk-1) [307, 358]and VEGF-R3 (Flt-4)[359].The primer 
utilised in this study did not distinguish between these isoforms. Pre-validated 
primers and probes were purchased for VEGF-A, VEGF-R1, and VEGF-R2 (Life 
technology, Paisley,Uk). Gene expression was normalised to B-actin ribosomal 
RNA (Applied Biosystems) as an internal standard. Data were analysed and 
processed using Sequence Detector System (SDS version 2.3) according to the 
manufacturer’s instructions. Results are expressed as relative to a standard 
cDNA obtained from a single sample of endometrial tissue and included in all 
reactions. 
 
5.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of vascular endothelial growth factor (VEGF) in serum was 
measured by ELISA. The component required for this procedure was supplied in 
the quantikine kit (R&D Systems Europe, Ltd, Abingdon, UK).the quantitative 
immunoenzymometric sandwich technique was followed according to the 
manufacturer’s instructions. A monoclonal antibody specific for VEGF was coated 
onto the microtiter plate provided in the kit. Standards with known amount of 
the cytokine and samples were pipetted into the wells and any VEGF was bound 
by immobilised antibody. Any unbound sample protein were washed away and an 
enzyme linked polyclonal antibody specific for VEGF was added to the well and 
allowed to bind to the VEGF which was bound during the first incubation. After a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution was 
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added to the wells and a colour developed in proportion to the amount of VEGF 
which was bound in the initial step. The colour development was stopped and 
the colour intensity was measured using spectrophotometer. A curve was 
prepared, plotting the optical density (OD) versus the concentration of VEGF in 
the standard wells. By comparing the OD of the samples to the standard curve, 
the concentration of VEGF in unkwon samples was determined. 
 
5.2.6 Immunohistoscoring and analysis 
Scoring of immunostaining intensity of VEGF-A in stromal endometrial tissue was 
subjected to histoscoring method, while the immunostaining intensity of the 
VEGF-A in glandual endothelial tissue was assessed in a semi-quantitative 
manner on a 4-point scale: 0=no immunostaining, 1= mild immunostaining, 2= 
moderate immunostaining, and 3=intense immunostaining. 90% of tissue sections 
were measured with a computerised image analysis system (Version 4.0, Digital 
Image Hub, Leica biosystems), and 10% of them was scored by the research 
fellow, a strong correlation between scores derived from the image analysis and 
subjective scores by the  observer was obtained.  
 
5.2.7 Statistics 
Data were subjected to statistical analysis using Mann-Whitney test or Kruskall-
Wallis for comparison between groups, and Spearman correlation test. Minitab 
statistical 16 software was used for statistical analysis and graph pad prism 6 
software was used for creating Figures. 
 
5.3 Results 
5.3.1 VEGF-A protein expression within the human endometrium 
across the menstrual cycle 
Standard immunohistochemical technique successfully demonstrated the 
expression of VEGF-A protein in both stromal and glandular epithelial 
compartments of endometrium (Figure 5.3&5.4). In addition, VEFG-A protein 
expression was demonstrated around blood vessels (Figure5.5). 
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Figure 5.3: The expression of VEGF-A protein in endometrial stromal cells (arrow). The 
brown stained cells are positive for VEGF-A and blue stained cells are negative for VEGF-A. 
 
 
 
 
Figure 5.4: The expression of VEGF-A protein in endometrial epithelial glandular tissue 
(EG). The brown stained cells are positive for VEGF-A and blue stained cells are negative for 
VEGF-A. 
 
EG 
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Figure 5.5: VEGF-A around arteries (red arrow) and veins (blue arrow) in human 
endometrium. The brown stained cells are positive for VEGF-A and blue stained cells are 
negative for VEGF-A. 
 
5.3.1.1 In women with normal uteri  
In stromal endometrial tissue, cellular expression of VEGF-A protein appeared 
higher in the nuclear compartment than the cytoplasmic compartment. 
However, the immunostaining analysis found no statistic significant variation in 
VEGF-A protein expression between cellular compartments. The pattern of 
VGEF-A protein expression in stromal endometrium displayed a highest 
infiltration level in the menstrual phase and the lowest level during the early 
secretory phase, with significant differences between the two levels (95% Cl 
(129.99, 30.00) P= 0.019). The expression of VEFG-A protein was higher in the 
proliferative phase than the early secretory phase as well (95% Cl (99.97, 0.02) 
p=0.04).In glandular endometrial tissue, the VEGF-A protein infiltration was 
higher in the menstrual phase than the secretory phase (95% Cl (0.199, 1.686) p= 
0.019) (Figure5.5). 
5.3.1.2 In women with uterine fibroids  
The pattern of VEGF-A protein expression in stromal endometrial increased 
across the menstrual cycle with no significant difference between phases.It was 
noticed that VEGF-A protein staining intensity in glandular endometrial tissue 
significantly increased throughout the menstrual cycle from the proliferative 
phase toward menstrual phase for women with uterine fibroids (P= 0.001)(Figure 
5.6). 
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Figure 5.6: : Representative sections of immunostaining of VEGF-A proteins a cross the 
menstrual cycle in women with normal uteri, proliferative( A), early secretory (C), mid-
secretory(E), and menstrual phase(G), in women withuterine fibroids, proliferative (B), early 
secretory (D), mid-secretory (F) and menstrual phase (H). In each section VEGF-A found in 
epithelial glands (g), and stroma (s) surface epithelial (Se) and in endometrial capillaries 
(arrows). Negative control tissue (I). The immunostaining positive cells for VEGF-A 
presented in brown colour and the immunostaining blue cells are negative for VEGF-A. 
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5.3.1.3 Differences in endometrial VEGF-A protein expression between 
women with uterine fibroids and women with normal uteri 
There was no difference in the VEGF-A  protein expression  throughout the 
menstrual cycle in the stromal endometrium between women with normal uteri 
and women with uterine fibroids except in the early secretory phase (97% Cl  (-
130.03, 0.00), p=0.043), where it was higher in endometrial samples for women 
with uterine fibroids(Figure 5.7). The difference in VEGF-A protein in glandular 
tissue between the two groups was only not significant P=0.587. 
 
135 120
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130
menstrual proliferative early secretory mid to late secretory
VEGF-A/Normal endometium VEGF-A/ uterine fibroids
 
Figure5.7: the expression pattern of VEGF-A protein in the stromal endometrial throughout 
the menstrual cycle for both women with uterine fibroids and women with normal uteri ( 
medians value was depicted). Proliferative phase n=9&7, early secretory phase n=8&4, mid-
late secretory phase n=5&7, and menstrual phase n=4&5 for uterine fibroids group and 
normal uteri group respectively. 
 
 
5.3.2 Expression of VEGF-A mRNA across the menstrual cycle 
5.3.2.1  In women with normal uteri 
Endometrial VEGF-A mRNA expression varied significantly across the menstrual 
cycle in women had HMB with normal uteri (p=0.006) (Figure 5.8). However,no 
difference in the expression of VEGFA was found between the proliferative and 
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mid- late secretory phase. The variation in the VEGF-A mRNA levels was 
consistent with immunostaining intensity results. 
5.3.2.2 In women with uterine fibroids 
The RT-PCR results show that the relative VEGF-A mRNA expression was 
significantly higher in the proliferative phase and mid-late secretory phase than 
the early secretory phase, with no difference between the proliferative and mid- 
late secretory phase (Figure 5.8). 
P
(n
=
9
)
E
S
(n
=
6
)
M
-L
S
(n
=
7
)
M
n
(n
=
4
)
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
1 2 0 0
1 4 0 0
In  n o rm a l u te r i
M e n s tru a l c y c le  s ta g e
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
V
E
G
F
-
A
 
m
R
N
A
K W  te s t
p = 0 .0 0 2
P
(n
=
6
)
E
S
(n
=
7
)
M
-L
S
(n
=
5
)
M
n
(n
=
3
)
0
2 0 0
4 0 0
6 0 0
8 0 0
In  f ib ro id  u te ru s
M e n s tru a l c y c le  s ta g e
K W  te s t
p = 0 .0 1 2
 
Figure 5.8: VEGF-A mRNA expression across the menstrual cycle in women had heavy 
menstrual bleeding (HMB) with normal uteri and with uterine fibroids;proliferative (P), early 
secretory (ES), mid-secretory (MS), late secretory (LS) and menstrual (Mn) phases. The 
actual values of the relative expression of VEGF-A mRNA were analysed by Kruskal Wallis 
test. 
 
5.3.2.3 Difference in the VEGF-A mRNA levels between groups 
Our RT-PCR data found no difference in the expression of VEGF-A in 
endometrium for women with HMB between uterine fibroids and normal uteri 
cases, and this finding was consistent with the immunohistochemistry data 
(Table 5.3). 
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Table 5.3: Summary of differences between groups for the relative VEGF-A 
mRNAexpression, representative in medians (Mann-Whitney test was used). 
 
  Endometrium/uterine 
fibroids 
Endometrium/normal uteri 
Comparison 
phase 
No. Median  No. Median  95% Cl  P 
value 
proliferative 6 270.7 9 147.6.6 (499.2.0,108.1) 0.68 
Early secretory 7 46.67 6 72.60 (49.71,67.25) 0.77 
Mid-late 
secretory 
5 160.5 7 365.0 (327.8,297.8) 0.54 
menstrual 3 173.3 4 705.9 (63.4,890.4) 0.11 
 
 
 
5.3.3 The expression of VEGF receptors across the menstrual 
cycle 
5.3.3.1 VEGF-R1 (flt-1) 
The RT-PCR results for VEGF-receptor 1 (VEGFA-R1) in women had with normal 
uteri demonstrated that the expression increased from the proliferative  across 
the menstrual cycle and obtained the highest  expression in the menstrual phase 
and the lowest expression in the early secretory phase with no statistical 
significant difference between the maximum and the minimum expression 
(Figure 5.9).In women with uterine fibroids, there was no difference in the 
expression of VEGFR1 across the menstrual cycle (Figure 5.9). 
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Figure 5.9:  Illustration of the differences in the relative expression of mRNA of VEGF-R1 in 
the endometrium throughout the menstrual phase; in proliferative (P), early secretory (ES), 
mid to late secretory (M-LS) and menstrual (Mn) for women with normal uteri and women 
with uterine fibroids. The actual values of the relative expression of VEGF-R1 mRNA were 
analysed by Kruskal Wallis test 
 
5.3.3.1 VEGF-R2 (KDR) 
The analysis of RT-PCR data for VEGF-R2 found that the expression of this 
receptor in endometrium for women had HMB with no uterine pathology, was 
significantly increase across the menstrual cycle (Figure 5.10).In women who had 
HMB with uterine fibroids; there was no any difference in the VEGFR2 expression 
between phases across the menstrual cycle. Nevertheless, the expression of that 
receptor increased from the proliferative to the secretory phase until obtained 
the highest expression in the menstrual phase (Figure 5.10). 
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Figure 5.10: differences in the relative expression of mRNA of VEGF-R2 in the endometrium 
throughout the menstrual phase; in proliferative (P), early (ES), mid to late secretory (M-LS) 
and menstrual (Mn) for women with normal uteri and women with uterine fibroids. The 
actual values of the relative expression of VEGF-R2 mRNA were analysed by Kruskal Wallis 
test 
 
 
5.3.3.2 Relation between VEGF-A and its receptors (ftl-1&KDR) 
The correlation between the VEGF-A and its two receptors was tested and our 
results found no relation between the mRNA levels of VEGF-A and the receptor 
VEGF-R1 across the menstrual cycle for both groups, moreover, The mRNA level 
of VEGF-R2 did not correspond to the level of VEGF-A across the menstrual 
cycle. 
 
The findings indicated to a higher expression of VEGF-R2 than VEGF-R1 in the 
proliferative phase (P<0.0001), and early secretory (p<0.05) for women with HMB 
(Figure 5.11). 
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Figure 5.11 : The differences in gene expression for VEGF-R1 and VEGF-R2 across the 
menstrual cycle; in proliferative (P), early secretory (ES), mid to late secretory (M-LS) and 
menstrual (Mn). *** for P ≤0.0001,* for P<0.05. The actual values of the relative expression of  
mRNA were analysed by Mann Witney test. 
 
5.3.4 Expression of VEGA in uterine tissue in women with 
fibroids 
5.3.4.1 Changes in VEGF-A mRNA level across the menstrual cycle in 
endometrium 
The result of RT-PCR data about endometrial VEGF-A in women with uterine 
fibroids is shown above (section 5.3.2.2). 
 
5.3.4.2 Changes in VEGF-A mRNA level across the menstrual cycle in 
myometrium 
RT-PCR data analysis shows that the expression of VEGF-A was higher in the 
proliferative phase than the secretory phase (P=0.035) (Figure 5.112). However, 
by excluding the outlier, the difference between the two phases was not 
significant (0.057). 
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Figure 5.12: The expression of VEGF-A mRNA in myometrium in women with uterine 
fibroids during proliferative (P) and secretory (S) phases. The actual values of the relative 
expression of VEGF-A mRNA were analysed by Mann Witney test. 
 
5.3.4.3 Changes in VEGF-A mRNA level across the menstrual cycle in 
fibroid 
There was no difference in the expression of VEGF-A mRNA level between the 
proliferative and secretory phase in fibroids tissue (Figure 5.13). 
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Figure 5.13: The expression of VEGF-A mRNA in fibroid tissue in the proliferative (P) and 
secretory (S) phases. Statistical analysis with and without outlier was done for the actual 
values of the relative expression of VEGF-A mRNA by Mann Witney test. 
 
 
5.3.4.4 Difference in the expression of VEGF-A protein between uterine 
tissue  
In addition to endometrium (section 5.3.1.2), shows wide infiltration of VEGF-A 
in both myometrium and fibroid tissue for women with different types of uterine 
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fibroids. Immunostaining intensity of VEGF-A protein was higher in the 
endometrium and fibroids tissue than the adjacent myometrium tissue (Figure 
5.14). 
 
 
Figure 5.14: Representative immunostaining tissue for uterine fibroid tissue of women had 
uterine fibroids, shows the expression of VEGF-A in endometrium (E) myometrium (M) and 
fibroid (F) 
 
 
 
5.3.4.5 Difference in the expression of VEGF-A mRNA between uterine 
tissue  
RTPCR data analysis shows no difference in VEGF-A mRNA level in endometrium, 
myometrium and uterine fibroids (p= 0.375) (Figure 5.15).  
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Figure 5.15: The expression of VEGF-A mRNA in uterine tissues and uterine fibroids in 
women with HMB. The actual values of the relative expression of VEGF-A mRNA were 
analysed by Kruskal Wallis test. 
 
 
 
5.3.4.6 Difference in the expression of VEGF receptors mRNA level in 
uterine tissue  
There was no significant variation in the two receptors (VEGF-R1 & VEGF-R2) 
mRNA expression between endometrium, myometrium and different type of 
uterine fibroids (p= 0.649&0.958 respectively) (Figure 5.16). 
 
VEGF-R2
En
do
m
et
riu
m
M
yo
m
et
riu
m
Fi
br
oi
ds
0
200
400
600
R
e
la
ri
ve
 e
xp
re
ss
io
n
 o
f 
m
R
N
A
VEGF-R1
En
do
m
et
riu
m
M
yo
m
et
riu
m
Fi
br
oi
ds
0
20
40
60
80
100
R
e
la
ri
ve
 e
xp
re
ss
io
n
 o
f 
m
R
N
A
 
Figure 5.16: Box plots show the differences in the relative expression of VEGF-R1 mRNA 
between uterine fibroid tissue; endometrium, myometrium and fibroid. 
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5.3.4.7 The expression of VEGF-A mRNA in women treated with GnRH 
agonists  
RT-PCR results for VEGF-A mRNA shows higher expression in the endometrial 
VEGF-A in women had GnRH agonists than that for women had no hormonal 
treatment (P= 0.007) (Figure 5.16).  
There was no difference in the expression of VEGF-A mRNA in fibroids tissue for 
women had GnRH and women had no hormonal treatment (P= 0.050) (Figure 
5.17).  
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Figure 5.17: The difference in the expression of VEGF-A mRNA in endometrium and fibroid 
tissue for women with uterine fibroids who had GnRH agonists and in women had no 
hormonal therapy. 
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5.3.5 VEGF-A serum levels across the menstrual cycle in women 
with HMB 
5.3.5.1 In women with normal uteri 
The experimental results of ELISA technique show no difference in VEGF serum 
level across the menstrual cycle for women had idiopathic HMB (Figure 5.18). 
5.3.5.2 In women with uterine fibroids 
No difference in the VEGF serum level across the menstrual cycle for women 
with uterine fibroids as well (Figure 5.18). 
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Figure 5.18: Serum levels of VEGF in women had HMB with normal uteri (A) and with uterine 
fibroids (B). The actual values were analysed by kruskal wallis test and show no difference 
in the serum levels of VEGF across the menstrual cycle. 
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5.3.5.3 Differences in VEGF serum level between groups 
There was no statistical difference in the concentration of serum VEGF between 
women with normal uteri and women with uterine fibroids in case of HMB (Table 
5.4). 
 
 
Table 5.4: Differences in VEGF serum level between women with uterine fibroids and women 
with normal uteri, both had HMB. 
 
 VEGF concentration in serum (pg/ml) (range) 
In women with fibroid uterus In women normal uteri 
menstrual N= 5 330.7(153.4-466.8) N=6 280.3(48.29-
765.65) 
Proliferative  N=10 443.1(78.21-443.1) N=9 246(68.25-492.6) 
Early  secretory N=8 292.1(128.9-507.0) N=4 362.4(160.4-693.7) 
Mid-late 
secretory  
N=4 197.8(51.41-283.1) N=5 204.2(71.36-520) 
In GnRH N=3 413.12 (185.13-575.9)   
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5.3.5.4 Relation between VEGF concentration in serum and estradiol level 
in women with HMB 
There was no correlation between the VEGF serum concentration and estradiol 
level in blood in women with normal uteri and women with uterine fibroids 
(Figure 5.19&5.120). 
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Figure 5.19: Correlation between the VEGF serum concentration and estradiol level in blood 
for women with no uterine pathology. Spearman correlation test was used. 
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Figure 5.20: Correlation between the VEGF serum concentration and estradiol level in blood 
for women with uterine fibroids was not statistically significant. Spearman correlation test 
was used. 
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5.4 Discussion 
In this study, the data presented a consistent relationship between the RT-PCR 
results and IHC results regarding the endometrial VEGF-A expression across the 
menstrual cycle for women with HMB and uterine fibroids compared with women 
who had idiopathic HMB. 
Although the endometrial VEGF-A increased across the menstrual cycle, it 
increased mainly during the menstruation in women with idiopathic HMB. 
However, this pattern was also obvious in these with HMB associated with 
uterine fibroids, where the endometrial VEGF-A increased mainly during 
menstruation. Previous studies about the expression of endometrial VEGF-A 
presented conflict results. Some of these reports highlighted high expression of 
VEGF-A in the secretory phase [320],while others pointed to high expression in 
the proliferative phase [94, 325, 326]and some of authors presented increased 
expression in the peri and post menstruation [313, 315].  
Almost all the previous studies agreed about the role of VEGF in 
neoangiogenesis. Endometrial regeneration within the remaining functionalis and 
the basalis layers and neoangiogenesis process occur simultaneously and shortly 
after starting the menstrual bleeding. This process is thought to be triggered by 
regional hypoxia. VEGF-A is one of the genes that have hypoxia response 
elements in its promoter and it is induced by hypoxia in many cells [360-362]. 
Therefore, VEFG-A is discovered in the endometrial stroma in the late secretory 
and menstrual phases (decidualised stroma) and in the menstrual and early 
proliferative phases (non- decidualised stroma), hence, in peri and post 
menstruation endometrial stroma can respond to hypoxia by augmented 
production of VEGF-A. The expression of VEGF-A in stromal and glandular 
endometrium during the secretory and proliferative phases also is under the 
regulation of estradiol and progesterone as well as the hypoxia and some 
evidence about the role of cyclic AMP (cAMP) as an independent regulatory 
pathway. In that, disturbances in these regulatory factors can lead to alternation 
in the VEGF gene expression in endometrium and cause menstrual abnormality.  
In this study , we could  not find a clear difference in endometrial VEGF-A 
production between women who  had idiopathic HMB and women who had HMB 
in the presence of uterine fibroids, although, the IHC data identified an increase 
in the endometrial VEGF-A during the early secretory phase in women with 
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uterine fibroids greater than that in women with normal uteri. On the other 
hand, this finding was not consistent with the RP-PCR data, which identified no 
difference in the endometrial VEGF-A production between the two groups across 
the menstrual cycle. These results suggest that endometrial VEGF-A plays the 
same role in heavy menstrual bleeding in women with uterine fibroids as that in 
idiopathic heavy menstrual bleeding.  
The present study also showed considerable endometrial expression of KDR 
(VEGF-R2) and flt-1 (VEGF-R1) mRNAs across the menstrual cycle in women with 
HMB, both KDR and flt-1 show highest expression in the menstrual phase. This 
finding is consistent with a report by Graubert et al. [315] and Nayak et al[363], 
who demonstrated high immunohistochmical KDR expression in premenstrual 
phase. In contrast, other RT-PCR analysis showed that KDR mRNA in isolated 
endometrial stroma was increased during the secretory phase [306]. However, 
other study found no variation in KDR and flt-1 mRNA values throughout the 
menstrual cycle [364]. 
 
The majority of studies that examined KDR and flt-1 in endometrium, 
concentrated on their expression in stromal and epithelial glandular cells. Some 
of these studies observed immunostaning infiltration of both KDR and flt-1 in  
the stromal and glandular endometrial tissue [365, 366],and other studies 
showed no significance of immunostaining for flt-1 compared with KDR[306]. The 
present study found a higher expression of KDR mRNA than flt-1mRNA during the 
proliferative, and menstrual phase, and this is in one part consistent with a 
result by Meduri et al. [365], where KDR was higher than flt-1 at the beginning 
and during the proliferative phase in women with normal menstrual cycles. In 
contrast, Mints et al. [314] found higher immunostaning expression of flt-1 than 
KDR particularly during the secretory phase. However, this finding was regarding 
VEGF receptors in endometrial blood vessels in women with HMB. Thus, the 
results on flt-1 and KDR expression in the human endometrium are still 
controversial. This variation may be due to differences in the experimental 
technique, sample preparation, and probes or antibodies used. 
 
The study showed similar pattern of expression of flt-1 across the menstrual 
cycle to that of VEGF-A in women with idiopathic HMB. This finding may indicate 
similar regularity factors. This suggestion is consistent with a report by Gerber 
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et al.[367] who indicated that unlike KDR, both VEGF and flt-1 are directly up 
regulated by hypoxia via hypoxia inducible factor -1 as both of them have a HIF-
1 consensus in their promoter region. Therefore, this boosts the enquiry whether 
flt-I might contribute to a modulated biological effect of VEGF-A in HMB 
patients. Although VEGA binds to flt-1 in high affinity [368], its  cellular effect  
appears to be more predominantly mediated by KDR in endothelial cells [369-
371].However, our results found no correlation  between the level of VEGF-A 
mRNA and KDR and flt-1 mRNAs, except in the proliferative phase where the 
increase in the VEGF-R2 corresponded to the production of endometrial VEGF-A. 
In addition, the study showed increase in flt-1 during the mid to late secretory 
phase. Therefore, this may indicate strong kinase activity of KDR in response to 
VEGF-A during the proliferative phase. Additionally, the negative regulatory 
action of flt-1 on angiogenesis [372, 373] and the mediatory action of flt-1 for 
endothelial cell migration [374, 375] mainly occurs during the mid-secretory 
phase in cases of HMB. 
The expression of VEGF-A protein showed stronger immunostaining intensity in 
uterine fibroids than in adjacent myometrium. This is consistent with a report by 
Gentry et al.[376]. However, this finding was not supported by our RT-PCR data 
where there was no difference in the VEGF-A mRNA level between uterine 
fibroids and myometrium  and this concurs with Harrison-Woolrych et al. 
1995[356] . Furthermore, the level of KDR and flt-1 mRNAs was insignificantly 
higher in uterine fibroids than myometrium[377]. Nevertheless, collected 
myometrium and uterine fibroid samples for RT-PCR were not in similar adjacent 
manner. In contrast, another study found higher level of VEGF mRNA expression 
in women with uterine fibroids than women with healthy myometrium[378]. 
Nonetheless, the later study investigated uterine fibroids and myometrium from 
different subjects and it had the advantage of bigger sample size. Our study 
suggests that the high expression of VEGF-A in uterine fibroids indicates that 
local angiogenesis may be important for the development and growth of this 
tumour. In addition, our findings suggest that  increase level of VEGF-A mRNA 
expression in myometrium in women with multiple uterine fibroids compared 
with expression of VEGF-A in case of single uterine fibroids as most our subject 
had multiple uterine fibroids. Hence, VEGF-A may have a role in the 
development and growth of uterine fibroids. Furthermore, development and 
growth of uterine fibroids may up regulate the VEGF production in myometrium 
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and cause development of further fibroids. However, VEGF is not mitogenic to 
smooth muscle cells, but is a principal mediator of angiogenesis[356].  
 
In this study, the collected tissue were clinical samples, which obtained mainly 
for clinical diagnosis or treatment and this to some extent constrained having 
enough  fresh samples for RT-PCR, so RNA was extracted from paraffin samples. 
However, the quality of RNA extracted from paraffin was quantified and 
compared with that extracted from frozen samples, but still a single RNA 
extraction method is preferred. Furthermore, the same reason constrains having 
larger sample size for all stages across the menstrual cycle. Nonetheless, the 
sample size was in similar to these of other studies investigating the same 
markers [94,215,314,365,379]. In our study, there was no excluding for 
confounding factors such as smoking and dysmenorrhea, which may affect the 
result with small sample size. Furthermore, if the expression of VEGF-A is 
different during the early and late proliferative phase, staging the proliferative 
phase would pick up more of the variation in expression of VEGF-A between 
proliferative and secretory phase and would validate more the results. However, 
many studies in the research field have not had staging the proliferative phase 
as well [215, 380]. 
GnRH-agonists are an effective therapy for a wide number of gynaecological 
disorders. In women with uterine fibroids, the administration of GnRH-agonists is 
associated with a significant decrease in uterine and fibroids volume and with an 
improvement in fibroids-related symptoms. These effects are reversible at the 
end of the therapy that is therefore considered as a preoperative treatment. 
 
Our data shows a positive immunoreactivity for VEGF-A in endometrium, 
myometrium and uterine fibroids in women preoperatively treated with GnRH 
agonists. In endometrium, there was a reduction in VEGF-A protein expression in 
stromal and epithelial cells after therapy, but the remaining stained cells 
maintained a marked immunostaining. A compensatory reaction could be a 
possible explanation like that seen in physiological condition. The effect of 
GnRH-agonist on the expression of VEGF protein in myometrium and uterine 
fibroids was similar pattern of endometrium, and it was identified in both 
smooth muscle cells and fibroblast. However, the expression of VEGF protein 
was strong in endothelial cells in treated uterine fibroids, and this consistent 
Chapter 5 S.Abukhnjr 2014 169 
 
with other work[381]. The persisting vascular reservoir of VEGF could be among 
the possible explanations of the rapid regrowth of uterine fibroids after GnRH-a 
therapy is stopped. Although the VEGF-A mRNA expression in myometrium and 
uterine fibroids showed no difference between treated and non-treated group. 
In endometrium, our data identified higher expression of VEGF-A in treated 
group than non-treated group. The effect of GnRH agonists of VEGF is 
controversial, while some authors found decrease in the VEGF level in plasma 
and follicular fluid in women treated with GnHR agonist[382-384], other reports 
demonstrated increase in its level.  However, some studies found no difference 
in its effect on EGF expression [385].nevertheless, hetrogencicty in used 
methodology may contribute this diversity. 
 
 
 
5.5 Conclusion 
In conclusion, the VEGF-A expression is higher during the menstrual phase than 
proliferative and secretory phases. It seems that VEGF-A is involved in heavy 
menstrual bleeding mechanism in women with uterine fibroids similar to these 
with women with idiopathic HMB. VEGF-A has been suggested to have a role in 
the development and growth of uterine fibroids, however, uterine fibroids may 
up regulate production in myometrium and cause further development of uterine 
fibroids.  
Additional investigations are required to identify the pattern of VEGF expression 
in case of HMB with larger sample size than that used in previous studies. 
Further investigations are needed to identify more about the signal pathway of 
flt-1 and its main role in mediating the VEGF-A function. Detailed research about 
the VEGF expression in myometrium for women with uterine fibroids compared 
with women with normal uteri may help to understand the pathophysiology of 
uterine fibroids.  
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Chapter 6 
6. Prostaglandin E2 in heavy menstrual bleeding 
and in presence of uterine fibroids 
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6.1 Introduction 
Prostaglandins (PGs) are part of the eicosanoid family and consist of five 
endogenous members, called prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), 
prostaglandin F2α (PGF2α), prostacyclin, and thromboxane A2. The 
prostaglandins are bioactive metabolites, derived from the action of cyclo-
oxygenase (COX) enzymes upon arachidonic acid (AA). In summary, 
cyclooxygenase enzymes (COX-1& COX-2) generate PGG2 from arachidonic acid, 
the former reduced to the unsTable intermediate (PGH2) from which other 
prostanoids derived by range of prostaniod enzymes and isomerase (Figure 6.1). 
COX-1 is a constitutive enzyme expressed in nearly all body tissues and cell types 
and generates PG for normal physiological function. However, previous studies 
have shown upregulation of COX-1 expression in carcinomas[386].Pro-angiogenic 
factors can rapidly induce COX-2 in cells such as growth factors, oncogenes and 
carcinogens and various types of stimuli (). A role has been identified for COX-2 
in different pathological conditions such as rheumatic diseases, inflammation 
and tumorigenesis [387]. Prostaglandin E2 is a vasodilator and works via four 
pharmacological classified subtypes of G protein- coupled receptor (EP1-
EP4)[388].These subtypes may be coexpressed on the same cell or on adjacent 
cells, indicating an autocrine/paracrine control of an autocoid biosynthesised 
and released in close proximity to the site of its action[389].  
 
 Prostanoids work mainly as primary mediators in pathological conditions such as 
inflammation, hypertension and cancer but they also have a crucial role in 
normal physiological function such as in the female reproductive system[390]. 
This concept was supported by observational studies which investigated the 
effect of COX-1 and COX-2 deficient mice. These observations confirmed that 
COX-1 has an essential role for determining the normal gestational period and 
parturition [391, 392]. Reduction in COX-2 has detrimental effects on ovulation, 
fertilization, implantation and decidualization, and this is an example of the role 
of prostaglandins produced by COX-2 in these processes [393-396]. COX-2 
expression and PGE2 synthesis is upregulated by pituitary gonadotropin before 
ovulation and this promotes follicle expansion and ovulation. Hence, 
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administration of exogenous PGE2 has been shown to save ovulation in mice 
[394]. In human reproduction, dysregulation in endometrial prostanoids can 
cause menstrual disorder [79,397,398]. 
 
In the normal menstrual cycle, cyclical tissue breakdown and remodelling occurs 
in human endometrium. This process is mainly under the influence of sex steroid 
hormones. Towards the end of menstrual cycle and parallel with the withdrawal 
of progesterone and sloughing of the functional layer of endometrium, COX-2 
expression is upregulated in human endometrium [269, 386, 399], with 
subsequent synthesis of PGE2 and PGF2α (a vasoconstrictor)[400]. This occurs at 
the same time as an increase in the expression of prostaglandin E2 receptors 
(EP2)[401]. In addition, COX-2 induced prostaglandins regulate leukocyte influx 
from the circulation to endometrium, and this leads to endometrial breakdown 
[402, 403]. Recent studies have determined a role for COX enzymes and PGS in 
the regulation of epithelial cell growth and angiogenesis[404]. In addition, 
overexpression of COX-2 and PGE2 synthesis are associated with increased 
cellular proliferation and apoptosis  resistance [405]. Furthermore, they have a 
direct effect on the endothelial cell function[406] and reflect their association 
with vascular function . Hence, treatment of endothelial cells with selective 
COX-2 inhibitors has been shown to reduce microvascular tube formation [404, 
407]. In addition, some studies performed in cancer cell lines suggested that 
PGE2 act via EP2 to generate VEGF expression through HIF-1 activation [62, 408]. 
Hence, it is assumed that there are possibly two pathways connecting  COX-2 up-
regulation with downstream angiogenic gene expression; increased PGF2 
expression leading to local ischemia/hypoxia and thus HIF-1 expression, and 
increased PGE2 expression directly inducing HIF-1expression[409]. 
 In women suffering from heavy menstrual bleeding, excessive expression of 
COX-2 and PGE2 synthesis in endometrium has been recognised[410]. In this 
group of women, a positive relationship between the volume of blood loss and 
PGE2 release in the  uterus has been identified [96].  
The aim of this chapter is to study the expression of COX-2 and the PGE2 
synthesis in human endometrium in heavy menstrual bleeding and the difference 
in presence of uterine fibroids. 
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6.2 Methods 
Materials and methods were discussed in chapter two. 
6.3 Results 
6.3.1 COX mRNA and protein expression within human 
endometrium in heavy menstrual bleeding across the 
menstrual cycle 
6.3.1.1 In women with idiopathic HMB 
The expression of COX enzyme mRNA in human endometrium in heavy menstrual 
bleeding was determined by Taqman quantitative RT-PCR analysis. For COX-1 
mRNA, no difference in the gene expression was identified across the menstrual 
cycle (Figure 6.1).  
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Figure 6.1: The expression of COX-1 mRNA in endometrium in women with idiopathic heavy 
menstrual bleeding. Proliferative (P), early secretory (ES), mid- late secretory (M-LS), and 
menstrual (Mn) phases. The actual values of the relative expression of COX1 mRNA were 
analysed using Kruskal Wallis and show no difference in the expression of COX-1 mRNA 
across the menstrual cycle.  
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Significant differences in the expression were noted for COX-2 between 
menstrual and proliferative phase (median of 0.78 (0.3, 4.7) and 31.7 (3.55, 230) 
respectively, P<0.05) (Figure 6.2). In addition, the immunostaining analysis 
shows that COX-2 protein was highly expressed in the endometrial epithelial and 
endothelial cells with no change across the menstrual cycle (Figure 6.3). 
However, COX-2 protein expression in endometrial stroma was higher during the 
mid-secretory than the menstrual phase (2.3±0.3, 1.2±0.2 respectively, p<0.05) 
(Figure 6.4& 6.5).   
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Figure 6.2: The expression of COX-2 mRNA in endometrium in women with idiopathic heavy 
menstrual bleeding.Proliferative (P), early secretory (ES), mid- late secretory (M-LS), and 
menstrual (Mn) phases. The actual values of the relative expression of COX2 mRNA were 
analysed using Kruskal Wallis test. 
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Figure 6.3: The expression of COX-2 protein in glandular epithelial cells (GE) and 
endothelial cells (arrows). The brown stained cells are positive for COX2 protein and other 
cells in blue colour show no COX2 protein expression. 
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Figure 6.4: Immunostaining intensity of COX-2 protein expression in endometrial stroma (S) 
and gepithelial glands (G) in women with idiopathic heavy menstrual bleeding during 
proliferative (P), secretory (S) and menstrual (M) phases. Semiquantitative 4 scale scoring 
method was used, 1 for mild (<10%), 2 for moderate (10-50%) and 3 for intense staining 
(>50%). 
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Figure 6.5: COX-2 protein expression in endometrium across the menstrual cycle for women 
with idiopathic heavy menstrual bleeding; negative control (N), proliferative (P), early 
secretory (ES), mid-secretory (MS), late secretory (LS) and menstrual (M) phases. The cells 
in brown immunostaining are positive for COX2 protein and other cells in blue colour show 
no COX2 protein expression. 
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6.3.1.2 In women with uterine fibroids 
In women with heavy menstrual bleeding and uterine fibroids, there were no 
significant differences in the expression of endometrial COX-1 across the 
menstrual cycle at the mRNA level (Table 6.1). In addition, the variation in COX-
2 gene expression (Figure 6.6) and intensity score of COX-2 protein expression 
(Figure6.7) was not significantly difference. On the other hand, COX-2 protein 
expression was reduced in stromal cells from the functional and the basal layer 
of the endometrium with no change for glandular epithelial and endothelial cells 
(Figure 6.8).  
 
Table 6.1: The expression of COX-1 protein in endometrium of women with uterine fibroids 
 The relative expression of COX-1 mRNA (median (range)) 
Menstrual 50.66 (1.4-144.5) 
Proliferative 10.21 (4.4-71.4) 
Early secretory 100.2 (3.9-165.4) 
Mid-late secretory 70.8 (14.2-173.6) 
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Figure 6.6: The expression of COX-2 mRNA across the menstrual cycle in women with HMB 
and uterine fibroids. The actual values of the relative expression of COX2 mRNA were 
analysed using Kruskal Wallis test. 
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Figure 6.7: Immunostaining score of COX-2 endometrial stroma in women with uterine 
fibroids. Semiquantitative 4 scale scoring method was used, 1 for mild (<10%), 2 for 
moderate (10-50%) and 3 for intense staining (>50%). 
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Figure 6.8: expression of COX-2 protein in stromal cells (arrows) in functional (f) was higher 
than that in basal layer (b) of endometrium in women with heavy menstrual bleeding and 
uterine fibroids while no difference in COX-2 expression in epithelial glandular cells (EG) 
between the functional and the basal layer of endometrium. The cells in brown 
immunostaining are positive for COX2 protein and other cells in blue colour show no COX2 
protein expression. 
 
 
6.3.2 COX-2 protein expression in myometrium and fibroid 
tissue in women with uterine fibroids 
In myometrium, the expression of COX-2 protein was mainly in perivascular cells   
(Figure 6.9). In uterine fibroids, there was wide infiltration of COX-2 protein 
(Figure 6.10).   
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Figure 6.9: COX-2 protein expression in myometrium in women with uterine fibroids and 
heavy menstrual bleeding; endothelial cells (EC), stromal cells (arrows) and negative 
control myometrium section (N). The cells in brown immunostaining are positive for COX2 
protein and other cells in blue colour show no COX2 protein expression. 
 
 
 
Figure 6.10: COX-2 protein expression in fibroid tissue in women with heavy menstrual 
bleeding. Negative control fibroid section (N). The cells in brown immunostaining are 
positive for COX2 protein and other cells in blue colour show no COX2 protein expression. 
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6.3.3 PGE2 and EP2 expression in endometrium in heavy 
menstrual bleeding. 
6.3.3.1 In women with idiopathic HMB 
Immunohistochemistry was used to identify the expression of PGE2 in 
endometrium and the results show no difference in PGE2 protein infiltration 
across the menstrual cycle (Figure 6.11& 6.12). Furthermore, the PGE2 protein 
expression was high in both epithelial glandular and stromal endometrial cells. 
By using the RT-PCR technique, the expression of EP2 mRNA, was not 
significantly various between phases throughout the menstrual cycle (Figure 
6.13). 
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Figure 6.11: Imunostaining intensity level of PGE2 protein in endometrium in women with 
idiopathic heavy menstrual bleeding across the menstrual cycle. Semiquantitative 4 scale 
scoring method was used, 1 for mild (<10%), 2 for moderate (10-50%) and 3 for intense 
staining (>50%). 
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Figure 6.12: High expression of PGE2 in endometrium for women with heavy menstrual 
bleeding throughout the menstrual cycle in both stromal and glandular endometrial tissue. 
The cells in brown immunostaining are positive for PGE2 protein and other cells in blue 
colour show no PGE2 protein expression.  
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Figure 6.13: The expression of EP2 mRNA in endometrium for women with idiopathic heavy 
menstrual bleeding across the menstrual cycle. (Log scale was depicted). 
 
 
6.3.3.2 In women with uterine fibroids 
In full thickness endometrium collected from women with uterine fibroids, PGE2 
protein expressed in both basalis and functionalis layer with reduction in the 
stromal compartment in the basalis layer. However, no change was noticed for 
epithelial, endothelial and intraglandular infiltration (Figure 6.14).   
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Figure 6.14: Immunostaining reactivity of PGE2 in endometrial layers (basalis and 
functionalis) for epithelial glandular (EG), stromal (S), intraglandualr (G) and endothelial 
cells (arrows). The cells in brown immunostaining are positive for PGE2 protein and other 
cells in blue colour show no PGE2 protein expression. 
 
 
In women with uterine fibroids, the expression of PGE2 protein was higher during 
the menstrual phase than the proliferative phase (2.8±0.2 (2-3) & 2.3±0.2 (1-3), 
P<0.05 respectively) but not the secretory phase (2.3±0.2 (2-3) (Figure 6.15). 
The difference in EP2 receptor mRNA was not statistically significant in 
endometrium across the menstrual cycle (Figure 6.16). 
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Figure 6.15:Imunostaining intensity level of PGE2 protein in endometrium in women with 
heavy menstrual bleeding and uterine fibroids across the menstrual cycle. Semiquantitative 
4 scale scoring method was used, 1 for mild (<10%), 2 for moderate (10-50%) and 3 for 
intense staining (>50%). 
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Figure 6.16:Comparison ofEP2 receptor  expression levelsin endometrium of women with 
heavy menstrual bleeding and heavy menstrual bleeding across the menstrual cycle. (Log 
scale was depicted)  
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6.3.3.3 Differences between groups 
There was no difference in the expression of PGE2 protein in endometrium for 
women with heavy menstrual bleeding between groups. In the addition, the 
level of EP2 receptor mRNA was not significantly different between them. 
 
 
6.3.4 PGE2 and EP2 expression in myometrium and fibroid 
tissue 
The immunohistochemistry results show higher infiltration of PGE2 protein in 
fibroid tissue in comparison with myometrium, where in the later PGE2 mainly 
infiltrating into endothelial cells and around blood vessels (Figure 17). 
 
 
 
 
Figure 6.17: The expression of PGE2 protein in myometrium (M) and uterine fibroid (F) in 
women with uterine fibroids. Black arrows point to blood vessels in myometrium. The cells 
in brown immunostaining are positive for PGE2 protein and other cells in blue colour show 
no PGE2 protein expression. 
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6.4 Discussion 
The data presented in this study identify the expression and localisation of COX-
2 and PGE2 in stromal, epithelial, and endothelial cells of the human 
endometrium across the menstrual cycle in women complaining of heavy 
menstrual bleeding with uterine fibroids and with no uterine pathologies. 
However, the expression of COX-2 was predominantly in glandular epithelial 
cells,whereas the expression of PGE2 was high in endometrial stromal and 
epithelial cells. Our results show over-expression of COX-2 and PGE2 synthesis in 
endometrium across the menstrual cycle, although COX-2 expression and PGE2 
up regulation was mainly during the mid-secretory and the menstrual phases for 
both groups. This was partly in agreement with previous studies [411-413], which 
demonstrated upregulation of COX-2 expression and PGE2 synthesis during the 
menstrual and the proliferative phase. However, the demography of studied 
subjects was different. The COX-1 mRNA was high in endometrium for women 
with heavy menstrual bleeding and this may indicate a role of COX-1 over –
expression in the pathophiology process of heavy menstrual bleeding. 
 In general, the premenopausal human endometrium undergoes phases of 
proliferation and apoptosis during successive menstrual cycles. These phases are 
observed largely in the functionalis layer of the endometrium, which is shed at 
menstruation before regenerating during the proliferative phase of the 
subsequent menstrual cycle. Over-expression of COX enzymes and enhanced 
synthesis of PGE2 may be due to dysregulation of prostanoids in endometrium, 
which may cause menstrual abnormality.  In heavy menstrual bleeding, stromal 
expression of COX-2 and PGE2 are predominantly localized in the functionalis 
layer of the endometrium and extend to the basalis and myometrial regions. 
Although previous studies suggest the crucial role of PGE2 in human 
endometrium particularly in cellular mitogenesis and survival, the exact role has 
not been fully clarified. On the other hand, over expression of COX-2 and 
enhanced synthesis of PGE2 have been shown to promote the proliferation and 
survival of cells in colon epithelial cells [405, 414] through up-regulated 
expression of antiapoptotic genes such as bcl-2 [414]. Therefore, in human 
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endometrium, it is reasonable that PGE2 may be activating similar mechanisms 
that promote glandular epithelial cell proliferation and/or survival. This is 
supported by recent data confirming over expression of bcl-2 endometrial 
glandular epithelial cells [415, 416].  
PGE2 function in glandular epithelial cells may also be associated with the 
regulation of uterine angiogenesis. Over expression of COX-2 and increased 
production of PGE2 in epithelial cells have been associated with the expression 
of angiogenic factors, such as vascular endothelial growth factor [417]. In the 
human endometrium, vascular endothelial growth factor expression is localized 
to the glandular epithelial cells throughout the menstrual cycle [318, 418], and 
PGE2 has been shown previously to up-regulate the expression of vascular 
endothelial growth factor in a number of different cell types [419]. In women 
with uterine fibroids, the expression of COX-2 and PGE2 synthesis upregulated in 
myometrium and the expression of PGE2 were high in perivascular and stromal 
cells but the expression of COX-2 was almost confined to perivascular tissue. 
Higher expression of both COX-2 and PGE2 synthesis is found in fibroid tissue 
than myometrium which reflects upregulation of COX-2 expression and PGE2 
synthesis in fibroblast cells. This may lead to up-regulation in the expression of 
vascular endothelial growth factor in fibroid tissue and thus enhanced fibroid 
development and growth.  
The measured EP2 receptor mRNA demonstrated high expression of EP2 receptor 
across the menstrual cycle particularly in the mid- late secretory and menstrual 
phase, which suggests an important role for PGE2 in heavy menstruating 
endometrium during these phases. In addition, the expression of PGE2 was 
associated with a high level of EP2 receptor mRNA ,but this was inconsistent 
with a report by Milne et al.[401]. PGE2 induces vasodilatation via perivascular 
EP2/EP4 receptor[388], whereas activation of EP receptors on endothelial cells 
may regulate angiogenesis. Endometrial angiogenesis takes place throughout the 
menstrual cycle, in the functionalis phase rather than the basalis [420]. 
Recently, COX-2 and PGE2 have been linked directly with endothelial cell 
function and angiogenesis[406]. Hence, treatment of endothelial cells with 
selective COX-2 inhibitors has been shown to reduce microvascular tube 
formation, and this can partly reverse angiogenic effect by means of PGE2 [407]. 
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Using non-steroidal anti-inflammatory drugs, which inhibit PG synthesis, as 
treatment of choice to reduce excessive menstrual blood loss  in women 
reporting heavy menstrual bleeding, is a further evidence of a role for PGE2 in 
uterine vascular [421]. In addition, increased receptor expression, has been 
observed in the uteri of women with heavy menstrual bleeding  [422] and the 
use of non-steroidal anti-inflammatory drugs to reduce menstrual blood loss also 
reduces PGE2-binding sites within the uterus [104], all this confirm the role of 
COX-2,PGE2 and EP2 receptor in menstrual abnormality. 
6.5 Conclusion 
It can be concluded that over-expression of COX 2 and PGE2 synthesis in 
endometrium in women with heavy menstrual bleeding reflect their crucial role 
in menstrual abnormality. Additionally, COX-1 suggested having a role in the 
mechanism of heavy menstruation as well. The upregulation of COX-2 
expression, PGE2 synthesis and EP2 receptor to high levels in myometrium and 
uterine fibroids, may indicate their role in development and/or growth of 
uterine fibroids. 
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Chapter 7 
7. The expression of IL8 in endometrium during 
menstruation 
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7.1 Introduction 
Interleukin-8 (IL-8) is a proinflammatory cytokine associated with neutrophil 
chemotactic/activating and T cell chemotactic activity[68]. IL8 acts via two G 
protein- coupled receptors (CXCR1 and CXCR2), which initiate various signalling 
cascades [66]. IL8 has a role in promoting angiogenesis (chemotaxis of 
endothelial cells)[71], mitogenesis in cancer [423] as well as vascular smooth 
muscle cells[424]. In addition, increased expression of IL-8 and/or its receptors 
has been characterised in endothelial cells, infiltrating neutrophils, and tumour-
associated macrophages, suggesting that IL-8 may act as an important regulatory 
factor for tumour growth [73]. Different types of cells can produce IL8 such as 
peripheral blood monocytes [72], endothelial cells[425], neutrophils[426], cells 
derived from human choriodecidual cells [427], fibroblasts, and keratinocytes 
[428]. 
 
In human endometrium, IL8 is mainly localised in glandular epithelial cells, 
which indicates that it may have other functions besides the recruitment of 
maternal leukocytes. In addition, it was demonstrated in endometrium across 
the menstrual cycle with upregulation during the late secretory phase[429] and 
menstrual phase[430]. In endometrium, IL8 is able to activate macrophages and 
recruit neutrophils and T cells. On the other hand it can act as an autocrine 
growth factor to promote angiogenesis in endometrial blood vessels, 
proliferation of endometrial stromal cells and it also facilitates tissue 
remodelling [431-433]. 
 
During normal menstruation, inflammation is an important event [79] and 
infiltration of inflammatory leukocytes is suggested to be essential for tissue 
breakdown and remodelling[434]. However, upregulation of this inflammatory 
process in endometrium can cause several pathological condition such as heavy 
menstrual bleeding [97]. Inflammation can be controlled by endogenous anti-
inflammatory mediators such as sex hormones[435], cytokine interleukin 10 
[436], protein annexin A1[437],lipid mediators involving lipoxin A4[438], resolvin 
D2 [439]and protectins[440]. A delicate balance between pro-inflammatory and 
anti-inflammatory mediators is essential for controlling inflammation which 
occurs during physiological events throughout the female reproductive tract. 
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Before the onset of menstruation, leukocytes influx into the endometrium by 
enhanced vascular permeability and assistance of chemokines and cytokines. As 
IL8 is suggested to play an important role in influx of leukocytes into 
endometrium, the upregulation of IL8 may cause high infiltration and 
transmigration of inflammatory leukocytes in endometrium. As a result, it may 
cause dysregulation in breakdown and remodelling process and lead to heavy 
menstrual blood loss.   
 
IL8 has been identified to be highly expressed in uterine fibroids [441, 442]and 
adjacent myometrium [442]. These observations bring a concept that IL8 may 
play a potential role in the growth of uterine fibroids. In addition, IL8 may have 
a profound biological and clinical significance, specifically in women with 
symptomatic uterine fibroids having abnormal bleeding.  
 
Pre-operative GnRH agonists administration lead to regression of uterine fibroids 
and it used by many gynaecologists in the clinical field to decrease their size 
preoperatively [381, 443]. Administration of GnRH agonists causes acute 
reduction in the circulating oestrogen level, which might influence alterations in 
cytokines and chemokines as well as modifications in vascular inflammation. 
However, these changes in cytokines and chemokines due to administration of 
GnRH agonists have not been fully clarified.  
 
 
7.2 Material and methods 
7.2.1 Tissue collection 
The collected tissue was discussed in details in section 2.2.1.1. 
7.2.2 Real time PCR 
RNA was extracted with TRI-reagent (Ambion, Life technologies, Paisley, Uk) 
following manufacturer’s guidelines using phase lock tubes (Microcentrifuge, 
Greiner bio-one GmbH, Stone House- England, UK). RNA samples were reverse 
transcribed using MultiScribe (Invetrogen, Life technologies, Paisley, UK) primed 
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with random hexamers according to the manufacturer's instructions (see section 
2.5.4). When there was not enough fresh endometrial samples , RNA was 
extracted from formalin –fixed paraffin- embedded samples using Ambien kit 
1975 (Recover All total nucleic acid isolation kit-Life technology, paisley, UK) 
according to the manufacturer's instructions (see section 2.5.1.2). Quality of RNA 
was assessed using an automated spectrophotometer RNA 6000 Nanodrop (Lab 
tech.com, Ringmer, East Sussex,UK), only half of the RNA samples were assisted 
by the Agilent 2100 Bioanalyser system in combination with RNA 6000nano chips 
(see details in section2.5.2).Once the RNA was extracted and quantified, the 
PCR reactions were carried out using an ABI Prism 7900 (Applied Biosystems) as 
previously described in section 2.5.6 using duplicate samples. A no reverse 
transcriptase (containing water) was used as template control. Pre-validated 
primers and probes were purchased for IL8 (Life technology, Paisley, UK).  
 
7.2.3 Immunohistochemistry 
The principle method for immunohistochemistry was followed to express the IL8 
gene in uterine tissue. The used antibody was IL8 at dilution of 1:50 from R&D 
(cat. no. AF-208 NA). Retrieve antigen was performed by microwaving sections in 
pressure cookers in citrate buffer pH 6.0. Vector biotinylated anti-goat (1:200 
dilutions) was used as secondary antibody. Sections were washed throughout the 
method by PBS with adding 0.1% saponin solution.  
Immunostaining was assessed in a semi-quantitative manner on a 4-point scale 
0=no immunostaining, 1= mild immunostaining (< 10%), 2= moderate 
immunostaining (10-50%), and 3=intense (>50%). Double scoring by the same 
observer with 4 weeks interval was performed. Coefficient correlation between 
manual and automated scoring manners and between double scoring methods 
wasaccepted at ≥ 7. 
 
7.2.4 Enzyme-linked immunosorbent assay (ELISA) 
The quantitative concentration of interleukin-8 (IL8) in serum was measured by 
ELISA. The component required for this procedure was supplied in the quantikine 
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kit (R&D Systems Europe, Ltd, Abingdon, UK).the quantitative 
immunoenzymometric sandwich technique was followed according to the 
manufacturer’s instructions. 
7.3 Results 
7.3.1 The expression of endometrial interleukin 8 protein in 
heavy menstrual bleeding 
Immunohistochemistry staining successively shows the expression of IL8 protein 
in the stromal and glandular compartment of endometrium in women with heavy 
menstrual bleeding and in surface epithelial across the menstrual cycle (Figure 
7.1).  
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Figure 7.1: The expression of IL8 protein in endometrial stromal (S), epithelial glandular 
(EG) and epithelial surface (ES) cells across the menstrual cycle; proliferative (D), secretory 
(early (B), Mid (E), late (C)) and menstrual phase (F).  IL8 infiltration was noted in glandular 
and surface epithelial cells in proliferative and secretory phase, but it is highly expressed in 
both stromal and epithelial cells during the menstrual phase. The cells in brown 
immunostaining are positive for IL8 protein and other cells in blue colour show no IL8 
protein expression. 
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7.3.1.1 In women with no uterine pathology 
Immunohistochemistry staining shows mild expression of IL8 protein in 
endometrial stromal, epithelial glandular and perivascular cells during the 
proliferative and secretory phase, although it is increased during menstruation. 
In endometrial stroma IL8 infiltration was higher in the menstrual phase than the 
proliferative and secretory phase ((3±0.0, 1.2±0.2 and 1.2±0.1 respectively), 
P<0.05) (Figure 7.2).  
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Figure 7.2: The expression of IL8 protein across the menstrual cycle in heavy menstrual 
bleeding. Semiquantitative 4 scale scoring method was used, 1 for mild (<10%), 2 for 
moderate (10-50%) and 3 for intense staining (>50%). 
 
. 
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7.3.1.2 In women with uterine fibroids 
immunostaining intensity of IL8 in endometrium for women with HMB and 
uterine fibroids during the menstrual phase was greater than the proliferative 
and secretory phase (3±0.0, 1.4±0.4 and 1.6±0.2 respectively, P<0.05) (Figure 
7.3). 
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Figure 7.3:The expression of IL8protein across the menstrual cycle in heavy menstrual 
bleeding. Semiquantitative 4 scale scoring method was used, 1 for mild (<10%), 2 for 
moderate (10-50%) and 3 for intense staining (>50%). 
 
. 
 
Our results found no difference in the expression of IL8 protein in endometrium 
for women with idiopathic HMB and women with uterine fibroids across the 
menstrual cycle. 
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7.3.2 The expression of endometrial IL8 mRNA in women with 
HMB 
7.3.2.1 In women with normal uteri 
RT-PCR data showed marked upregulation of IL8 mRNA in the late –secretory and 
menstrual phase in comparison to proliferative and secretory phases (p<0.0001) 
(Figure 7.4). 
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Figure 7.4: the endometrial IL8 mRNA level across the menstrual cycle in women with 
idiopathic HMB. Kruskal Wallis test was used (KW). 
 
 
7.3.2.2 In women with uterine fibroids 
The measured IL8 mRNA showed a higher expression of the marker in 
endometrium during the late secretory and menstrual phases than other phases 
(p <0.001) (Figure 7.5). 
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Figure 7.5: The endometrial IL8 mRNA level across the menstrual cycle in women with HMB 
and uterine fibroids. Kruskal Wallis test was used (KW). 
 
7.3.3 The expression of IL8 in uterine fibroid 
7.3.3.1 In women with no hormonal therapy 
The expression of IL8 protein in myometrium was determined in endothelial cells 
and minimal expression was found in stromal cells. On the other hand, there was 
over-expression of IL8 protein in uterine fibroids (Figure 7.6) 
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Figure 7.6: The expression of IL8 protein in uterine tissue for women with uterine fibroids. 
(SE) surface epithelium, (S) endometrial stromal cells, (EG) pithelial glandular cells, and 
perivascular (black arrow). The cells in brown immunostaining are positive for IL8 protein 
and other cells in blue colour show no IL8 protein expression. 
 
7.3.3.2 In women who had received GnRH 
The immunostaining results show excessive reduction in the expression of IL8 in 
uterine tissue in women who had received GnRH agonists before hysterectomy in 
comparison with the expression of IL8 in uterine tissue for women who had 
received no hormonal therapy (Figure 7.7). The expression of IL8 mRNA was very 
low, in that it was undetermined after 40 cycles by RT-PCR. 
 
Figure 7.7: A reduction in the expression of IL8 protein in endometrium, myometrium and 
fibroid tissue was noted in women who had received GnRH agonists. The cells in brown 
immunostaining are positive for IL8 protein and other cells in blue colour show no IL8 
protein expression. 
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7.3.4 Serum level of IL8 in women with heavy menstrual bleeding 
There was no difference in the level of IL8 in serum throughout the menstrual 
cycle for women with idiopathic HMB and heavy menstrual bleeding with uterine 
fibroids (Table 7.1). However, IL8 level in serum was higher in women who had 
received GnRH agonists before hysterectomy than those who had received no 
hormonal therapy (P< 0.001) (Figure 7.8).  
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Table 7.1: The level of IL8 in serum for women with complaint of heavy menstrual bleeding 
 IL8 concentration in serum (pg/ml),median(range) 
In women with fibroid uterus In women normal uteri 
Menstrual N= 5 13.2 (8.4-23.63) N=6 17.25 (10.19-38.48) 
Proliferative  N=10 12.05 (8.18-19.21) N=8 11.52 (8.08-18.96) 
  Secretory N=8 11.96 (6.86-23.04) N=10 9.75 (5.64-26.37) 
In GnRH N=3 35.35 (28.17-62.7)   
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Figure 7.8: The difference in IL8 serum level between women had GnRH agonists and 
women had no hormonal preparations three months before the biopsy taken. Mann-Witney 
test was used 
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7.4 Discussion 
Although the precise role of cytokines in heavy menstrual bleeding is not 
completely known, a compelling body of evidence suggests an inflammatory 
basis for the physiology of menstruation. Menstruation occurs in women of 
reproductive age, and the expression of cytokines such as IL-8 in the 
endometrium fluctuates in a predicTable manner throughout the menstrual cycle 
[429]. Endocrine factors are involved in modulation of the tissue-specific 
changes in endometrium and the expression of chemotactic factors that are 
involved in the influx of the leukocytes during the menstrual cycle. Other report 
suggests that sex steroids regulate chemokine expression differently in 
endometrium a cross the menstrual cycle[444]. Endothelial cells play a role in 
leukocyte extravasation into the endometrium and in the regulation of the 
tissue-specific changes associated with the leukocyte migration. By mean, the 
endothelial cell layer acts as the porter of the endometrium for immune cells.  
Using immunohistochemistry, it can be confirmed that IL-8 is expressed in all 
endometrial compartments in women with HMB. The antibody used in this study 
revealed a significant increase in IL-8 staining in endometrial stromal cells, 
without significant difference between epithelial and stromal cells. It was 
observed that there was a significant increase in the IL-8 immunostaining of 
stromal cells in endometrium during the menstrual phase compared with 
proliferative and secretory phase. This result indicates that in endometrium 
from women with heavy menstrual bleeding endometrium , IL8 is mainly 
upregulated in the stromal compartment as has been demonstrated in previous 
studies although these have reported IL8 expression in glandular and surface 
epithelial but not in endometrial stroma [445] . However, those studies 
investigated the expression of IL8 in women with no heavy menstrual bleeding. 
This suggests that upregulation of IL8 in stromal cells may contribute to HMB. IL8 
is a potent chemokine, and it is reported to control the migration and activation 
of leukocytes during menstruation. Therefore, overexpression of IL8 may 
potentiate the chemotaxis and activation action of IL8 and lead to inflammatory 
cells accumulation in the endometrium, which is a key event in menstruation. 
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We observed that IL-8 mRNA increase markedly in endometrium of women with 
heavy menstrual bleeding during the late secretory and the menstrual phase. 
This was in consistent with other reports that demonstrated increased IL8 
premenstrually [27, 399, 429, 430, 446], but we did not observe a significant 
difference in IL-8 immunoreactivity in late secretory phase from the same group 
of patients. One possible explanation is that even though IL-8 protein production 
is highly expressed in women with HMB during the late secretory phase, only two 
samples were collected during this phase. Therefore, it was not possible to show 
a difference. However, the study proposes that the increase in IL-8 expression in 
endometrium of women in the reproductive age, particularly during the 
menstrual phase may contribute to the pathophysiology of heavy menstrual 
blood loss. As a result, the increase in IL-8 expression may potentiate leukocyte 
extravasation and migration into the endometrial tissue under the effects of 
steroids. This supports the hypothesis that IL8 upregulated when circulating 
leukocytes influx into endometrium before menstruation as an essential step for 
tissue breakdown and remodelling.  
The study of the women with uterine fibroids, found that the expression pattern 
of endometrial IL8 was not different from women with no fibroids. This study 
demonstrated a reduction in the infiltration of IL8 in endometrium to 
myometrium tissue. However, IL8 was abundant in fibroid tissue, and this is 
consistent with a recent report [441]which may indicate a role of IL8 in the 
growth of uterine fibroids particularly since it is known that fibroblasts have the 
ability to produce IL8[428]. 
GnRH-agonistisan effective treatment formany gynaecologic disorders. In 
patients with uterine fibroids, the administration of GnRH-agonists is associated 
with a significant decrease in uterine fibroid volume and with an improvement in 
fibroid-related symptoms. These effects are reversible at the end of the 
therapy, which is therefore considered as a preoperative treatment.  
This study found that the expression of IL8 mRNA and protein productionwas 
reduced in endometrium, myometrium and fibroid tissue in women pre-treated 
with GnRH agonists. This has been reported before in myometrium and fibroid by 
Senturk et al. [442].Therefore, it is suggested that inhibition or reduction of IL8 
production in endometrium, prevents recruitment and migration of leukocytes 
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into endometrium, and this maybe one of the mechanisms by which GnRH 
affects menstruation. Also, reducing the number of immune cells recruited into 
the endometrium lead to a decrease in their secretory products (cytokines and 
chemokines) and as a result, this allows the anti-inflammatory mediators to 
prevent menstruation. In addition, suppressing the production of IL8 in uterine 
fibroids may be one of mechanisms forthe reduction in fibroid growth. However, 
the level of IL8 in blood was higher in this group of women as has been 
previously reported [447].It may be hypothesized that GnRH agonists may 
promote the production of pro-inflammatory mediators in blood and suggest the 
induction of inflammation in vascular endothelial cells. Hence, this provokes the 
detrimental effect of use of GnRH agonists such as hot flashes, where it is 
previously reported that serum IL8 concentration in women with hot flashes was 
higher than that in women without hot flashes[448]. 
 
7.5 Conclusion 
It would be concluded that IL8 has a vital role in heavy menstrual blood loss. In 
addition it plays a role in the growth of uterine fibroids. Reduction in the IL8 
production may be one of the mechanism by which GnRH agonists reduce the 
size of uterine fibroids. 
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8.1 General discussion 
Heavy menstrual bleeding is the main menstrual disorder affecting women in 
their reproductive years, which places a considerable burden on general practice 
and secondary health service resources. In addition, it is the most common 
indication for hysterectomy [87]. It has been suggested that changes in the life 
style may contribute to this medical disorder, especially in communities where 
women would experience a greater number of menstrual cycles due to reduction 
in family size and incidence of lactational amenorrhoea compared to women 
with larger family size and lactating women.  
Although the mechanism of the physiological aspects of the menstrual cycle has 
been well established, the exact mechanism of heavy menstrual cycle is not fully 
clear. However, it has become clear that complex cellular and molecular 
systems are involved in the mechanism of abnormal menstrual bleeding [498]. 
The molecular mechanism of menstruation in response to progesterone 
withdrawal is characterised by complex events, which in part involves the 
production of prostaglandins that are vasocontrictors and lead to reduction in 
the blood flow to the endometrium. This is following by increased expression of 
locally acting mediators such as cytokines, angiogenic factors, protease enzymes 
and further prostaglandins. All these changes together with influx of leukocytes 
into the endometrium comprise the process of menstruation. 
Many previous investigations have supported the role of local disturbance of 
prostaglandin synthesis, secretion and metabolism in several endometrial 
pathologies, particularly those that are associated with disturbance in menstrual 
bleeding and painful menstruation. In addition, a role for COX enzymes and 
prostaglandins has been determined in reproductive tract pathology such as 
heavy menstrual bleeding, endometriosis and cancer [96, 387, 499]. This 
understanding has lead to the introduction of the use of non-steroid anti-
inflammatory drugs as treatment for such complaints. Non-selective NSAID and 
selective COX-2 inhibitors, however, have been associated with gastrointestinal, 
renal and cardiovascular problems, which highlight the need for further 
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understanding of COX which is the rate limiting enzyme in prostanoid production 
[500, 501]. 
Under normal circumstances, it has been suggested that the responsible cells for 
prostaglandin production, constitutively express COX-1 and are induced to 
express COX-2 in response to external stimulation. In heavy menstrual bleeding, 
significant elevation in the level of mRNA expression of both COX-1 and COX-2 
has been demonstrated [398]. As a consequence an increase in the level of the 
rate limiting enzymes of prostaglandins production in women with heavy 
menstrual bleeding leads, to the upregulation of the prostaglandins production 
and signalling. This present study demonstrates significantly increased levels in 
mRNA expression of both COX-1 and COX-2 in endometrium during the secretory 
phase, and the expression of COX-2 protein is mainly upregulated at the mid-
secretory phase.  The established role of COX enzymes in the regulation of 
angiogenic factors, the over-expression of Cox-enzymes during the secretory 
phase maybe implicated in the disturbance of endometrial angiogenesis in heavy 
menstrual blood loss through disturbing in the balance of these factors. These 
angiogenic alternations may affect vascular development, composition and 
structural integrity or permeability. Reduction in the control of blood volume 
loss is one of the mechanisms of heavy menstrual blood loss [149].  
Eventually, vascular permeability and leakage at the time of menstruation will 
be determined by the ratio of pro-and anti-angiogenic factors.  COX-2 enzyme is 
thought to have the ability to augment the expression of VEGF (angiogenic 
factor) via hypoxia induced factor1 (HIF1), therefore, the over-expression of 
COX-2 enzyme in HMB would suggest up-regulation of the endometrial VEGFA. 
The over-expression of both VEGFA mRNA and protein during mid-late secretory 
and menstrual phase in endometrium obtained from women with HMB in this 
study supports this suggestion. On the other hand, the over-expression of VEGF 
can up-regulate the expression of COX-2 in several WAYS. In addition to 
upregulation in the expression of angiogenic factors, COX enzymes may promote 
the action of angiogenic factors in HMB by decreasing anti-angiogenic factors, 
where a reduction in expression of cathepsin D mRNA and protein has been 
demonstrated in endometrial epithelial cells over-expressing COX-2 enzyme 
[502]. 
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The remodelling of endometrium during the menstrual cycle requires tight 
control of angiogenesis factors to coordinate the growth of new vessel 
formation.  Thus, aberration in angiogenic factors would dysregulate the 
neoangiogenesis process and affect endometrial repair.  The VEGF expression in 
endometrium is upregulated largely during the menstruation in normal cycles, 
where the endometrial repair process starts in day 2 of the cycle. This may 
indicate to a role of VEGF in the endometrial repair process. Both hypoxia and 
PGF2α have been found to play a key role in regulating the VEGF expression. 
Hypoxia acts via the HIF-1α to upregulate the expression of VEGF, whereas the 
PGF2α acts through HIF-1α independed pathway. 
 
By investigating the angiogenic factor vascular endothelial growth factor in 
endometrial stromal and endometrial glandular epithelial cells in women with 
HMB, this thesis demonstrates VEGF-A protein expression in both stromal and 
glandular endometrial cells and around the endometrial blood vessels. This 
supports the hypotheses that suggest VEGF regulates epithelial and stromal 
development in endometrium under the influence of oestrogen and 
progesterone; thereby it regulates the growth and differentiation of 
endometrium during the menstrual cycle. This expression is increased 
throughout the menstrual cycle, but takes place mainly at mid-secretory phase 
and reaches the highest in the menstrual phase. In addition, The VEGF-A mRNA 
level has the same pattern of expression as the VEGF-A protein.  The importance 
of VEGF-A in endometrium is representative in promoting neoangiogenesis, 
which is the key process in regeneration and remodelling of endometrium during 
the menstrual cycle. Comparing the expression level of VEGF-A in endometrium 
in women with normal menstrual blood loss and women with HMB fall out with 
the remit of this thesis. However, in chapter 2, in endometrium of women with 
PBAC score of less than 100 points, the level of VEGF-A mRNA was higher than 
those with higher PBAC score (>100). The work of some authors supports this 
concept and they found out that the endometrial VEGF-A level is lower in 
women with normal blood loss than in women with HMB[94]. This result 
hypothesised that because of the role of VEGF-A in new vessels formation that 
should start couple of days before the end of the menstrual phase to enhance 
the regeneration and proliferation of endometrium, low VEGF-A levels may lead 
Chapter 8 S.Abukhnjr 2014 211 
 
to a lack in new vessel formation and this allows disrupted vessels to bleed for a  
longer time and leads to HMB. This can be a logical explanation, although in this 
thesis, comparison between endometrial VEGF-A mRNA levels for women with 
high PBAC score and low PBAC score was regardless of the menstrual phases, 
moreover, concerns about the process by which pictorial blood loss assessment 
chart was used and the  low sample size gives a possibility of having this result 
by chance.  
The most known role of IL8 as a CXC chemokine is a potent chemoattractant for 
neutrophils. However, it also has mitogenic properties and an important role in 
the process of angiogenesis in vivo, indicating that IL8 is a key marker in 
endometrial repair. The upregulation of IL8 mRNA and protein expression shortly 
after progesterone withdrawal during the menstrual phase, where the 
endometrial repair process takes place, support this hypothesis. Both hypoxia 
and PGE2 upregulate the expression of IL8. The hypoxia acts via the HIF-1α to 
upregulate IL8 production and PGE2 act through another nuclear transcription 
factor present in the endometrial tissue in premenstrual time (NF-KB). However, 
the synergistic up-regulation of IL-8 mRNA observed in endometrial cells exposed 
to PGE2 and hypoxic conditions simultaneously indicates interaction between 
HIF-1α and NF-KB in regulating IL-8 expression.  
The ratio of PGF2α/PGE2 decreases in endometrium of women with heavy 
menstrual bleeding due to an increase in the production of PGE2 and decrease in 
the expression of PGFα2 receptors. As a result, the vasoconstriction of spiral 
arterioles may reduce and/ or decrease and a hypoxic insult may happen. 
Hence, the PGE2/hypoxia-induced pathway interaction would be affected, 
resulting in aberration in IL8 expression, and the endometrial repair process, 
which may cause heavy menstrual blood loss. In this study, the IL8 protein 
expression in endometrial stromal, glandular and endothelial cells is highly 
upregulated during the menstrual phase compared to mild expression during the 
proliferative and the secretory phase. Whereas, the IL-8 mRNA is upregulated 
during the late secretory phase and reaches the highest expression during the 
menstrual phase. According to previous work, the expression of IL8 protein in 
the normal menstrual cycle is upregulated during menstruation and it is faint 
during other phases. The expression of IL8 protein in this study for women with 
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heavy menstrual bleeding indicates upregulation throughout the menstrual cycle 
and is in keeping with the expression pattern been previously in normal cycles.  
Upregulation of IL8 expression is accompanied by upregulation in the influx of 
neutrophils into the endometrium. In this study, neutrophils showed increased 
expression in the late secretory phase and menstrual phase compared to faint or 
absent expression in the rest of the cycle, this suggests that their infiltration 
into the endometrium is regulated by IL8 and they play a part in endometrial 
repair.  
Both neutrophil and uNK cells have a key role in the angiogensis process, thus 
dysregulation in the infiltration of these cells may contribute to menstrual 
abnormality. Some neutrophils show expression of VEGF in other studies, and 
this supports their function in angiogensis promotion. The uNK has a role in 
production of angiogenic growth factors similar to VEGF. Although evaluating 
this hypothesis was not the aim of the present study, the study has a propensity 
to support this thought as both VEGF and uNK upregulated postovulation, during 
the mid-secretory phase, late secretory and menstrual phases, and uNK cells 
show perivascular expression, indicating their role in remodelling of spiral 
arterioles. Therefore, they have a fundamental and major importance in 
promotion of angiogenesis. Macrophages contributed to remodelling of arterioles 
through macrophage-mediated phagocytosis and activate MMP-9. The 
postovulation expression of macrophages indicates their functional remodelling 
of arterioles.  
 
The comparative study failed to find a significant difference in the expression of 
VEGF, PGE2, COX-1, COX-2, and IL8 either protein or mRNA, between 
endometrial tissue for women with heavy menstrual bleeding and uterine 
fibroids and women with HMB and normal uteri. This result indicates that these 
vascular markers contribute to HMB in both women with fibroids and women 
with normal uteri in the same manner. However, small cohorts in both groups 
could be a reason for not obtaining a difference between groups, particularly 
throughout the menstrual phases. In addition, if the nearer site of fibroids from 
the endometrium would affect more the endometrial physiology, in this study a 
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considerable number of women were with subserosal fibroids, and the majority 
of them were with intramural fibroid.  Women with any type of uterine fibroids 
may have HMB, but submucosal fibroids are the type of fibroid most likely 
associated with menstrual abnormality. It would be valuable to compare samples 
of each type of fibroid separately with uteri without pathology, but small cohort 
size when the results were grouped by fibroid position limited this.   
The study failed also to find differences between the two groups regarding the 
endometrial leukocyte infiltration. The factors that caused the limitations 
discussed above may also play a role in this result as well. The intramural, and 
subserosal fibroids are not associated with endometrial distortion, hence, they 
may not upregulate leukocyte influx into the endometrium. In addition, in the 
present study, the comparison of endometrial leukocytes depends on the 
relative number of leukocytes in the endometrial stroma in both groups. 
However, differences between leukocyte in endometrium from women with 
fibroids and women with normal uteri may be determined by investigating cell 
activities instead /or besides cells number. The activity of leukocytes can be 
evaluated by investigating the activity pathway for these cells which are 
represented in the expression of some activating ad inhibiting receptors, and 
some cytokines that play a crucial role in activating leukocytes. 
This study indicates high expression of VEGF protein in fibroid tissue, which is 
significantly higher than that in myometrial tissue. The upregulation of VEGF 
expression seems to be situated in the extracellular matrix and fibroblasts, 
indicating to a fundamental role of VEGF in the growth and may be the 
development of uterine fibroids. Fibroid tissue has less vascularity than normal 
myometrium and they rarely transfer to malignancy. If VEGF is an angiogenic 
factor and the best known role is a promoting factor of neoangiogensis, the 
presence of VEGF in fibroid tissue raises a question regarding its role there. The 
study suggests another unidentified function of VEGF. However, condensation of 
fibroid tissue which may concentrate the expression of VEGF in the fibroid tissue 
would be another explanation of this high expression of VEGF in fibroid tissue. In 
the study, differences in the VEGF mRNA levels between fibroids and myometrial 
tissue are not significant, which may support the later explanation.  
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 All COX-2, PGE2 and IL8 have higher protein expression in fibroid tissue than in 
myometrial tissue, indicating their role in growth and may be the development 
of uterine fibroids. These markers as discussed above have a fundamental role in 
angiogensis process; their expression in myometrial tissue is concentrated mainly 
around blood vessels, indicating their effect on endothelial cells. However, their 
role in fibroids is not fully elicited. On the other hand, their expression in fibroid 
tissue seems to be influenced by steroid hormones.  
This study elicited down regulation of the expression of these local markers in 
fibroid tissue from women who received GnRH agonists before operation. Hence 
changes in the steroid hormonal level may dysregulate the expression of these 
markers in the fibroid tissue. The GnRH is well known as a therapeutic option to 
reduce the size of fibroid and reduce the blood loss during surgery. The 
downregulation of these pro-inflammatory markers by using this drug indicates 
their role in the growth of fibroids and points to the inflammatory pathway as a 
manner in fibroids expansion. Nevertheless, the relative expression of VEGF 
mRNA is significantly upregulated in endometrium from women who had GnRH 
agonists compared with the VEGF mRNA level in endometrium from women who 
received no hormonal therapy. This increase in the VEGF mRNA level, which was 
associated with a hypoestrogenic condition, would support the hypothesis that 
there is a lower level of endometrial VEGF in women with HMB than that from 
women with normal blood loss. However, for women who received GnRH, the 
endometrial VEGF protein expression shows downregulation in some areas and 
high concentration in others. That raises a possible explanation, that cells 
exposed to GnRH work in a compensatory manner, where some of cells reduce 
the expression of VEGF another increase the expression of VEGF protein. 
Women, who receive GnRH, usually have very thin endometrium, and this causes 
condensation in the endometrial structure, which might be the reason for 
increase in the level of VEGF mRNA expression. This difference in the VEGF 
mRNA level is interesting and further evaluation would be valuable as this is the 
first time this result has been reported. This result may be obtained by chance 
because of small sample size in this group (3 subjects) but it was very consistent 
and marked.  
The serum level of VEGF shows no difference between women who received 
GnRH agonists and women who had no any hormonal therapy. On the other hand, 
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the serum level of IL8 in the group that received hormone was significantly 
higher than that of the other group. Therefore the study indicates a relation 
between using GnRH agonists and hot flashes; where the later increase the 
inflammatory mediators in blood, suggesting induction of inflammation in the 
vascular endothelial cells.  
 
8.2 Summary 
In normal menstrual cycle, progesterone withdrawal results in an upregulation of 
inflammatory mediators, production of proteases such as MMPs and plasminogen 
activators, leukocytes influx and expression of VEGF-R2 in endometrial 
basalis[82]. 
Hypoxia is coincident with progesterone withdrawal and upregulation of VEGF, 
which acts via binding to VEGF-R2 in the basalis layer and the shedding of 
endometrium takes place in the endometrial superficial (functionalis) layer. 
Both stromal cells and leukocytes play a role in upregulation of MMPs, which is 
under a paracrine/autocrine action and a play a fundamental role in 
extracellular breakdown.  The endometrial repair takes place in day 2 of the 
menstrual cycle and chemokines such as IL8 and IL15 play a key role in this 
process beside the proangiogenic factors as VEGF. Endometrial shedding and 
repair is a complex process, including cellular and molecular mechanisms (Figure 
10.1).  
Aberration in these pathways contributed to menstrual abnormalities. In heavy 
menstrual bleeding a higher expression of COX-2, PGE2 has been elicited, 
whereas the level of VEGF needs further investigation. 
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Figure 8.1: Summary of the endocrine and paracrine control of menstruation. 
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8.3 Work in the future 
This interesting work tried to find out the mechanism by which uterine fibroids 
lead to heavy menstrual bleeding by investigating the expression of VEGF and 
other cytokines in endometrium for women with HMB and uterine fibroids and 
compare these data with the levels in endometrium from women with HMB and 
no uterine pathology.  Regardless of  the negative results that the comparative 
study found, which may have been contributed to in part by having small cohorts 
in each stage of the menstrual cycle, the thesis supports some findings from 
work undertaken while this study was in progress, but also raised  new questions 
regarding other findings.  
The author suggests that upregulation of the studied markers is the end-step 
contributing to heavy menstrual blood loss in presence of uterine fibroids. This 
upregulation of the expression of these makers works in the same manner in 
both uterine fibroid and absence of uterine pathology. The difference may be in 
the mechanism by which uterine fibroids stimulate the regulatory factors of 
these local markers. Finding an alternative hypothesis through which fibroids can 
cause HMB is a challenge for future work. The other challenge in the future is to 
come to a conclusion regarding the relationship between uterine fibroids and 
menstrual abnormality, whether it is an association or causation.  In simple 
words, women with susceptibility to uterine fibroids may also have susceptibility 
to menstrual abnormality.  In that there is requirement for knowledge of the 
gene structure and sequence in the human endometrium across the menstrual 
cycle, and abnormality of these genes in menstrual disorders. It is also important 
to enhance our knowledge on the aberration in gene expression in uterine 
fibroids. 
These approaches can provide a great understanding of various genetic and 
molecular pathways when applied to specific endometrial pathology such as 
uterine fibroids. 
Exploring the global transcriptional and signalling effect of drugs such as SPRMs 
on the endometrium of women with HMB and uterine fibroids, this offers an 
understanding of the effect of these drugs and their benefits in presence of 
uterine fibroids. 
In the near future, it would be great if I have the opportunity to help in 
discovering the mechanism by which uterine artery embolisation affects the 
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endometrium and reduces the menstrual blood loss, and changes in the 
expression of local markers after the procedure.
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of endometrial vascular endothelial growth factor -A and its receptors in 
idiopathic heavy menstrual bleeding and in the presence of uterine 
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